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Abstract 
Programmed cell death protein 1 (PD-1) blockade has proven clinical utility in 
relapsed/refractory Hodgkin Lymphoma (HL). Interestingly, a recent study in HL from my 
laboratory demonstrated that PD-1, aside from T cells, is also expressed on NK cells. In 
addition, the “missing-self” hypothesis dictates that NK cells have capacity to lyse target 
cells with lost expression of Major Histocompatibility Complex molecule I (MHC-I). Hence, 
the frequent absence of MHC-I on Hodgkin-Reed-Sternberg (HRS)-cells, the malignant cells 
in HL, suggests that manipulation of host NK cells might be a viable strategy to enhance 
PD-1 blockade therapy outcomes.  
The Inositol-requiring enzyme-1-X-box binding protein 1 (IRE1-XBP1) pathway has been 
demonstrated to play an important role in a range of immune cells, and notably its role varies 
across tested settings. For instance, in macrophages it is required for the optimal secretion 
of TNFα, whereas in B cells and eosinophils it is a key factor involved in cell differentiation. 
The role of this pathway in Natural Killer (NK) cells and in NK cells from patients with HL has 
not yet been explored.  
Here, I outline new data identifying a hitherto unrecognized mechanism that is pivotal to how 
NK cell function, including the relatively poorly understood processes of NK cell migration, 
and NK cells Immune Synapse (NKIS) formation. 
Firstly, I demonstrate that splicing of the unfolded protein response (UPR)-related 
transcription factor XBP1 to its active form XBP1s is induced during NK cell-mediated direct 
cytotoxicity against various blood cancer cell lines. Notably, the induction of the IRE1-XBP1 
pathway was not associated with up-regulation of known XBP1s target molecules implicated 
in ER stress alleviation, indicating the XBP1 splicing in NK cells occurs independently from 
the canonical UPR system. 
Then, utilising a small molecule inhibitor, 4-methyl umbelliferone 8-carbaldehyde (4µ8c), I 
interrogated the role of the IRE1-XBP1 pathway in NK cell function. Inhibition of the IRE1-
mediated splicing led to significant decrease in XBP1s expression, which was associated 
with impaired migration, NKIS formation and secretion of IFNγ and TNFα. These findings 
further demonstrate the importance of the IRE1-XBP1 pathway in NK cell function.  
Next, I show that in pre-therapy HL patient blood samples, there is a ~2-fold reduction in 
XBP1s in response to activation by a HL line, compared to blood from healthy donors. 
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Notably, this observation was restricted to the CD56brightCD16- subset of cells that my 
laboratory has previously shown to be expanded and to display high expression of PD-1 in 
patients with HL. The cells with suppressed XBP1s activation displayed impaired NKIS 
formation, degranulation, and secretion of IFNγ and TNFα. Not only did addition of PD-1 
blockade enhance IFNγ secretion and NKIS formation to a PD-L1/PD-L2 gene amplified 
HRS-line, but critically the beneficial impact of PD-1 blockade on IFNγ and NKIS formation 
was partially reversed by inhibition of the XBP1s-pathway. Manipulation of the IRE1-XBP1 
pathway to enhance anti-tumour responses should be further explored as a novel lymphoma 
treatment strategy to enhance host NK cell immunity.  
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1.1 NK CELL SUBSETS 
Human Natural Killer (NK) cells are a heterogeneous population phenotypically defined as CD3-
CD56+ lymphocytes. NK cells can be divided into two sub-populations based on differential 
expression of the neural cell adhesion molecule 1 (NCAM-1, CD56), namely: CD56bright and CD56dim 
(Figure 1.1). Most NK cells belong to the CD56dimCD16+ population, which dominates in the 
peripheral blood (90%) and exhibits high level of cytotoxicity and is capable of antibody-dependent 
cell-mediated cytotoxicity (ADCC) [1]. The minority subset (10%) within the peripheral blood is the 
CD56brightCD16-, which generally resides in secondary lymphoid organs and produces cytokines 
following stimulation but is only weakly cytotoxic before activation. One theory is that the cells of 
this subset are precursors of the CD56dim CD16+ NK cells [2].  
 
Figure 1.1: The conventional subsets of human NK cells. The CD56brighCD16- subset produces high levels of cytokines 
following stimulation (A). These cells exert a high capacity to perform lymphokine-activated killing, but only limited 
ability to instigate ADCC due to low expression of CD16, and natural cytotoxicity. Both adhesion molecules, CCR7 and 
L-selectin, are responsible for homing properties of these cells to lymph nodes. In contrast, CD56dimCD16+ cells produce 
modest amount of cytokines, but are potent mediator of ADCC and natural cytotoxicity (B). These cells express a high 
level of KIRs and have more granular morphology. 
NK cell subsets express various chemokine receptors and adhesion molecules that affect their homing 
preferences. In the contrary to CD56dim NK cells, CD56bright NK cells express CC-chemokine receptor 
7 (CCR7) - a lymph node homing receptor and L-selectin (CD62L) – a molecule that enables members 
of this subset to adhere to the lymph node’s high endothelial venules. Therefore, these factors may 
play a critical role in trafficking of the CD56bright cells to lymph nodes [3] [4].   
Over twenty years ago, the third subset of NK cells, CD56negCD16+, was identified in patients with 
chronic viral infections such as HIV or HCV [5] [6] [7]. Later, it was shown that these cells also exist 
in healthy people but represent only few percent of total NK cells in the blood. In HIV-infected 
individuals CD56negCD16+ cells are characterized by decreased expression of activating receptors 
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and elevated expression of inhibitory receptors. Generally, they exhibit lower capacity to perform 
cytolysis, proliferate and produce cytokines [8] [9]. 
1.2 NATURAL KILLER CELL FUNCTION 
 Direct Cytotoxicity 
NK cells are important innate effector cells that possess the unique ability to lyse abnormal cells 
without previous sensitization (Figure 1.2) [10] [11]. Target cell death can be executed by various 
mechanisms, including degranulation and death receptor engagement [12]. The principal mechanism 
of NK cell mediated direct cytotoxicity involves recognition of a target cell and formation of an 
immunological synapse (IS), followed by the exocytosis of lytic granules, which leads to a target cell 
lysis [13]. The content of lytic granules includes: perforin - a membrane-disrupting protein, 
proteolytic enzymes known as granzymes, Fas ligand (FasL), TNF-related apoptosis inducing ligand 
(TRAIL), and granulysin [14] [15] [16]. Of the various granzymes present in the lytic granule, 
granzyme B is a critical molecule that triggers apoptotic target cell death via caspase-dependent and 
independent mechanisms [17] [18].  
 
Figure 1.2: NK cell mediated direct cytotoxicity. The increased expression of activating ligands at the surface of 
malignant cells induces NK cell activation and subsequent target cell lysis. 
Another mechanism initiates extrinsic apoptotic pathway through activation of death receptors, Fas 
or TRAIL receptor (TRAIL-R), present on target cells [19]. These molecules engage with cognate 
ligands expressed on NK cells (FasL and TRAIL) what activates a caspase enzymatic cascade that 
triggers apoptosis. Moreover, engagement of activating receptors of NK cells causes release of 
chemokines and cytokines, which further modulate the immune response. Among these molecules 
are tumour necrosis factor α (TNFα), interferon γ (IFNγ) or granulocyte-macrophage colony-
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stimulating factor (GM-CSF). Additionally, IFNγ may induce expression of death receptors on target 
cells, thereby making them more prone to TRAIL/FasL-mediated cytotoxicity [14]. 
 Antibody-Dependent Cell-mediated Cytotoxicity 
As mentioned previously, another type of NK cell-mediated cytotoxicity is ADCC (Figure 1.3). In 
this case, antibody-coated target cells are recognized by NK cells through engagement of their CD16 
(FcγRIIIA) receptor with Fc portion of IgG antibody [20] [21]. CD16 is present within the cell 
membrane and associates with homo- or heterodimers of FcϵRI-γ and CD3-ζ chains, which possess 
immune tyrosine-based activating motifs (ITAM) that are crucial for the rapid generation of 
intracellular messengers. Following FcγR engagement, ITAMs undergo phosphorylation what results 
in activation of tyrosine kinases such as ZAP-70 and SYK, as well as phosphatidylinositol (PI)-3 
kinase (PI3K), nuclear factor-κB (NF-κB) and ERK pathways. Collectively, these mechanisms trigger 
NK cell degranulation, TNF family death receptor signalling and secretion of cytokines such as IFNγ, 
which consequently leads to the opsonised cell death [14] [22].  
 
Figure 1.3: NK cell-mediated ADDC. Tumour cell coated with monoclonal antibody is recognized by NK cell through 
binding of its CD16 receptor with Fc portion of IgG antibody that induces Antibody-Dependent Cell-mediated 
Cytotoxicity.  
 Cytokine Secretion 
Apart from the ability to kill malignant or infected cells, NK cells have the capacity to rapidly produce 
a variety of cytokines and chemokines in response to stimulation [3]. NK cells, mainly the 
CD56brightCD16- population, are the primary source of TNF-α, IFNγ and GM-CSF. Secretion of these 
cytokines significantly shapes responses mediated by other immune cells such as T cells, dendritic 
cells (DC), macrophages, and neutrophils [12]. For example, IFNγ released by NK cells can increase 
expression of the major histocompatibility complex class I (MHC-I) molecule on antigen presenting 
cells (APC) [23]. Moreover, IFNγ secreted by NK cells primes responses mediated by the CD4+ T 
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helper type 1 (Th1) cells [10]. These responses are further enhanced by DCs, which mature in 
response to IFNγ secreted by NK cells [24]. Equally important is TNFα, a powerful cytokine with 
pleiotropic functions including tumour killing or immune response editing. As an illustration of its 
function, TNFα is known to augment B cell proliferation and induce monocyte and macrophage 
differentiation [25] [26] [27] [28]. NK cells are also known to secrete several other factors, including 
immunoregulatory cytokines such as IL-5, IL-10, IL-13 and the chemokines MIP-1α, MIP-1β, IL-8, 
and RANTES (CCL5). The latter facilitates recruitment of other effector cells to the inflammation 
site [29] [30]. 
Thus, NK cells are not only the cytotoxic cells but also immunoregulatory cells that can orchestrate 
anti-cancer responses by shaping the responses of other immune cells [31]. 
1.3 NATURAL KILLER CELL RECEPTORS 
NK cells harbour a variety of transmembrane receptors [32]. Their effector functions, such as 
cytotoxicity, cytokine production or proliferation depend on the balance between inhibitory and 
activating signals received by these receptors [22] [33]. NK cell receptors possess various adaptor 
molecules which facilitate signal transduction. These adaptor molecules include: DAP12, CD3ζ or 
FcRγ, which further transduce signals via cytoplasmic domain motif: ITAM or immunoreceptor 
tyrosine-based inhibitory motif (ITIM), activating or inhibiting signals respectively [34] [35]. 
Whereas DAP10, another adaptor molecule, uses alternative signalling via YINAM motif [34] [12, 
35].  
Interaction between activating receptors and their ligands induces phosphorylation of tyrosine residue 
and activates downstream kinases (SYK or ZAP70), which leads to a signalling cascade, NK cell 
degranulation and cytokine secretion. In case of inhibitory receptors, following the phosphorylation, 
phosphatases deactivate signalling kinases, what results in inhibition of NK cell function [22] [33].  
According to the “missing-self” hypothesis, introduced by Karre, target cells with reduced or lost 
MHC-I molecule expression, which under normal circumstances is expressed by each healthy cell, 
are recognized by NK cells as “missing-self” and if activating signals are unopposed by inhibitory 
signals NK cell kills target cell (Figure 1.4) [36] [37]. Individual types of NK cell receptors (NKRs) 
will be discussed in turn. 
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Figure 1.4: The “missing-self” hypothesis. The loss of MHC-I molecule on malignant cell renders them sensitive to NK 
cell-mediated cytotoxicity. A balance between activating and inhibitory signals received by the receptors at NK cell 
surface regulates the recognition of healthy cell by NK cells. Malignant cells with lost MHC-I molecule expression, such 
as HRS cells (malignant cells in Hodgkin lymphoma), are recognized as “missing-self” and induce NK cell-mediated 
cytotoxicity. 
 Killer Cell Immunoglobulin-like Receptors 
Killer cell immunoglobulin-like receptors (KIRs) are part of the immunoglobulin superfamily (IgSF) 
[2]. These receptors prevent NK cell-mediated killing of normal cells but promote lysis of cancerous 
or virally infected cells, with reduced or lost expression of the MHC-I [22] [36] [38] [39].  
KIRs family includes both activating and inhibitory receptors, which signal through ITAM or ITIM 
associated with DAP-12 or FcεRI-γ adaptor molecules [40] [39]. Structurally, they are characterized 
by the presence of type I transmembrane glycoproteins with two (KIR2D) or three (KIR3D) Ig-like 
domains, with either short or long cytoplasmic tail. The latter determines their functional properties, 
and hence the long tail associated with ITIM mediates inhibitory signals, while the short tail 
associated with ITAM mediates activating ones. Primarily, KIRs are known to recognize MHC-I 
molecules, such as human leukocyte antigen (HLA)-A, -B, and -C, what provides NK cells with 
inhibitory signals. Specificity for HLA-C or HLA-A/B allotypes is dictated by the extracellular Ig-
domains, precisely KIR2DL recognizes HLA-A and KIR3DL recognizes HLA-A/B. Likewise, 
selected HLA molecules are also ligands for the activating KIRs. So far, it has been established that 
KIR2DS1 recognizes HLA-C and HLA-A, KIR2DS4 can recognize HLA-C2, and KIRDL4 
recognizes HLA-G (Figure 1.4) [41] [39]. 
The expression of KIR on individual NK cells is regulated by the methylation of the KIR gene [34]. 
Each individual has a unique repertoire of KIRs, with the exception for KIR2DL4 which is expressed 
universally by all NK cells [32] [34]. Interestingly, this receptor, despite having a long cytoplasmic 
tail, acts as activating receptor responsible for induction of IFNγ secretion without triggering NK cell 
mediated killing [32]. 
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Inhibitory KIRs are an attractive target for immunotherapy targeting NK cell activity. These receptors 
play a critical role in allotransplantation, where KIR-MHC-I mismatch between donor and recipient 
ensures NK cell activity upon transplantation, which leads to elimination of cancer cells, despite the 
expression of the MHC-I on their surface. This approach has clinical utility in both acute myeloid 
leukaemia (AML) and multiple myeloma (MM) patients. Another strategy utilizes monoclonal 
antibodies (mAbs) blocking KIR receptors, specifically KIR2DL1/L2/L3, which represent half of the 
total NK cell repertoire. Blockade of these KIRs prevents engagement of inhibitory ligands (HLA-C) 
that normally inhibit NK cell function [41]. The interaction of KIRs and self-HLA class I molecules 
leads to inhibition of NK cell mediated cytotoxicity [42].  
 C-type Lectin Receptors 
The C-type lectin like receptors (CTLR) family is a heterogeneous group of NK cell receptors. 
Members of this family are heterodimers that possess common subunit CD94 bound to the NKG2 
molecule. The latter ensures signalling via extracellular and cytoplasmic domains that are responsible 
for the functional specificity of CTLRs. The CD94:NKG2 family comprises of four closely related 
members: NKG2A, NKG2C, NKG2E and NKG2F [32]. Within this family, NKG2A is the only 
inhibitory receptor. It contains a long intracytoplasmic tail bearing ITIM. The remaining receptors 
transduce activating signals with the use of short cytoplasmic tails associated with ITAM [43]. The 
ligand for these activating receptors, CD94:NKG2A, C and E, is the non-classical MHC-I molecule 
HLA-E [44] [45] [46] [47]. 
Although not capable of forming complexes with CD94; the homodimer NKG2D is grouped within 
the CTLR family [48]. NKG2D is expressed by all NK cells and its intracellular domain associates 
with adaptor protein DAP10 to transduce signals via recruitment of PI3K that leads to cytotoxicity 
and cytokines release [49] [50]. The ligands for NKG2D include the MHC-I chain-related peptides 
(MIC) A (MICA) and B (MICB), and UL16 binding proteins (ULBPs) [48] [51] [52]. These ligands 
are abundantly expressed on “stressed” cells or cells which undergo a malignant transformation [53]. 
Moreover, many tumour cells release NKG2D ligands in a soluble form to prevent NK cell activation 
and subsequent NK cell mediated killing of target cells. Furthermore, these soluble ligands contribute 
to down-regulation of NKG2D expression on effector cells. Multiple studies have shown that sera 
from cancer patients exert increased levels of soluble NKG2D ligands what correlates with disease 
severity [2]. 
Another member of this family NKp80, nearly universally expressed by NK cells, contains an unusual 
hemi-ITAM-like cytoplasmic domain triggering NK cell mediated cytotoxicity [54]. Almost all NK 
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cells express this activating receptor. Interestingly, ligand for NKp80, activation-induced C-type 
lectin (AICL), is stored intracellularly and surfaces upon NK cell stimulation. This ligand is expressed 
by haematopoietic cells, particularly myeloid cells in AML and chronic myeloid leukaemia (CML). 
It is also found in non-haematopoietic cells of carcinoma and melanoma cells. Engagement of AICL 
expressed on these cells with NKp80 increases their susceptibility to NK cell mediated cytotoxicity 
[54] [55] [56]. 
 Natural Cytotoxicity Receptors 
Natural Cytotoxicity Receptors (NCRs) belong to activating receptors from the IgSF and are able to 
trigger direct cytotoxicity upon engagement with ligands such as: non-MHC-I molecules or pathogen-
derived molecules [57] [58]. The signals received by these receptors are transduced via adaptor 
molecules associated with ITAM. Interestingly, NKp44 receptor is the only member of this family 
that also contains adaptor molecules bearing ITIM, a motif usually transducing inhibitory signalling 
[Hudspeth, 2013]. NKp46 and NKp30 receptors are constitutively expressed by resting NK cells and 
their expression increases upon NK cell stimulation. Conversely, expression of NKp44 is detected 
solely upon activation of NK cells [59, 60]. Recent studies indicate that each of the NCR genes can 
undergo alternative splicing what results in generation of multiple splice variants. Each of these 
variants may exert different functionality [61]. Apparently, alternative splicing of NCR genes is 
driven by cytokines present in particular tumour microenvironment. 
NKp46, identified as the first NCR family member, is the leading receptor mediating cell death of 
tumour cells that lack MHC-I [62]. Multiple studies have shown a negative correlation between 
absence of NKp46 expression and efficient clearance of tumours, such as lymphoma or melanoma 
[58]. NKp46 engages with a range of ligands including: heparan sulfate proteoglycan (HSPG) – 
present on many tumour cells, as well as bacterial proteins such as vimentin, Plasmodium falciparum 
erythrocyte membrane protein-1 (PfEM-1), or viral proteins - hemagglutinins (HA) and 
hemagglutinin neuraminidases (HN) expressed by a range of virally-infected cells [63]. After 
engaging its ligands NKp46, endowed with two extracellular domains, transduces signals via ITAM, 
what leads to target cell lysis and release of cytokines [64] [65].  
NKp44 has a single extracellular domain that likely transmits signals through the ITAM-bearing 
adapter molecule DAP-12. NKp44 cytotoxic activity towards target cells decreases following its 
blockade with specific mAbs; notably this is decreased further by a co-blockade of NKp46 suggesting 
that these two receptors cooperate towards clearance of target cells [66]. Ligands for this receptor are: 
NKp44L, proliferating cell nuclear antigen (PCNA), and various virus-derived proteins [63]. 
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Wherein, ligation of PCNA potently inhibits either NK cell mediated cytotoxicity of tumour cells and 
IFN-γ secretion. PCNA-mediated inhibition of NK cell function perhaps occurs through the inhibitory 
ITIM motif present in the structure of the splice variant NKp44-1. 
Another receptor within this family NKp30 is endowed with one extracellular domain [67] [62]. Its 
expression on NK cells is down-regulated in the presence of TGF-β, a cytokine often found to be 
extensively secreted in a tumour microenvironment [62]. Currently, there are several known ligands 
for NKp30: HSPG, HLA-B associated transcript 3 (BAT-3), B7-H6 (expressed on many tumour cell 
lines), and human cytomegalovirus tegument protein (HCMV-pp65) [63] [68]. Both ligands, BAT-3 
and B7-H7, are expressed by multiple tumour cells what implicates NKp30 involvement in tumour 
clearance. However, NKp30 appears to also mediate NK cell interactions with DCs, what has 
significant impact on shaping the overall immune responses [68]. 
 The NK cell immunological synapse 
The NK cell immune synapse (NKIS) formation is a finely-tuned, stepwise process of which key 
components include: adhesion to a target cell, actin polymerization and rearrangement at the IS, lytic 
granule convergence, microtubule-organizing centre (MTOC) and lytic granule polarization toward 
the synapse, granule secretion, and detachment of NK cell following target cell destruction (Figure 
1.5) [69, 70]. 
 
Figure 1.5: Schematic of NK cell immune synapse formation process. The NKIS formation is a multiple step process 
that initiates by conjugate formation between NK cell and a target cell. At the interphase of the IS actin undergoes 
rearrangements to form a stable synapse. In the next step, MTOC polarization occurs, followed by the lytic granule 
polarization, which leads to granule secretion at the IS and eventually target cell apoptosis. 
 
Adhesion of NK cell to a target cell is an indispensable checkpoint to establish a stable connection 
and subsequent immune synapse. Within the NKIS interface we can distinguish two sections referred 
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to as peripheral supramolecular activation cluster (pSMAC) and the central SMAC (cSMAC). The 
first section is a ring-shaped structure comprised of adhesion molecules, such as lymphocyte function-
associated antigen 1 (LFA-1), that cluster at the contact point of NK cell and target cell. As follows, 
LFA-1 induces actin polymerization and subsequent accumulation of F-actin filaments within the 
pSMAC [71] [72] [73]. Conversely, activating receptors, responsible for the cytotoxic response i.e. 
NKG2D, NKp30, or NKp46, cluster in the cSMAC [72]. In the aftermath of signalling transduced 
via activating receptors NK cell can either mediate target cell lysis or secrete cytokines [74] [75] [70].  
To deliver a lethal hit to a target cell, further rearrangements of the NK cell cytoskeleton are required. 
In particular, the MTOC, a structure that organizes the microtubule cytoskeleton, undergoes dynamic 
changes and is polarized toward the target cell to ensure transport of lytic granules to the IS [70]. 
Concomitant rearrangement of F-actin at the synapse interface leads to formation of granule-sized 
pores, which enable lytic granules secretion [76] [77] [78]. It has been reported that myosin IIA may 
facilitate lytic granules passage through the F-actin network of the IS or be involved in induction of 
confined changes in the F-actin structure to allow polarized lytic granules access to the membrane 
[70] [79] [80] [81]. As the lytic granules reach a target cell, perforin disrupts its membrane to enable 
entry of granzymes into the cell and subsequent target cell death [82]. In the final step, the NK cell 
detaches from the target cell and is able to engage with the next target [83]. 
1.4 NK CELL BASED THERAPIES IN CANCER 
The fact that NK cells can recognize and kill an array of tumour cells without prior sensitization 
renders them a promising tool for anti-cancer therapy [84]. As mentioned previously, NK cell 
function is tightly regulated by a balance between activating and inhibitory signals received by a 
mosaic of receptors expressed at the cell surface. These receptors enable NK cells to engage with and 
eliminate abnormal cells. Each abnormal cell has a unique suite of ligands, which upon binding to 
specific receptors on NK cell will induce a response, such as cytokine secretion, cytotoxicity or 
proliferation. [42]. NK cells are known to attack tumour cells with lost or down-regulated expression 
of MHC-I molecules, which is often a case in hematopoietic malignancies [85] [84]. Moreover, given 
that NK cells are “ready to kill”, as oppose to T cells that require a certain time to acquire anti-tumour 
activity, makes them an attractive tool for immunotherapy [42] [32]. Indeed, an 11-year follow up 
study of healthy participants demonstrated that low NK cell activity is associated with the increased 
cancer risk [86] [42] [37].  
Recent progress in the field of NK cell biology and concomitant improved understanding of their 
function allowed for the development of novel immunotherapeutic strategies [32]. Generally, NK cell 
CHAPTER 1: General Introduction 
11 
immunotherapy can be achieved either by activating endogenous NK cell response or using 
exogenous NK cells via adoptive cell transfer. So far, several strategies for NK cell immunotherapies 
for human cancer have been proposed and selected therapies will be discussed further [84]. 
 Monoclonal antibody therapies  
NK cell function can be modulated by targeting specific receptors expressed at the cell surface. Of 
importance among activating receptors is CD16, a molecule that enables ADCC of antibody-coated 
tumour cells. Specifically, the Fc portion of antibody coating a tumour cell is bound by CD16 receptor 
present on NK cell, what initiates NK cell mediated killing of malignant cell [87]. One such antibody, 
with a proven clinical success in patients with various lymphoid malignancies (follicular lymphoma 
- FL, diffuse large B-cell lymphoma - DLBCL), is rituximab, a molecule targeting CD20 antigen 
expressed on the malignant cells [88]. Moreover, the ADCC activity of NK cells can be enhanced by 
means of bispecific or trispecific antibodies. This type of antibodies combines the binding avidity and 
biologic activity of two or three antibodies into one molecule, targeting at least one tumour antigen 
and at least one surface antigen on NK cell. By crosslinking these epitopes, the antibody facilitates 
the interaction between a tumour cell and NK cell. For instance, in MM patients, a recombinant 
bispecific protein (ULBP2-BB4) promotes ULBP2 interaction with NKG2D receptor present on NK 
cells, and BB4 moiety binding to CD138 receptor expressed by the neoplastic cells. This bispecific 
antibody showed enhanced NK cell-mediated killing of malignant plasma cells both in the allogeneic 
and autologous setting [89] [90].  
Further, NK cells express also an array of inhibitory receptors, and blockade of these receptors, which 
serve as checkpoints in NK cell activation, emerges as a promising tool for immunotherapy. Recently, 
anti-PD-1 mAb has been the focus of multiple studies due to the great success in unleashing the anti-
tumour efficacy of immune cells with a proven clinical efficacy [87]. Anti-PD-1 mAb targets 
programmed cell death protein-1 (PD-1), which is expressed on a range of activated immune cells, 
including NK cells. Conversely, its cognate ligands PD-ligand 1 (PD-L1, CD274) or PD-ligand 2 
(PD-L2, CD273) are expressed on a variety of tumour cells [90]. A large body of evidence suggests 
that the PD-1/PD-L1/PD-L2 axis is implicated in tumour immune escape in many solid cancers, as 
well as haematological malignancies, including Hodgkin lymphoma (HL), non-Hodgkin lymphoma 
(NHL), and MM [91]. In fact, PD-1 and PD-L1 blockade was found to trigger a robust NK cell 
response, what orchestrates that not only T cells but also NK cells mediate the effects of PD-1/PD-
L1 blockade. Shaping the anti-tumour response via NK cells may be of importance in cases where 
tumour cells express low levels of MHC-I and high levels of PD-1 ligands [92]. In a recent study of 
HL, it was demonstrated that PD-1/PD-L1 axis plays a critical role in tumour immune evasion due to 
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expansion of the CD3-CD56brightCD16-CCR7+PD-1+ subset of NK cells, which function was inhibited 
directly by malignant cells, as well as the CD163+PD-L1+/PD-L2+ tumour-associated monocytes 
(TAMs). Upon PD-1 blockade NK cells orchestrated enhanced degranulation which was consistent 
with increased killing of malignant cells [93]. Another study on patients with MM, has also shown 
PD-1 expansion within NK cell compartment. Additionally, in vitro experiments demonstrated that a 
blockade of PD-1 boosted NK cell mediated cytotoxicity of autologous malignant cells. However, 
the exact mechanism of PD-1 blockade effect on NK cell function remains to be elucidated [90] [42].  
Normally, all nucleated cells in the host express MHC-I molecules, which once recognized by 
inhibitory KIRs on NK cells protect them from NK cell-mediated lysis. Hence, disruption of 
inhibitory KIRs through mAb-mediated blockade could enhance NK cell-mediated killing of tumour 
cells, and therefore, KIRs have become a target for immune checkpoint blockade to unleash NK cell 
killing potential against tumour cells that still express MHC-I molecules. A monoclonal antibody, 
known as lirilumab, blocks three inhibitory KIRs: KIR2DL1, KIR2DL2 and KIR2DL3; its 
application has been shown to enhance NK cell activity against tumour cells in vitro and in the phase 
I clinical trials in AML patients [94] [95] [42] [96] [97]. 
NKG2A is another inhibitory receptor on NK cells, which recognizes MHC-I ligand HLA-E, and it 
was shown that signalling via this receptor inhibits NK cell-mediated anti-tumour activity in a range 
of malignancies. Thus, NKG2A is a potential target for checkpoint blockade therapy. Currently, 
several clinical trials utilizing a monalizumab, a mAb blocking NKG2A receptor, are ongoing. In the 
future, the combinatorial approach targeting a different aspect of NK cell function might prove 
beneficial for the treatment of cancer [89] [42] [92]. 
 Adoptive NK cell transfer  
Alternative way to modulate the host’s immune system to fight cancer is adoptive cell transfer (ACT) 
therapy. Either autologous or allogeneic cells transfer can be considered to replace, repair, or enhance 
the function of the immune system. Several strategies can be pursued with regards to ACT therapy, 
such as: depletion or enrichment of specific cell subsets, expansion of selected hematopoietic cell 
subsets, activation of lymphocytes for immunotherapy, and genetic modification of lymphoid cells 
[87]. Particularly attractive strategy for immunotherapy is the transfer of NK cells, as they do not 
require prior sensitization to eliminate malignant cells and can induce a potent cytokine response [87]. 
NK cell products for adoptive transfer can be prepared from: umbilical cord blood, cell lines, and 
adult donor leukapheresis products. The benefit of using adoptively transferred adult NK cells is that 
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these cells are educated in healthy hosts and have the potential to have greater anti-tumour activity 
[98].  
Initially, the therapeutic potential of NK cells was explored by adoptive transfer of Interleukine-2 
(IL-2) activated NK cells. However, the outcomes of this approach were disappointing due to high 
toxicity of IL-2 and the inhibition of NK cell function by engagement of their inhibitory receptors 
KIRs with self-MHC-I molecules expressed on malignant cells [85] [98] [99].  
Subsequently, trials encompassing allogeneic NK cell transfer were investigated. The revolutionary 
study by Ruggeri et al., demonstrated that alloreactive NK cells transfer to patients with AML not 
only could eliminate relapse and graft rejection, but also protect them against graft vs host disease 
(GvHD). The great advantage of allogeneic NK cells is that they are derived from healthy donors, 
therefore they govern more powerful killing activity, and unlike T cells, they do not induce GvHD 
[100]. The observations in AML patients indicated that allogeneic transfer of NK cells with KIR 
mismatch is associated with anti-tumour activity, thereby specific selection criteria for KIR-
mismatched donors have been established. This in turn, led to clinical studies of the allogeneic 
transfer of NK cells with promising results [101] [102] [103]. Further, Miller et al. have established 
safety and efficacy of alloreactive NK cells transfer in patients with meta-static melanoma, renal cell 
carcinoma, refractory HL and refractory AML [104]. A recent study by Bachanova et al., indicates 
that allogeneic transfer of NK cells promotes remission in NHL patients with low level of 
immunosuppressive cells, such as regulatory T cells (Treg) and myeloid derived suppressor cells 
(MDSC) [105]. This clinical evidence strongly supports a therapeutic role for allogeneic NK cells in 
controlling human malignancies [106] [107] [37] [90]. 
Another alternative is the use of pre-established clinical grade NK cell lines expanded to high 
numbers and cryopreserved as an “off-the-shelf” therapy. Importantly, prior modulation of these cells 
might be used to further enhance their effector functions [42] [37] [108]. Moreover, combination of 
NK cell transfer with checkpoint inhibitors or immunomodulatory drugs may provide enhanced 
efficacy [42] [1] [90].  
1.5 THE UNFOLDED PROTEIN RESPONSE 
The Unfolded Protein Response (UPR) system is responsible for maintenance of protein homeostasis. 
Once cells are exposed to endoplasmic reticulum (ER) stress, signalling pathways within the UPR 
system are initiated to reduce protein translation, upregulate expression of the ER enzymes and 
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chaperones involved in protein folding, and degrade the misfolded proteins. Nonetheless, if the ER 
stress cannot be resolved the UPR triggers cell death through apoptosis [109] [110].  
Three arms of the UPR system operate in parallel with the use of different signal transduction 
mechanisms. Each pathway is initiated with an ER membrane-bound sensor component, specifically: 
Inositol Requiring Kinase 1α (IRE1α) and X-Box binding Protein 1 (XBP1); Pancreatic ER Kinase 
(PERK) and Activating Transcription Factor 4 (ATF4); and ATF6 [111].  
 The IRE1-XBP1 pathway 
The IRE1 is a type I ER transmembrane protein with both kinase and endoribonuclease (RNase) 
activity. The serine/threonine kinase domain is located on N-terminal of the ER luminal domain (LD), 
while the C-terminal endoribonuclease domain resides in the cytosol. Out of two mammalian 
isoforms of IRE1, IRE1α and IRE1β, only IRE1α is ubiquitously expressed, while the other isoform 
is expressed exclusively by the intestinal epithelial cells [112] [113]. 
In the absence of unfolded proteins, Binding immunoglobulin Protein (BiP) associates with IRE1- 
luminal domain (IRE1-LD) to keep it inactive. With the increase of unfolded proteins in the ER, BiP 
releases IRE1-LD and binds the unfolded proteins, whereas IRE1 undergoes dimerization, followed 
by auto phosphorylation, what leads to its activation [114] [115] [116]. The activated IRE1 processes 
the XBP1U mRNA by splicing out a 26-nucleotide-long intron, what in turn shifts the open reading 
frame of XBP1 mRNA. In the aftermath, a stable form of XBP1 is expressed – spliced XBP1 (XBP1s). 
The latter is an active transcription factor that translocates to the nucleus to induce the upregulation 
of specific target genes involved in ER-associated degradation (ERAD) and protein folding (Figure 
1.6) [117-119]. 
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Figure 1.6: A schematic representation of the IRE1-XBP1 pathway. In the absence of unfolded proteins BiP associates 
with IRE1 and maintains it in a monomeric inactive form. In a stressed cell, BiP associates to misfolded proteins, while 
IRE1 undergoes dimerization followed by autophosphorylation, which ultimately leads to its activation. Activated IRE1 
mediates the splicing of XBP1 mRNA by excision of the intron from the XBP1 transcript, which results in the production 
of a potent transcription factor, XBP1s. The latter regulates many UPR target genes to promote protein folding in the ER 
lumen, ER-associated degradation (ERAD) of misfolded proteins and ER biogenesis. 
 A role of IRE1-XBP1 pathway in immunity 
XBP1s is a transcription factor that plays an important role in several immune cell types. First, it was 
shown to be involved in terminal differentiation of B lymphocytes to plasma cells, as well as in the 
production of antibodies and interleukin 6 (IL-6), a cytokine essential for plasma cell differentiation 
[120] [121]. Subsequently, it was found that stimulation of macrophages via Toll Like Receptors 
(TLRs) leads to the activation of IRE1 and subsequent upregulation of XBP1s. Interestingly, 
activation of the IRE1-XBP1 pathway occurred independently of the two other branches of the UPR 
and was required for the optimal secretion of specific cytokines, such as IL-6, TNFβ, and IFNβ [122]. 
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Again, XBP1s was shown to be a prerequisite for DCs differentiation and survival [123]. Conversely, 
in ovarian cancer patients, XBP1s was found to cause tumour-associated DCs (tDC) dysfunction. 
Specifically, the tumour microenvironment generates metabolic by-products, such as unsaturated 
aldehyde 4-hydroxy-trans-2-nonenal (4-HNE), which induces a sustained ER stress in tDCs. In other 
words, constitutive activation of the IRE1-XBP1 pathway driven by 4-HNE, leads to the 
accumulation of lipids in tDCs, and as a result disrupts their homeostasis and impairs the antigen 
presentation. In this case, tumour cells hamper the normal activity of tDCs to eliminate T cell-
mediated anti-tumour responses. Accordingly, therapeutic silencing of XBP1 in tDCs enhances anti-
tumoural responses against ovarian cancer cells [124]. Apart from this, induction of XBP1s was 
shown to be essential for differentiation of the CD8+ T cells into effector cells during an acute 
infection, however the exact mechanism of this process remains unknown [125]. In the recent study 
of ovarian cancer, tumour-infiltrating CD4+ and CD8+ T cells were found to have increased level of 
XBP1s. Notably, the increase of XBP1s was associated with decreased production of IFNγ [126].   
1.6 HODGKIN LYMPHOMA  
Several cases of HL were described for the first time by Thomas Hodgkin in 1832 [127].  Initially, it 
was referred to as Hodgkin’s disease and only after it was realized it is a type of lymphoma the name 
was changed to Hodgkin lymphoma [128]. HL occurs in 3 cases per 100.000 people, and accounts 
for 10% of all lymphomas [127] [129]. HL is characterized by a unique bimodal distribution of age-
specific incidence rates with two peaks in the age groups of 15-34 years, and older than 55 years. 
Moreover, it affects men more frequently than women [130].  Based on the histological picture and 
phenotype of malignant cells, HL is divided into classical HL (cHL), and nodular lymphocyte-
predominant Hodgkin lymphoma (NLPHL) that accounts for 5% of cases. The HL can be further 
divided into 4 different subtypes: nodular sclerosis (NSHL), mixed cellularity MCHL), lymphocyte-
depleted (LDHL), and lymphocyte-rich classical Hodgkin’s lymphoma (LRCHL) [129] [131]. The 
hallmark of HL is a presence of malignant cells known as mononucleated Hodgkin cells and 
multinucleated Reed-Sternberg (RS) cells. The latter population of cells stems from Hodgkin cells 
that undergo a process similar to endomitosis, a nuclear division without cellular one, which in turn 
leads to formation of bi- and multinuclear RS cells [132] [129].  
A typical malignant lymph node in HL contains a scarce number (0.1-2%) of Hodgkin and Reed-
Sternberg (HRS) cells, which are embedded into a rich infiltrate of variegated immune cells. The 
presence of an inflammatory microenvironment promotes survival of HRS cells and facilitates an 
immune attack evasion [128] [129]. HRS cells constitutively express CD30, and CD15 (70-80%), but 
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only in minority of cases they express CD20 [133] [128]. Interestingly, HRS cells show decreased 
expression of B cell markers but they frequently express markers typical for other haematopoietic 
cell lineages, such as T cells (CD3, CD4), dendritic cells (fascin, CCL17), myeloid cells (colony-
stimulating factor 1 receptor and α1-antitrypsin), or cytotoxic molecules (granzyme B, perforin) 
[128]. The reason why HRS cells express such diverse markers is a global dysregulation of signalling 
pathways, which either suppress the expression of B cell markers or support expression of other 
immune cell phenotypes. Pathways that are frequently affected in HRS cells include: NF-κB, janus 
kinase (JAK)–STAT, PI3K–AKT, ERK, AP-1, NOTCH 1 and receptor tyrosine kinases [128].   
The expression of such a unique compilation of markers and restricted number of malignant cells in 
the tumour microenvironment made it challenging to establish HRS cell origin [132]. However, the 
advent of new technologies enabled precise analysis of HRS cells, which allowed for cell origin 
determination. Detection of rearranged and somatically mutated immunoglobulin (Ig) V genes in 
dissected HRS cells eventually revealed their B-cell origin, as these genes are highly specific for the 
germinal centre (GC) B cells. Under normal circumstances, the GCB cells that acquire unfavourable 
mutations, rendering Ig V genes non-functional, undergo immediate apoptosis. Even though, HRS 
cells harbour similar mutations they manage to avoid apoptosis and initiate lymphomagenesis. Hence, 
majority of HL cases are of GCB cell origin, and only limited cases (1-2%) with T cell receptor 
rearrangement are of T cell origin [128] [129] [132]. 
In almost 40% of HL cases, the HRS cells are latently infected by Epstein-Barr virus (EBV) [132] 
[128]. Generally, EBV can cause different types of latency, but HRS cells show EBV latency II, 
which is demonstrated by the expression of a set of viral proteins, such as: EBV nuclear antigen 1 
(EBNA1) and latent membrane proteins 1 and 2a (LMP1 and LMP2a). EBNA1 is a prerequisite of 
viral genome replication and is expressed by all EBV-positive cells. It’s been shown that EBNA1 not 
only can down-regulate tumour-suppressor genes, but also upregulate CCL20 to attract Treg cells 
into the HL microenvironment [127]. LMP1 clusters in the cell membrane and acts as CD40 receptor 
which triggers the stimulation of NF-κB and PI3K/AKT pathways. Finally, LMP2a is endowed with 
a cytoplasmic motif, which mimics the ITAM motif of B cell receptor (BCR). As CD40 and BCR 
signalling are critical survival signals for GCB cells, it is speculated that LMP1 and LMP2a can rescue 
B cells with unfavourable mutations from apoptosis by mimicking these signals. Hence, EBV 
infection of GCB cells may provide an explanation as to why and how these crippled B cells survive 
and initiate lymphomagenesis [129] [132] [127]. 
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 The Tumour Microenvironment in HL 
HRS cells represent a small fraction (0.1-2%) of cells found in a typical lymph node of HL patient. 
These malignant cells are embedded into an inflammatory tissue, which consists of different immune 
cell types, including: T cells, macrophages, B cells, mast cells, eosinophils, macrophages, plasma 
cells, and broad connective tissue encompassing fibroblasts and collagen fibres (Figure 1.7).  
 
Figure 1.7: The tumour microenvironment in HL. Figure illustrates a typical tumour microenvironment of the Hodgkin 
lymphoma with scarce number of malignant cells ~2% infiltrated by recruited cells. 
The predominant population in such a lymph node is T cell family, which encompasses different 
subsets, specifically T helper (Th) cells, T reg, and cytotoxic T lymphocytes (CTLs). The first two 
groups promote HRS cells survival and protect them from the anti-tumour immune responses [127] 
[133] [134]. The immune cells are attracted to the tumour microenvironment (TME) by a range of 
cytokines that are secreted by the HRS cells. Specifically, chemokines such as CCL5, CCL17/TARC, 
CCL22/MDC, and IL-5 facilitate recruitment of CD4+ T cells into the tumour milieu. The histological 
sections often show that HRS cells are surrounded by a rosette of T cells, which not only form a 
physical barrier against cytotoxic cells, but also promote the HRS cells survival by various ligand-
receptor interactions, including CD80 and CD40-CD40L. These interactions provide pro-survival 
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signals for HRS cells and protect them from elimination by the immune system [135] [133] [127] 
[134]. Further, secreted by HRS cells CCL5 attracts mast cells and macrophages which are 
immunosuppressive. Importantly, the number of tumour infiltrating macrophages correlates with HL 
patient’s prognosis, as these cells might support the growth of HRS cells and prevent an effective 
immune response towards HRS cells [131] [132].  
Moreover, fibroblasts are a substantial component of the malignant lymph node, and they form typical 
for HL scar tissue. The recruitment of fibroblasts and subsequent formation of fibrosis in the 
neoplastic tissue is driven by the presence of cytokines, such as IL-13, TNFα, TGFβ, and fibroblast 
growth factors. As follows, fibroblasts activated with these cytokines and CD40/CD40L interaction 
contribute to production of diverse cytokines/chemokines including eotaxin and RANTES that attract 
eosinophils or Treg cells and promote proliferation of HRS cells. Furthermore, fibroblasts in the HL 
microenvironment are a source of collagen type I. The interaction between HRS cells and collagen 
has been shown to activate DDR1, a receptor tyrosine kinase (RTK) that is frequently expressed in 
HL and renders malignant cells resistant to apoptosis [132] [129] [136].  
The eosinophils attracted to the tumour microenvironment stimulate CD30L/CD30 interaction with 
HRS cells. A recent study implicates the exosome vesicles in delivering the CD30 molecule to CD30L 
positive cells to stimulate interleukin 8 (IL-8) production. This interleukin, secreted also by HRS 
cells, facilitates attraction of neutrophils [127]. 
The microenvironment in HL represents a unique niche of reactive immune cells, with the malignant 
cells accounting for up to 2% of cells in the affected lymph node. These inflammatory cells are 
recruited to the lymph node to enable interactions with HRS cells, which in turn provides prerequisite 
signals for HRS cells survival and proliferation. The fact that HRS cells thrive in the malignant lymph 
node, while are typically not present in the peripheral blood circulation, further supports the 
importance of the interplay between malignant cells and the tumour infiltrating cells. 
 Immune evasion mechanisms in HL 
As discussed in previous sections, HRS cells rely on the rich inflammatory microenvironment and 
employ a multitude of signalling pathways to support their growth and anti-apoptotic phenotype. 
These malignant cells have also developed an array of immune evasion mechanisms to thrive in the 
tumour microenvironment and avoid an immune attack. 
Over the past years, a range of strategies utilised by HRS cells to suppress anti-tumour activity of 
surrounding immune cell infiltrate were identified. The major component of the malignant lymph 
node – T cells, along with HRS cells secrete immunosuppressive cytokines, such as IL-10 and TGFβ, 
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which inhibit cytotoxic T cell function [128]. The latter molecule is also known to dampen NK cell 
proliferation and cytotoxic activity by down-regulation of activating receptors NKG2D and NKp30 
[137]. Further, HRS cells shape the immunosuppressive microenvironment by direct interactions with 
immune cells. Indeed, HRS cells overexpress a surface molecule FasL that binds to a cognate receptor 
on cytotoxic T cells and induces their apoptosis. Although, HRS cells express Fas receptors on their 
surface, they manage to avoid Fas-induced apoptosis due to overexpression of cellular FADD-like 
interleukin 1β –converting enzyme-inhibitory protein (cFLIP) that inhibits death receptor signalling 
[138]. 
Similarly, galectin-1 is overexpressed on the surface of HRS cells, which can induce apoptosis of 
activated T cells in HL and promote Treg cells mediated suppression [139, 140]. Moreover, galectin-
1 overexpression is associated with reduced infiltration of T cells, whereas blockade of galectin-1 
enhances T cell mediated responses [141]. Furthermore, HRS cells were found to express high level 
of PD-1 ligands, namely PD-L1, and PD-L2. Signalling mediated via PD-1/PD-L1/PD-L2 axis leads 
to T cell exhaustion, which is a reversible state of T cell activation and proliferation inhibition. The 
large body of evidence indicates that upregulation of PD-1 ligands on HRS cells is attributable to the 
amplification of 9p24.1 gene locus. The expression of these ligands is further intensified by the 
enhanced JAK2 signalling typical for HL. Likewise, EBV upregulates expression of PD-L1 through 
LMP1, a molecule that induces JAK-STAT and AP-1 pathways [142] [135] [134]. It has also been 
demonstrated that HRS cells induce PD-L1 expression on TAMs to further enhance the 
immunosuppressive environment [142]. 
Frequent loss of MHC-I molecule is another mechanism that enables HRS cells to escape CD8+ T 
cell surveillance. Several lines of evidence indicate that lack of MHC-I expression and β2-
microglobulin (B2M) at the surface of HRS cells pertains to 80% of HL cases. The gene for B2M, a 
component of the MHC-I complex, carries inactivating mutations in a proportion of cases, which 
explains why the immunohistochemistry stains have shown either a complete loss of MHC-I or 
intracellular accumulation of MHC-I heavy chains. The retention of the MHC-I heavy chains may 
result from the loss of β2-microglobulin expression, which normally assembles the MHC-I molecule 
and transports it to the cell surface.  Similarly, the MHC-II molecule expression is also reduced at the 
surface of HRS cells, which is caused by a recurrent chromosomal translocation of the MHC-II 
transactivator (CIITA). Inactive CIITA gene leads to reduced expression of the MHC-II molecule and 
hampered antigen presentation to CD4+ T cells [134] [132] [143] [144] [145]. 
Conversely, almost 60% of HL cases with the loss of MHC-I expression were found to overexpress 
the non-classical MHC-I molecule HLA-G. The latter is the ligand for inhibitory receptors present on 
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a range of immune cells including NK cells or T cells, and the engagement of these receptors with 
HLA-G may lead to the immune evasion [146, 147]. 
Another immune evasion mechanism employed by HRS cells involves a high expression level of the 
disulphide-isomerase ERp5 and the disintegrin-metalloproteinase ADAM10. These enzymes are 
capable of shedding the ligands for NKG2D, such as MICA and ULBP3, from the cell membrane. As 
a result, HRS cells manage to escape T cell or NK cell mediated cytotoxicity due to the lack of cognate 
ligands for NKG2D. In fact, high levels of soluble NKG2D ligands, in patient’s serum are correlated 
with disease progression in a range of blood cancers, including MM, CLL, NHL, and AML [148].  
Collectively, HRS cells are able to efficiently escape from the host immune attack through various 
mechanisms, including release of chemokines modulating an immunosuppressive microenvironment 
as well as the expression of surface molecules gaining immune privilege through the reduction of 
HRS cell immunogenicity. 
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1.7 AIMS AND HYPOTHESIS 
 Hypothesis 
I. NK cell stimulation involves activation of the IRE1-XBP1 pathway (Aims A and B - Chapter 
3).   
II. Activation of the IRE1-XBP1 pathway is impaired in NK cells of HL patients (Aims C, D, 
and E - Chapter 4).  
 Aims 
The primary aim of this thesis is to determine if and how the IRE1-XBP1 pathway activation is 
associated with NK cell function in the context of HL.  
Aim of chapter 3: 
A. To determine if the IRE1-XBP1 pathway is activated following NK cell stimulation by target 
cell lines representing a range of blood cancers. 
B. To investigate if blockade of the IRE1-XBP1 pathway is relevant for NK cell effector 
function.  
Aim of chapter 4:   
C. To determine if the IRE1-XBP1 pathway is impaired in circulating pNK of pre-therapy HL 
patients. 
D. To characterise in detail, the nature of NK-cell dysfunction and its relationship with the IRE1-
XBP1 pathway in HL. 
E. To test the ability of PD-1 blockade to reverse IRE1-XBP1 pathway associated pNK cell 
dysfunction. 
 
 
 
 
CHAPTER 2: Materials and Methods 
23 
CHAPTER 2: 
Materials and Methods 
 
 
 
 
CHAPTER 2: Materials and Methods 
24 
2.1 ETHICS 
The study protocols used in this thesis were approved by The Translational Research Institute (TRI) 
Human Research Ethics Committee (Brisbane, Australia) and the Princess Alexandra Hospital 
Human Research Ethics Committee (Brisbane, Australia).  Informed consent was obtained from all 
subjects prior to sample collection. 
2.2 STUDY POPULATION 
Table 2.1: Demographic information on Hodgkin lymphoma patients tested in the study. 
Pre‐therapy Hodgkin lymphoma study population 
Age (range)  Sex  Histology  Stage I/IIA vs IIB/III/IV 
  
60% F: 
40% M 
60 % Nodular Sclerosing;    
Median 31 years  10 % Lymphocyte Rich;  40% vs 60% 
(16‐73)  30% Nodular Lymphocyte 
Predominant; 
  
2.3 MEDIA AND BUFFERS 
Foetal Bovine Serum (FBS) (Life Technologies): 
Prior to aliquoting and storage at -20oC, the FBS was heat inactivated at 56°C for 60 minutes. 
Donor Equine Serum (ES) (Hyclone, ThermoFisher Scientific): 
Prior to aliquoting and storage at -20oC, the ES was heat inactivated at 56°C for 60 minutes. 
Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies): 
Medium was supplemented with 100U/mL of Penicillin (Bristol-Myers Squibb), 100µg/ml 
Streptomycin (Bristol-Myers Squibb), and 292µg/ml L-glutamine (Life Technologies) before use. 
R10 Medium  
RPMI (with penicillin/streptomycin/L-glutamine) supplemented with 10% FBS. 
Recombinant human Interleukin-2 (IL-2) (Promega):  
Solution of IL-2 resuspended in RPMI medium at a concentration of 60U/µl.  
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Recombinant human Interleukin-15 (IL-15) (PeproTech): 
Solution of IL-15 at a concentration of 100ng/µl. Stored at -20°C until use. 
Freezing Medium 
80% FBS and 20% dimethyl sulfoxide (DMSO) (Sigma-Aldrich) 
TBE (10×) 
108g Tris, 55g boric acid (Sigma-Aldrich), 40ml 0.5 M Ethylenediaminetetraacetic acid (EDTA) pH 
8 (Sigma-Aldrich), 800ml of MilliQ H2O. Heat and stir with a magnetic stirrer. Use 1X working 
solution (diluted in MilliQ H2O). 
FACS Buffer 
PBS (Life Technologies) supplemented with 2% FBS 
MACS Buffer 
PBS (Life Technologies) supplemented with 0.5% FBS and 2mM EDTA (Sigma-Aldrich) 
Nuclease-Free Water:  
UltraPure™ DNase∕RNase-Free Distilled Water (Life Technologies) 
Agarose Gel 
Appropriate amount of Agarose powder (Sigma-Aldrich) is added to 100mL 1x TBE depending on 
the required percentage of gel. For instance, 2 g is added to 100ml 1x TBE to obtain 2% agarose gel. 
This is then heated in a microwave to dissolve powder.  After cooling down the liquid to ~60C, 5μL 
of SYBR safe DNA gel stain (Life Technologies, Grand Island, USA) is added to 100mL of gel. 
0.5% Paraformaldehyde 
A 1ml of 16% paraformaldehyde (EMS) is added to 31 ml of PBS (Life Technologies) to obtain 0.5% 
paraformaldehyde. 
Buffered glycerol with anti-fade 
A 10ml of 0.2M TRIS buffer (pH 8.0) and 500mg of n-propyl gallate is added to 90ml of 90% 
glycerol. 
CHAPTER 2: Materials and Methods 
26 
2.4 CELL CULTURE AND STORAGE 
 Expansion of SNK10 cell line 
SNK10 cells, kindly provided by Prof Martin Rowe at the Institute for Cancer Studies, Birmingham, 
UK following permission from Dr Norio Shimizu [149]. Cells were cultured at 3 × 105 cells/mL in 
R10 medium with 120U/mL IL-2.  Fresh medium and IL-2 was added to cultures twice a week and 
cells were expanded when confluent. 
 Expansion of KHYG-1 cell line 
KHYG-1 cells, purchased from Japan Collection of Research Bioresources (JCBR) cell bank, were 
cultured at 3 × 105 cells/mL in R10 medium with 100U/mL IL-2.  Fresh medium and IL-2 was added 
to cultures twice a week and cells were expanded when confluent. 
 Expansion of NK-92 cell line 
NK-92 cells, purchased from American Type Culture Collection (ATCC), were cultured at 3 × 105 
cells/mL in RPMI medium supplemented with 12.5% of FBS, 12.5% ES, and 200U/mL IL-2.  Fresh 
medium and IL-2 was added to cultures twice a week and cells were expanded when confluent. 
 Expansion of NK-92 cell line 
NK-92.MI cells, purchased from ATCC, were cultured at 3 × 105 cells/mL in RPMI medium 
supplemented with 12.5% of FBS, 12.5% ES.  Fresh medium was added to cultures twice a week and 
cells were expanded when confluent. 
 Culture of target cell lines 
To assess NK cell effector function the cell lines K562, KM-H2 and HDLM-2 were used. K562 cell 
line was grown in R10 medium which was changed twice a week. KM-H2 and HDLM-2 cell lines 
were grown in R20 medium which was changed twice a week. Cells were expanded when confluent.  
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 Cryopreservation of Cells and Thawing of Cryopreserved cells 
Cells to be cryopreserved were counted and assessed for viability with the use of Trypan Blue stain 
(Sigma-Aldrich).  Subsequently, cells were pelleted at 1500 rpm for 5 min and resuspended at 1 × 107 
cells/mL in freshly made Freezing Medium.  1mL aliquots were added to cryovials (Thermo Fisher 
Scientific) and transferred into a cryo-freezing container (Mr Frosty™; Nalgene, NalgeNunc) that was 
stored at -80oC for 24 hours before being transferred to Liquid Nitrogen for long term storage. 
 Thawing of Cryopreserved cells 
Cryovials containing the frozen cells were removed from liquid nitrogen and transported on dry ice. 
Vials were then immediately placed into a 37oC water bath. Thawed cells were transferred to a 10mL 
tube (BD Biosciences) containing 9ml of warmed R10 medium. Cells were then centrifuged at 
1500rpm for 5min to wash away DMSO. Afterwards, cells were resuspended in an appropriate 
amount of culture medium and transferred into the appropriate culture vessel. 
2.5  PERIPHERAL BLOOD MONONUCLEAR CELLS SAMPLES 
PROCESSING 
Cryovials containing the frozen cells were removed from liquid nitrogen and transported on dry ice. 
Vials were then immediately placed into a 37oC water bath. Once 60-70% of vial content is thawed, 
cells were mixed by pipetting up and down, and transferred to a 10mL tube (BD Biosciences) 
containing 9ml of warmed RPMI medium. Cells were then centrifuged at 1500rpm for 5min to wash 
away DMSO. The washing step was performed twice. Afterwards, cells were resuspended in an 
appropriate amount of culture medium and counted. To break down clumps present in thawed samples 
cells were treated with 200 Kunitz of DNase I (Sigma) for 15 min at 37°C. If clumps persist in the 
sample, cells were then passed through a 70µM mesh cell strainer (Miltenyi Biotec, Germany) into a 
fresh conical tube. The cell suspension was then ready for cell counting and for downstream 
applications. 
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2.6  INHIBITION OF IRE1-XBP1 PATHWAY 
 Inhibition of IRE1-mediated splicing of XBP1 
During ER stress, IRE1 undergoes phosphorylation and excises a 26-nucleotide intron out of XBP1 
mRNA. This leads to a frame shift in the protein's code and results in a production of the active 
protein XBP1s. To interrogate the importance of XBP1 splicing during NK cell-mediated 
cytotoxicity, IRE1-mediated splicing of XBP1 was inhibited with 8-formyl-7-hydroxy-4-
methylcoumarin (4µ8c, Sigma-Aldrich), a potent and selective IRE1α inhibitor. 4μ8C blocks 
substrate access to the active site of IRE1 and selectively inactivates both XBP1 splicing and IRE1-
mediated mRNA degradation [150]. For inhibition in NK cells, 60μM of 4µ8c was added to cultures 
at the same time as target cells. 
 Induction of the Endoplasmic Reticulum stress 
Thapsigargin (TG) is a highly potent and selective inhibitor of calcium dependent ATPases. It 
depletes calcium storage in the ER that leads to subsequent reduction of calcium dependent 
chaperones activity, and in turn contributes to accumulation of unfolded proteins and activation of 
the UPR [151] [152]. NK cells were treated with this molecule at a final concentration of 100nM/ml 
for 2 or 6 hours depending on the assay. For this, cells were cultured in the RPMI medium 
supplemented with appropriate amount of IL-2 (refer to section 2.3).  
  CHECKPOINT BLOCKADE  
 PD-1 blockade assay 
Pembrolizumab is a humanized IgG4К isotype antibody that targets PD-1, a checkpoint inhibitor 
expressed on immune effector cells and implicated in tumour immune-escape mechanisms. 
Pembrolizumab has distinctive immunomodulatory activity and is used in the immunotherapy of 
cancer to enhance cytotoxic activity of effector cells toward cancer cells [153]. For blocking assay, 
NK cells were pre-incubated for 72hrs with this antibody at the final concentration of 10µg/ml. In 
parallel, a batch of NK cells was pre-incubated with human IgG4К isotype control antibody 
(BioLegend) to control for the non-specific binding affinity to cells. 
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2.7  STIMULATION OF NK CELLS 
 Stimulation with target cells – Direct cytotoxicity 
To stimulate SNK10 cells to kill by direct cytotoxicity, NK cells were incubated at a 1:1 ratio with 
K562 target cells.  This ratio was used based on the established protocols within the laboratory.  This 
ratio triggers a powerful NK cell stimulation that allows detection of effector molecules. Stimulation 
was performed in NK cell culture medium as described in section 2.3.  NK cells were stimulated for 
2 hours for RNA extraction unless stated otherwise. For RNA extractions, 3 × 105 NK cells were 
incubated with the same number of target cells.   
Following stimulation with target cells, NK cells were separated from target cells using the NK cell 
isolation kit (Miltenyi Biotec, Germany), as per the manufacturer’s instructions, prior to RNA 
extraction.  Briefly, cells were centrifuged at 1500rpm for 10min and then resuspended in 40μL of 
MACS buffer and 10μL if NK cell biotin-antibody cocktail.  To allow for binding it was incubated 
for 10 min at 4oC prior to addition of a further 30μL of MACS buffer and 20μL of NK cell micro-
bead cocktail.  This was incubated for 15 min at 4oC and after this time, cells were washed in 1mL of 
MACS buffer and centrifuged at 1500rpm for 10 min.  During this spin, LS columns were rinsed with 
3ml of MACS buffer. Pelleted cells were resuspended in 500μL of MACS buffer and applied on the 
prepared column flow through into collection tubes.  Columns were washed with 3ml of MACS 
buffer.  After collection of the flow through, isolated NK cells were centrifuged, supernatant removed, 
and RNA was then extracted. For RNA extraction protocol refer to section 2.8.1. An aliquot of cells 
before and after isolation was collected and NK cell purity was assessed using the flow cytometry. 
On average, the NK cells were demonstrated to be more than 90% pure (Figure 2.1). 
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Figure 2.1: Isolation of Stimulated NK cells using MACS.  SNK10 cells, KHYG-1 cells and NK-92 cells were 
separated from target cells following stimulation using MACS. Purity of isolated NK cells was more than 90% as 
presented on the graph showing NK cell purity before (A) and after isolation (B). 
2.8 GENE EXPRESSION PROFILING 
 RNA extraction – RNeasy Mini Kit 
Total RNA from NK-cells was extracted using the miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. Briefly, cell pellets (3 × 105 cells) were lysed by addition of 700μL of 
QIAzol lysis reagent.  The cell suspension was vortexed for 1 min to homogenize the cells and then 
left on the benchtop for 5 min to facilitate dissociation of nucleoprotein complexes. 140μL of 
chloroform was then added to this homogenised lysate and mixed by vigorous shaking. The 
homogenate was left at the benchtop for another 3 min and then centrifuged for 15 min at 12.000 x g 
at 4°C to separate out the RNA phase. The latter was then transferred to a new tube and admixed with 
1.5 volume of 100% ethanol. The sample was then transferred into a RNeasy Mini spin column and 
centrifuged at 8.000 x g for 15 sec at RT, the flow through was discarded and this was repeated with 
remaining sample.  The column was then washed with 350µl of RWT buffer and centrifuged for 15sec 
at 8.000 x g. Then the RNA bound to the membrane underwent DNase treatment by application of 
80μl of DNase I incubation mix (10μl of DNase I diluted with 70μl RDD buffer, Qiagen) directly on 
the RNeasy Mini Spin Column membrane and incubation for 15 min at RT. After this time the column 
was washed with 350μL of RW1 buffer and twice with 500μL of RPE buffer, centrifuged at 8000×g 
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for 15 sec each time except for the last wash when the column was centrifuged for 2 min to dry out 
the membrane and eliminate the residual ethanol.  Dried columns were then placed in a new 1.5mL 
eppendorf tube and RNA eluted by centrifugation for 2 min at 8000×g to 14μL of RNase-free water. 
RNA quantification was performed using the NanoDrop 2000 spectrophotometer (ThermoFisher 
Scientific). All RNA samples were stored at -80ºC.  
 Random Primed First Strand cDNA Synthesis 
RNA templates were reverse-transcribed to cDNA using SuperScript® III Reverse Transcriptase (Life 
Technologies). For this, 300-1000ng of RNA diluted to 12µl in ultra-pure water (Life Technologies), 
0.5µl of random hexamers (500µg/mL; Promega, Madison, USA) and 1μL of 10mM dNTPs (500μM 
final concentration; Promega) were incubated for 5min at 65ºC and then placed on ice for 2 min. 
Afterwards, the mix was combined with 0.5μL RNasin (40U/mL; Promega), 4μL of 5X first-strand 
buffer, 1μL of 0.1M DTT, and 1μl of Super Script® III Reverse Transcriptase (200U/mL). This 
sample was subjected to the following RT-PCR program: 25˚C 10 min, 50˚C 1hr and 70˚C 15 min 
using the Applied Biosystems 2720 thermocycler. Samples were diluted to receive the final 
concentration of cDNA 2.5 ng/µl. 
 Primers used for PCR analysis 
Primers used for Real Time RT-PCR were designed using Primer3 software 
(http://primer3.wi.mit.edu/).  Primers were designed to amplify 100- 150bp regions within the open 
reading frame of selected genes. Default settings within the Primer3 software were used.  All primers 
were ordered from Integrated DNA Technologies and arrived as lyophilizate. Primers were 
resuspended in Ultra-pure water (Life Technologies) to obtain a stock concentration of 100μM and 
working concentration of 10μM.  A list of primers used can be found in Table 1. 
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Table 2.2: Primers used for Real Time PCR. 
 
Gene 
 
Sequence Forward (5’ to 3’) 
 
Sequence Reverse (5’ to 3’) 
IFNG GAGTGTGGAGACCATCAAGGA CAGCTTTTCGAAGTCATCTCG 
      
GZMB CCCTGGGAAAACACTCACAC TTCGCACTTTCGATCTTCCT 
      
TNF TCTGGGCAGGTCTACTTTGG GGTTGAGGGTGTCTGAAGGA 
      
FASLG ATCCTGAGCCATCGGTGAAA ACCCCTACAATTGCACTGGA 
      
NKG2D ATCGCTGTAGCCATGGGAAT GGAATACAGCACTCCATATTGTT 
      
CD16 TGAGGTGTCACAGCTGGAAG TGAGTGTGGCTTTTGGAATG 
      
XBP1u CGCAGCACTCAGACTACG GAAGGGCATTTGAAGAACAT 
      
XBP1s GAGTCCGCAGCAGGTGC CAAAAGGATATCAGACTCAGAATCTGAA
      
B2M ACTCTCTCTTTCTGGCCTGGAG CATTCTCTGCTGGATGACGTGAG 
      
GAPDH AATCCCATCACCATCTTCCA TGGACTCCACGACGTACTCA 
 
 Real Time RT-PCR 
Gene expression profiling was performed by qPCR using the Roche Light Cycler 480 System. 10μl 
reaction containing 5μl of PowerUp SYBR Green Master Mix (Applied Biosystems by Life 
Technologies), RNase-free H2O, 0.2μM forward and 0.2μM reverse primers, and 5ng of DNA per 
well. Each sample was analysed in triplicate. Samples were then subjected to an initialization step (1 
cycle at 95°C for 10 min), followed by 45 cycles of amplification: denaturation at 95°C for 15sec, 
annealing along with elongation at 60°C for 60sec. Finally, the reaction ended with Melting Curve 
analysis to assess whether SYBR green has produced single, specific products. 
Quantification of samples was determined using the Light Cycler 480 software (Roche) relative 
quantification analysis. Relative quantification analysis provides the relative expression of samples 
compared to a control sample. For all real time analysis in this thesis untreated SNK10 cells were 
used as the control sample.   
Relative expression values given using comparative quantification analysis were normalised to the 
expression of the house-keeping gene B2M to account for slight variations in cDNA concentrations. 
Experiments were repeated three times as indicated in results with technical triplicates and water 
negative controls.   
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2.9  PRIMARY NK CELL EXPANSION 
 Expansion of NK cells from Peripheral Blood Mononuclear Cells 
Primary NK (pNK) cells were expanded from cryopreserved PBMCs. For this, NK-cells were 
stimulated with irradiated feeder lymphoblastoid cell lines (LCL) on day 1 (effector: stimulator ratio 
1:5) and cultured in 24-well flat bottom plates at 1.0 x 106 cells/mL in RPMI 1640 (Gibco, Life 
Technologies) with 10% fetal bovine serum (Gibco, Life Technologies), 100U/mL 
penicillin/streptomycin (Bristol-Myers Squibb), and 100 U/ml IL-2 (Promega), and 10ng/ml IL-15 
(PeproTech) at 37°C in a 5% CO2 incubator. Then every 2-3 days, cultures were supplemented with 
IL-2/IL-15 and re-stimulated with LCL (on day 7-10) at an effector: stimulator ratio 1:5. Expansion 
was typically for 14 days.  
 
Figure 2.2: Primary NK cell expansion assay. On day 1 and then every 2-3 days PBMCs from HL patients were 
stimulated with irradiated LCLs (ratio 1:5) as well as IL-2 and IL-15 to ensure optimal expansion of pNK cells. At the 
end of expansion process, typically on day 14, expanded pNK cells were isolated using NK cell isolation kit and MACS 
column-based system for downstream applications. 
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 Isolation of Expanded NK Cells  
Following expansion of primary NK cells, untouched NK cells were purified using the NK cell 
isolation kit (Miltenyi Biotec, Germany) as per the manufacturer’s instructions.  Briefly, 108 PBMCs 
were centrifuged at 1500rpm for 10min and then resuspended in 400μl MACS buffer and 100μl NK 
cell biotin-Antibody cocktail was added and incubated for 10 min at 4oC. To allow for binding it was 
incubated for 10 min at 4oC prior to addition of a further 300μl of MACS buffer and 200μl of NK cell 
micro-bead cocktail.  This was incubated for 15 min at 4oC and after this time, cells were washed 
with MACS buffer and centrifuged at 1500rpm for 10 min.  During this spin, LS columns were rinsed 
with 3ml of MACS buffer. Pelleted cells were resuspended in MACS buffer and applied on the 
prepared column flow through into collection tubes. Columns were washed with 3ml of MACS 
buffer.  
After collection of the flow through the purity of isolated NK cells was assessed by expression of 
CD3, CD56 and CD16 using the flow cytometry. On average, the CD3-CD56+ NK cells were 
demonstrated to be more than 85% pure. Primary NK cells were then incubated with the anti-PD-1 
or isotype control antibodies prior to the functional assays. 
 FACS-sorting of the primary NK cells 
Following expansion of primary NK cells, NK cells were purified for downstream application (actin 
accumulation assay) by FACS-sorting.  
For this, expanded cells were collected, centrifuged at 1500rpm for 5 min, resuspended in medium 
and counted. Prior the staining, cells were washed with PBS. Cells were stained at density 2x106 
cells/ml. To sort only viable cells, Zombie NIR dye was used to exclude dead cells. Further cells were 
washed with FACS buffer, and a surface staining antibody cocktail containing CD3, CD14, CD19, 
CD16, and CD56 was applied. Prior to sorting, cells were washed twice with FACS buffer and 
resuspended at cell density 1x107 cells/ml in PBS containing 10% FBS. Example of gating strategy 
of pNK cells is presented below on Figure 2.3. 
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Figure 2.3: A gating strategy of FACS sorted pNK cells. Fluorochrome-conjugated surface markers used for the surface 
characterization of the subsets are shown in the respective plot. The initial gate was defined based on forward- and site-
scatter (A), followed by discrimination of doublets using FSC-A and FSC-H (B), as well as SSC-A and SSC-H (C). 
Further dead cells were removed from the analysis using Zombie NIR stain (D). Finally, lineage negative 
(CD3/CD14/CD19) but CD56+ cells were sorted for downstream applications (E). 
2.10 NK CELL ABSOLUTE COUNTS 
To determine the size of NK cell compartment within PBMCs of healthy participants and HL patients, 
the absolute counts of NK cells were calculated. For HL patients, NK cell numbers were back-
calculated by cross-referencing clinical data on the number of lymphocytes and monocytes within 
patient’s peripheral blood at the time of diagnosis with the flow cytometry data obtained for each 
patient. For healthy participants, a set value of 2500 was used as an average number of lymphocytes 
and monocytes in healthy individuals and cross-referenced with the flow cytometry results.  
Briefly, based on flow cytometry data NK cell percentage was calculated as follows:  
𝑁𝐾 𝑐𝑒𝑙𝑙 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 ൌ ሺCounts of CD3-CD56൅ cells/ Counts of Live cellsሻ x 100.   
Then to establish the NK cell counts per µl, flow cytometry data was cross referenced with clinical 
data: 
NK cell counts per µl ൌ ሺNK cell percentage x Counts of Lymphocytes and Monocytesሻ. 
To calculate counts of specific NK cell subsets, information on the percentage of respective subset 
from flow cytometry data was cross referenced with NK cell counts per µl. 
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2.11  FLOW CYTOMETRY 
 Table of Antibodies 
All antibodies used were specific to humans and they are all listed in Table 2.3. 
Table 2.3: List of antibodies used for flow cytometry. 
Marker Clone Fluorophore Dilution Supplier 
CD3 UCHT1 FITC 1:100 BD Pharmingen  
CD14 MɸP9 FITC 1:200 BD Biosciences 
CD19 HIB19 FITC 1:100 BD Biosciences 
CD56 NCAM16.2 BUV395 1:400 BD Biosciences 
CD16 3G8 PE-Cy7 1:400 BD Biosciences 
CD107a H4A3 APC 1:200 BD Biosciences 
IFNϒ B27 APC 1:100 Biolegend 
NKG2D 1D11 APC 1:50 BD Pharmingen  
FASL DX2 BV711 1:100 BD Biosciences 
TNFα Mab11 FITC 1:30 Biolegend 
Granzyme B GB11 Alexa Fluor 700 1:20 BD Biosciences 
PD-1 PD1.3.1.3 PE 1:200 Miltenyi 
PD-L1 MIH1 PE-Cy7 1:30 BD Biosciences 
PD-L2 MIH18 BV711 1:50 BD Biosciences 
XBP1s Q3-695 PE 1:20 BD Biosciences 
CD3 SK7 APC-Cy7 1:50 BD Biosciences 
CD14 MɸP9 APC-H7 1:400 BD Biosciences 
CD19 SJ25C1 APC-H7 1:200 BD Biosciences 
 
 Assessment of cell viability staining 
Cell viability was assessed with the use of Zombie NIR™ Fixable Viability kit (Biolegend).  For this, 
cells were washed in PBS buffer and then resuspended in Zombie NIR™ dye diluted 1 in 2000 in 
PBS buffer (Life Technology). Cells subjected to high temperature by microwaving for 4 sec were 
used as a positive control.  Cells were then incubated in the dark for 15 min at RT and then washed 
with PBS buffer prior to the next staining step. At the end, samples were acquired on the Fortessa 
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X20 (BD Biosciences) and analysed using FlowJo_v10 software (Tree Star Inc., Ashland, USA).  
Gating strategy is presented in Figure 2.4.   
 
Figure 2.4: Live/dead cells gating strategy. Zombie NIR™ Fixable Viability kit was used to distinguish viable cells 
from dead cells. Shown are KHYG-1 cells that were subjected to high temperature to induce cell death. 
 NK Cell-Mediated Killing Assay 
To determine NK cell-mediated killing of target cells, a flow cytometry-based method was used. 
Briefly, pNK cells were enumerated and resuspended at a concentration of 0.5 x 106 cells/ml. 100 μL 
of pNK cells were added to wells of 96-well plate. CTV-labelled target cells were also resuspended 
at 0.5 x 106 cells/ml and 100 μL were added to appropriate wells to obtain a 1:1 effector: target cell 
ratio. For each experiment target controls without effector cells were also seeded. In addition, 5 000 
CountBright counting beads (ThermoFisher) were added to each well to allow for cell number 
calibration. Each experimental condition was performed in triplicate. After 6 hours of incubation at 
37°C, cells were washed with PBS and stained for markers of interest. Flow cytometry was performed 
using the Fortessa X-20 and a minimum of 1 000 events were collected in the beads gate.  
The number of cells in each gate was determined using FlowJo software (Tree Star Inc.). Briefly, 
beads (B) and cells were gated based on forward scatter (FSC) and side scatter (SSC).  The cells were 
then further divided into CTV positive target cells (T) and CTV negative effector cells (E). These raw 
values were then analysed to determine the effectiveness of NK cell-mediated cytotoxicity. Initially 
this involved calibrating each cell value to the number of beads: for calibrated targets (T’) T was 
divided by B. To determine the level of NK cell-mediated killing of target cells, the T’ value of each 
experimental well was divided by the average T’ value of target control wells. This value gave the 
percentage of surviving target cells and the number of cells killed was determined by subtracting this 
value from 1. The reduction in absolute numbers of targets by NK cells was determined by 
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comparison to control wells (targets without effectors) and expressed as a percentage. To determine 
if any observed differences were statistically significant analysis was performed as described in 
section 2.13.   
 Surface Staining 
Flow cytometry was utilised to assess the size of various populations of cells in a sample and 
expression level of diverse markers by specific cell subsets. To identify different populations based 
on expression of various surface markers, cells (1 × 105 to 1 × 106 depending on assay) were washed 
in FACS buffers and resuspended in antibody cocktail diluted with FACS buffer to a total volume of 
100 µl (refer to Table 2) and incubated at 4oC for 20 min in the dark. The optimal antibody amount 
was determined based on titration. Following incubation, cells were washed twice with FACS buffer, 
pelleted (1500rpm/5min), and subjected to the subsequent staining step or resuspended with 300μL 
of FACS buffer prior the acquisition on the flow cytometer. Flow cytometry was performed using the 
Fortessa 20X (BD Biosciences) and analysed using FlowJo_v10 software (Tree Star Inc., Ashland, 
USA). 
 CD107a Staining 
This staining allows for detection of the surface expression of CD107a (LAMP-1) that occurs during 
NK cell degranulation following stimulation. NK cells contain pre-formed cytolytic granules in their 
cytoplasm and these lytic vesicles consisting of perforin and granzymes are contained in lysosomes 
coated with lysosomal-associated membrane proteins (LAMPs). During the process of degranulation, 
the membrane of secretory lysosomes fuses with the plasma membrane of the activated NK cell and 
the lytic granules content is then released at the immunological synapse inducing death of the target 
cells [154].  
To detect CD107a surface expression during NK cell-mediated cytotoxicity, NK cells were incubated 
with target cells at a 1:1 ratio for 1 hour. After this time, CD107a-APC antibody (1/200 dilution) and 
GolgiSTOP (1/1500 dilution, monesin, BD Biosciences) were added to each well. Addition of the 
antibody this early during NK cell activation assay allows for the cumulative amount of CD107a to 
be detected, whereas monensin prevents the re-internalization of the secretory vesicles from the 
surface and allows for the visualization of this marker. Cells were then incubated for a further 5 hours 
and washed twice with FACS buffer prior to being subjected to the next staining step or acquisition 
on the Fortessa X-20 (BD Biosciences). Flow cytometry data were analysed using FlowJo_10 
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software (Tree Star Inc., Ashland, USA). Statistical analysis of changes in CD107a expression was 
done using GraphPad Prism 7 software. 
 Intracellular staining 
Flow cytometry was also used to assess the production of IFNγ, TNFα, Granzyme B (see table 2).  
For this, cells were resuspended in culture media appropriate for tested cells and stimulated with 
target cells at a 1:1 ratio for 1 hour. After this time GolgiPLUG (Brefeldin A, BD Biosciences) was 
added to each well at a 1:1000 final dilution as its component, brefeldin A, prevents the exocytosis 
of cytokines and allows for the visualization of cytokine production following NK cell stimulation. 
Then cells were incubated for further 3 hours (unless stated otherwise).  
At the end of incubation, cells were washed in FACS buffer and subsequently fixed and permeabilised 
by incubating in 100µl of Cytofix/Cytoperm solution (BD Biosciences) for 20 min at 4°C. Cells were 
then washed twice with BD Perm/Wash™ buffer (BD Biosciences), pelleted and resuspended in 
antibody cocktail diluted with BD Perm/Wash™ buffer and left to stain for 30 min at 4oC.  After this 
time cells were washed twice in BD Perm/Wash™ buffer prior to acquisition on the Fortessa-X20 
(BD Biosciences) and analysed using FlowJo_v10 software (Tree Star Inc., Ashland, USA).  Example 
of IFNγ gating strategy can be found in Figure 2.5. Statistical analysis of changes in expression of 
these proteins was done using GraphPad Prism 7 software. 
 
Figure 2.5: Intracellular staining of IFNγ.  Intracellular staining was used to detect any changes in the secretion of 
IFNγ in unstimulated SNK10 cells (A) and during direct cytotoxicity (B). 
 Intranuclear staining  
Upon activation IRE1 excises a 26-nucleotide fragment out of XBP1 mRNA what leads to generation 
of an active transcription factor XBP1s that operates in the nucleus. To detect XBP1s protein in NK 
CHAPTER 2: Materials and Methods 
40 
cells the BD Pharmingen™ Transcription Factor Buffer Set was utilised as it allows for staining of 
intracellular and intranuclear proteins. For this, NK cells were cultured in appropriate medium with 
target cells in a 1:1 ratio for 2 hours (unless stated otherwise). Cells then underwent live/dead staining 
(refer to section 2.11.1) and/or surface staining (refer to section 2.11.2).  
After the cell surface staining procedure was completed, cells were pelleted and resuspended in 150µl 
of freshly prepared 1x Fix/Perm Buffer working solution and incubated at 4°C for 50 min in the dark. 
Then cells were topped up with 100µl of 1x Perm/Wash buffer and centrifuged at 2000rpm at 4°C 
for 5min. After decanting the supernatant cells were washed with 150µl of 1x Perm/Wash buffer and 
pelleted prior to the intracellular staining with 100μl of anti-XBP1s antibody diluted with of 1x 
Perm/Wash buffer at 4°C for 50min in the dark. Cell were then washed twice with 150µl of 1x 
Perm/Wash buffer and pelleted. Prior to acquisition on Fortessa-X20 cells were resuspended in 300μl 
of FACS buffer. Collected data was analysed in the FlowJo_v10 software (Tree Star Inc., Ashland, 
USA). Gating strategy is shown in Figure 2.6. Statistical analysis of changes in XBP1s expression 
was done using GraphPad Prism 7 software. 
 
Figure 2.6: Intranuclear staining of XBP1s. Intranuclear staining was used to detect changes in XBP1s expression in 
unstimulated NK cells (NK-92, A) and during direct cytotoxicity (B). 
 CFSE staining 
To distinguish NK cells from target cells prior to RNA extraction, target cells were pre-stained with 
CFSE dye (Sigma-Aldrich). For this, K562 target cells were pelleted at 1500rpm for 5 min and 
resuspended in 5 ml of RPMI.  An equal volume of CFSE diluted in RPMI (final dilution 1:10000) 
was then added and incubated for 1 min at room temperature. After 1 min cells were pelleted at 
1500rpm for 5 min and washed twice with 5ml of R10 to remove non-incorporated dye. Stained cells 
were then resuspended in R10 and recounted prior to being used for the assay. 
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 Cell trace dyes 
To distinguish NK cells from target cells during the flow cytometry, the CellTrace™ Violet (Life 
Technologies) dye was utilised. Target cells were pre-stained with CellTrace™ Violet dye prior to 
being added to NK cells, since the CellTrace™ dye easily binds to intracellular amines and ensures a 
stable fluorescent staining, cells could be fixed with aldehyde-based fixatives. Prior to the staining 
target cells were counted, pelleted and resuspended at 1x 106 cells/ml in PBS. The CellTrace™ dye 
was then added to cells with the optimal dilution for K562 cell line being 1:5000 and for HDLM-2 or 
KM-H2 cell lines 1:10000. Cells were then incubated for 20 min at 37°C, in the dark. After that time, 
five volumes of R10 medium was added to the cells and incubated for 5 min to remove any free dye 
remaining in the solution. Cells were then pelleted by centrifugation at 15000rpm for 5 min, 
supernatant decanted and pellets were resuspended in fresh medium. Cells were re-counted prior to 
being used in the assay.  
2.12 NK CELL MOTILITY AND IMMUNE SYNAPSE FORMATION  
 Conjugate formation assay 
Formation of a stable conjugate between NK cell and target cell is a prerequisite for their executive 
function as it facilitates signal transduction at the contact site. To substantiate a stable connection 
between NK cell and a target cell the interaction mediated by the integrin LFA-1 on NK cell and 
ICAM on target cell has to occur. The initial interaction between these cells allows for subsequent 
signalling that involves other molecules and ultimately leads to formation of a stable intercellular 
conjugate [155]. 
The cell populations to be tested were pre-stained using nonspecific fluorescent dyes, specifically 
HDLM-2 cells with CellTrace™ Violet at dilution 1:10.000, and KHYG-1 cells with CellTrace™ 
deep red at dilution 1:5.000. Once labelled, 100µl of target cells resuspended to a density of 2x106 
cells/ml is aliquot into FACS tubes, and admixed with a 100µl of NK cells at a density of 1x106 
cells/ml. The E:T ratio of 1:2 was selected as it resulted in optimal number of conjugates. Cells were 
then spun down cells at 20 × g for 1 min and incubated at 37℃ in a water bath for 5, 15, and 30 min 
to allow for conjugation. At the end of each time point, cells were vortexed at high speed for 3sec to 
disperse loosely associated cells, and immediately fixed by adding 300µl of ice-cold 0.5% 
paraformaldehyde. Finally, the conjugates were analysed by flow cytometry to quantitatively measure 
the degree of conjugation. Gating strategy is shown in Figure 2.7 
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The percent of conjugated NK cells was calculated as follows: 
% 𝑜𝑓 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑒𝑑 𝑁𝐾 𝑐𝑒𝑙𝑙𝑠 ൌ double positive countsሺdouble positive counts ൅ NK cell countsሻ 𝑥 100% 
 
Figure 2.7: Gating strategy of NK cell-HRS cell conjugates. KHYG-1 cells were labelled with APC dye and HDLM-
2 cells with CTV dye. The panel shows conjugate formation in the absence (A) or presence of IRE1 blockade (B) upon 5 
mins incubation. The cell counts presented in the top and bottom right quadrants are used to calculate the % of KHYG-1 
cells in conjugates. For instance, 4475/(3336+4475)*100% = 57.3 % and upon IRE1 blockade 4378/(3189+4378)*100% 
= 57.8 %.  
 Actin accumulation assay 
KHYG-1 or FACS-sorted CD3-CD56+ pNK cells (1.5x105) were mixed with HDLM-2 cells (1.5x105, 
pre-stained with cell tracker red, Thermofisher Scientific) and incubated in FACS tubes at 37 C and 
5% CO2 for 15 min. Conjugates were then transferred to silane-coated microscope slides (Electron 
Microscopy Sciences) and incubated for another 15 min at 37 C. After a final incubation of 30 min., 
cells were washed with PBS (Life Technologies) and fixed and permeabilized using 4% Para-
Formaldehyde for 20 min at room temperature. After fixation, coverslips were permeabilized in 
0.25% Triton-X-100 for 5 min. Blocking and antibody dilution were performed in PBS/0.2% 
NaAzide/0.25% BSA. F-actin was stained with Alexa Fluor 488 phalloidin (Life Technologies) for 
30 min. At final stage cells were stained with DAPI for 10 min. Cells were mounted using Menzel-
Glaser 22 mm x 40 mm coverslips (Fisher Scientific) and buffered glycerol with anti-fade mountant 
(Harvard OMX). Between the staining repetitive washing steps were performed with PBS.  
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 NK-cell immune synapse formation analysis  
Confocal microscopy was performed using the Nikon spinning disc confocal microscope. Images 
were collected using the Nikon Plan Fluor 40X objective (NA = 1.3). The NIS-Elements software 
was used for image acquisition. Image sets to be compared were acquired during the same session 
and using the same acquisition settings.  
Quantitative image analyses of conjugates were performed using ImageJ analysis software. 
Quantification of F-actin polarization at the immune synapse was based by random selection of 30 
conjugate images containing an APC–stained HDLM-2 cell in contact with a NK cell. To quantitate 
recruitment of F-actin to the immunological synapse, polarization of actin at the NK cell contact site 
was measured and then scored based on the median thickness of actin for untreated cells. Conjugates 
were thereby stratified into three groups with strong (score=1), moderate (score=0.5), or weak 
(score=0) actin polymerization at the immune synapse site. An overall score for each condition was 
presented as the percentage of conjugates with actin accumulation. Data were plotted using the 
GraphPad Prism 7.0 software. Statistical significance was determined using a Student’s t-test (two-
tailed). 
 NK cell migration 
Transwell assay was used to examine NK cell random migration. Briefly, 1 x 105 KHYG-1 cells with 
pembrolizumab or isotype control in the presence or absence of 60µM of 6-Bromo-2-hydroxy-3-
methoxybenzaldehyde (6-bromo, Sigma-Aldrich) were seeded into 6.5mm transwells with 5.0µM 
pores (Corning) placed in a 24-well tissue culture plate (Corning) and incubated for 5 hours at 37℃ 
(Figure 2.8). Cells were collected and transferred to FACS tubes, spun down, and stained with Zombie 
NIR dye to exclude dead cells from analysis. Prior to acquisition on Fortessa-X20, 10µl of counting 
beads was added to each tube to normalize the number of migrant NK cells to the number of beads.  
Transwell assay was also used to examine NK cell migration. Briefly, 1 x 105 KHYG-1 cells pre-
cultured with pembrolizumab or isotype control in the presence or absence of 60µM of 4µ8c or 6-
bromo were seeded into 6.5mm transwells with 5.0µM pores (Corning) placed in a well, of 24-well 
plate, and incubated for 5 hours at 37℃ (Figure 2.8). Cells were then collected and transferred to 
FACS tubes, spun down and stained with Zombie NIR dye to eliminate dead cells from analysis. Prior 
to acquisition on Fortessa-X20, 10µl of counting beads was added to each tube to normalize the 
number of migrant NK cells to the number of acquired beads.  
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Figure 2.8: A schematic of migration assay. NK cells (KHYG-1 cell line) were seeded at the transwell chamber (A) 
and allowed to migrate within 5 hours to the bottom chamber (B). The number of migrant NK cells was assessed with the 
use of flow cytometry.  
2.13 STATISTICAL ANALYSIS 
All statistical analysis was done using GraphPad Prism 7.00 (GraphPad Software, San Diego, 
California, USA).  Comparison of measurements was done using paired 2-tailed T-tests (except where 
stated otherwise in results). The P values were interpreted as presented in Table 2.4.   
Table 2.4: P values summary. 
P Value Wording Summary 
< 0.001 Extremely significant *** 
0.001 to 0.01 Very significant ** 
0.01 to 0.05 Significant * 
>0.05 Not significant ns 
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3.1  INTRODUCTION 
 NK cell effector function 
Over the last several decades, the importance of NK cells in mediating anti-tumour responses 
has become increasingly recognized [31]. However, limited understanding of the molecular 
signalling and intercellular interactions that control NK cell function hinders development of 
therapies that modulate their function.  
NK cells are a component of the innate arm of the immune system that have the capacity to 
directly kill target cells without prior sensitization [10] [3]. The recognition of target cells by 
NK cells is regulated by the balance between activating and inhibitory signals. Once the 
balance is tilted towards NK cell activation the signalling cascades leading to the target cell 
lysis and cytokine secretion are triggered [23]. The IRE1-XBP1 pathway has important and 
highly diverse contributions to the function of various immune effector cells. It is unknown 
whether the IRE1-XBP1 pathway is a part of these signalling cascades involved in NK cell 
activation. I sought to investigate the role of this pathway in NK cell-mediated anti-tumour 
responses. 
 The NK cell immunological synapse 
NK cell function involves cytoskeleton integrity and capacity to migrate, recognize, and kill 
target cells. A pre-requirement for NK cell-mediated responses is direct contact between NK 
cell and target cells. Upon this interaction, dynamic rearrangements of cellular molecules occur 
that ultimately lead to formation of an organized interface termed the immunological synapse 
[156]. This structure is the site that regulates NK cell functions and allows for direct secretion 
of the lytic granule content onto the target cell to facilitate target cell lysis. However, these 
functions are regulated by a complex network of interactions between membrane proteins, 
cytoskeleton, and signalling pathways. Specifically, the contact between the NK cell and a 
target cell initiates the interactions between various NK cell receptors and adhesion molecules. 
Of importance are integrins that ensure the communication between the intracellular and 
extracellular microenvironments. These molecules transmit “outside-in” signals (such as 
chemokines) received by the surface receptors to mediate cell polarization and chemotaxis. 
Whereas the signals generated in the cytoplasm are transmitted by integrins to the cell surface 
in a process termed “inside-out signalling” that regulates adhesiveness and migration [157]. 
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Lymphocyte function-associated antigen 1 (LFA-1), known also as α, β-integrin or 
CD11a/CD18, plays a fundamental role in NK cell activation, as it mediates binding of NK cell 
to target cell upon engagement of its ligand, intracellular adhesion molecule I (ICAM-1), on 
target cells [158] [159]. Formation of a stable conjugate between NK cell and target cells is a 
key step prior to establishing the immunological synapse and subsequent NK cell-mediated 
cytotoxicity [158]. Cell adhesion, mediated by LFA-1, initiates conformational changes, such 
as actin rearrangements, that are critical for the formation of the immunological synapse. Then, 
to trigger integrin functions, talin which contains binding sites for F-actin, type I 
phosphatidylinositol 4-phosphate 5-kinase (PIPKIγ), and vinculin, is recruited to the IS. In turn, 
talin, through association with vinculin and PIPKIγ, mediates two signalling pathways that 
recruit Arp2/3 and Wiskott Aldrich Syndrome protein (WASP) to the site of LFA-1 ligation 
and induces localized actin polymerization. The actin nucleating protein complex Arp2/3, 
which is responsible for the formation of branched filaments by actin, must be first activated 
by a nucleation promoting factor, and the primary nucleation promoting factor in 
haematopoietic cells is WASP. The latter molecule is polarized to the IS due to localized 
increase of phosphatidylinositol (4,5)-bisphosphate (PIP2) mediated by LFA-1/ICAM-1 
signalling [159]. Actin-regulatory protein WASP is expressed in human NK cells and is 
required for actin accumulation at the immunological synapse [160] [156]. Accumulation of F-
actin in NK cells at the interface of the NK cell and its target cell is an early step denoting the 
formation of an immunological synapse [155]. 
Collectively, signals emanating from activating receptors regulate the affinity and avidity of 
LFA-1 binding of ICAM-1. Also, the interaction between LFA-1 and ICAM-1 stabilizes the 
intercellular adhesion between cytotoxic cells and their targets promoting the delivery of 
cytotoxic granule contents toward susceptible targets [161]. These processes are essential for 
the initiation of NK cell–mediated cytotoxicity [160]. I interrogated the IRE1-XBP1 pathway 
to establish its relevance in the formation of a stable immunological synapse and the 
downstream effector functions mediated by NK cells. 
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3.2 AIMS 
Based on studies in other immune cells, and pre-existing data on NK cells generated in my 
supervisor’s laboratory, I hypothesised that stimulation of NK cells with various blood cancer 
target cells will lead to activation of IRE1-XBP1 pathway. 
The over-arching aim of this chapter was to determine whether activation of the IRE1-XBP1 
pathway occurs, and if so to establish the role of the pathway in specific components of NK 
cell effector function. 
The specific aims of this chapter are: 
1. To determine if the IRE1-XBP1 pathway is activated following NK cell stimulation by 
target cell lines representing a range of blood cancers. 
2. To investigate if blockade of the IRE1-XBP1 pathway is relevant for NK cell effector 
function.  
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3.3  RESULTS 
 XBP1 splicing occurs upon stimulation of NK cells with K562 
As described earlier, the IRE1-XBP1 pathway has been shown to play an important role in a 
range of immune cells [121] [123] [122] [125] [162]. I hypothesized that activation of this 
pathway, defined by increase in the expression of XBP1 spliced isoform, occurs in NK cells in 
response to stimulation with target cells. Based on the previous results from our laboratory, 
XBP1 splicing occurs in SNK10 cells in response to the target cell line K562; the latter is a 
MHC-I-negative erythroleukaemia cell line that is known to be a highly NK cell-sensitive 
target [163]. To confirm as well as extend these data, I compared two additional NK cell lines, 
KHYG-1 and NK-92, with SNK10. The latter line was isolated from a patient with chronic 
active EBV infection [149], while the KHYG-1 cell line was derived from a patient with 
aggressive NK cell leukaemia carrying p53 mutation [164], and the NK-92 cell line was derived 
from a patient with rapidly progressive non-Hodgkin's lymphoma; these cells demonstrate 
characteristics of activated NK cells and have potential use in adoptive immunotherapy [165] 
[166] [167].  
To interrogate XBP1 splicing, NK cells were stimulated with the target cell line K562 in a 1:1 
ratio for 2 hours and then the mRNA or protein expression of XBP1s was assessed (Figure 3.1). 
The mRNA fold change of XBP1s in stimulated SNK10 cells was three times higher than in 
unstimulated SNK10 cells, and the protein has increased two-fold. Furthermore, the XBP1 
splicing also occurred in the other two NK cell lines stimulated with K562 cells. Unexpectedly, 
the increase in the XBP1s mRNA expression was not as prominent in these two cell lines, 
whereas the XBP1s protein expression was significantly higher for KHYG-1 and NK-92 cells 
(11.93% ±0.74; 12.4% ±1.23) than SNK10 cells (4.1% ±0.35). Collectively, these results 
demonstrate that stimulation of NK cells with K562 cells induces XBP1 splicing across 
different NK cell lines. Furthermore, these results suggest a role for the IRE1-XBP-1 pathway 
in NK cell function. 
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Figure 3.1: Stimulation of various NK cell lines induces XBP1 splicing. RT qPCR was utilised to determine 
changes in the XBP1 splicing in unstimulated NK cells and those stimulated with K562 targets (direct 
cytotoxicity) for 2 hours. The expression was normalised to the housekeeping gene B2M and presented as relative 
to expression in unstimulated NK cells (dotted line) (A). Flow cytometry was employed to interrogate changes in 
the protein expression of XBP1s in the same set of unstimulated and simulated NK cell lines (B). A representative 
FACS plot presents changes in the protein expression of XBP1s across different NK cell lines (C). Analysis: 
paired two-tailed Student’s t-test (n=3), *P<0.05, **P<0.01. 
Typically, to ensure successful expansion of NK cell lines in vitro, the culture is supplemented 
with IL-2. To investigate whether the XBP1 splicing is induced by this cytokine, I utilised a 
cell line (NK-92.MI, purchased from ATCC) that is independent of IL-2 supplementation 
because it has been stably transfected with the human IL-2 cDNA retroviral MFG-hIL-2 vector. 
The results indicate that stimulation of these cells with K562 targets induces the XBP1 splicing 
further suggesting that it is not restricted to the presence of exogenous IL-2 (Figure 3.2).  
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Figure 3.2: The XBP1 splicing occurs in an IL-2-independant NK-92.MI cell line. RT qPCR was utilised to 
determine changes in the XBP1u and XBP1s expression in unstimulated NK-92.MI cells and those stimulated 
with K562 targets (direct cytotoxicity) for 2 hours. Real time expression was normalised to the housekeeping gene 
B2M and presented as relative to expression to unstimulated NK-92.MI cells (dotted line).  
 XBP1 splicing is a common marker of NK cell-mediated cytotoxicity  
Next, I sought to determine whether XBP1 splicing occurs following NK cell stimulation 
irrespective of the target cell type. In these experiments, the SNK10 cell line was selected as a 
model NK cell line, whereas target cells were represented by HDLM-2 and KM-H2 lines, both 
HL cell lines. While HDLM-2 cell line does not express MHC-I molecules, the KM-H2 cell 
line expresses following MHC-I molecules: HLA-A, HLA-B, and HLA-C [168]. Given that 
NK cell function is restricted by MHC-I molecules, comparing both HL cell lines enabled me 
to establish whether the presence of MHC-I on target cells imposes any differences in terms of 
the IRE1-XBP1 pathway activation. Initially, SNK10 cells were stimulated with target cells in 
a 1:1 ratio for 2, 4 or 8 hours to determine the optimal stimulation time with HL lines. A time-
course experiment was done to interrogate the transcript expression level. Based on the RT 
qPCR results, XBP1 splicing was optimal at the 8 hours’ time-point, which resulted in an almost 
three-fold increase of XBP1s expression when compared to unstimulated SNK10 cells (Figure 
3.3).  
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Figure 3.3: XBP1 splicing occurs in SNK10 cells following the stimulation with Hodgkin Lymphoma target 
cells. Real time PCR was utilised to determine changes in the XBP1s expression in unstimulated SNK10 cells and 
those stimulated with K562 targets (direct cytotoxicity) for 2, 4, and 8 hours. Real time expression was normalised 
to the housekeeping gene GAPDH and presented relative to expression in unstimulated SNK10 cells (Log2Fc=0). 
Analysis: paired two-tailed Student’s t-test (n=3), ns - not significant, *P<0.05, **P<0.01. 
Next, to evaluate the protein expression, SNK10 cells were stimulated with each target cell 
type in a 1:1 ratio for 8 hours. The stimulation of NK cells with HDLM-2 resulted in significant 
increase of XBP1s protein expression (SKN10: 3.15±1.38%, SNK10+HDLM-2: 14.94±0.49%; 
Figure 4.B/C). Similarly, stimulation of NK cells with KM-H2 cells also induced the XBP1 
splicing (SKN10: 3.15±1.38%, SNK10+HDLM-2: 17.36±1.07%; Figure 3.4.B and C). These 
results indicate that XBP1 splicing occurs in NK cells in a variety of blood cancer (lymphoid 
and leukaemia) lines. 
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Figure 3.4: XBP1s expression increases following the SNK10 cells stimulation with different HL cell lines. 
Real time PCR was utilised to determine changes in the XBP1 splicing in unstimulated NK cells and those 
stimulated with K562 targets (direct cytotoxicity) for 2 hours. The expression is normalised to the housekeeping 
gene GAPDH and presented relative to expression NK cells (dotted line) (A). Flow cytometry was employed to 
interrogate changes in the protein expression of XBP1s in the same set of unstimulated and simulated NK cell 
lines (B). A representative FACS plot presents changes in the protein expression of XBP1s in SNK10 cells in 
response to different target cells (C). Analysis: paired two-tailed Student’s t-test (n=3),***P<0.001. 
 
 The IRE1-XBP1 pathway is activated during NK cell-mediated 
cytotoxicity in a non-canonical manner 
Typically, the ER stress response including activation of the UPR system is initiated by the 
accumulation of unfolded or misfolded proteins in the cell [169]. The UPR system regulates 
the expression of multiple chaperones and molecules involved in the protein folding to alleviate 
the ER stress and restore a cellular homeostasis. These responses are mediated through three 
distinct downstream effector molecules encompassing PERK, ATF6 or IRE1, with the IRE1-
XBP1 pathway representing the most evolutionary conserved branch of the UPR system [170] 
[171]. As demonstrated in the previous section of this chapter, the engagement of target cells 
by NK cells induces XBP1 splicing and leads to the increased expression of XBP1s in NK cells.  
CHAPTER 3: XBP1s activation is associated with appropriate function of NK cells 
54 
To test whether stimulation of NK cells with target cells activates the canonical IRE1-XBP1 
pathway ER stress response, I evaluated the expression of known XBP1 target genes. For this 
RT qPCR was utilised and the transcript expression of DNAJB9, DNAJB11, DNAJC3, PDIA6, 
and DERL1 genes, involved in increased protein folding capacity, were interrogated [150]. To 
do so, the NK cell lines were stimulated with either target cells (K562) or TG, a known inducer 
of ER stress via the canonical IRE1-XBP1 pathway, to establish whether the expression of 
these genes increases along with the induction of XBP1 splicing. Then NK cells were separated 
from target cells, subjected to RNA extraction, followed by RT-PCR. As expected, TG alone 
induced activation of the ER-stress response, as shown by the induced expression of DERL1, 
PDIA6, DNAJC3, DNAJB11, and DNAJB9. Conversely, the mRNA expression analysis 
demonstrated that activation of the IRE1-XBP1 pathway in target-stimulated NK cells did not 
significantly up-regulate the expression of these genes (Figure 5, 6 and, 7). These observations 
were consistent across different NK cell lines. 
 
Figure 3.5: The UPR is not activated during SNK10 cell-mediated cytotoxicity. Real-time PCR analysis was 
utilised to assess the expression of well-described targets of XBP1s including DNAJB9, DNAJB11, DNAJC3 and 
PDIA6. No changes were observed in SNK10 cells alone (unstimulated) or co-cultured with K562 target cells 
(direct cytotoxicity). Real time expression data is normalised to the housekeeping gene B2M and presented relative 
to expression by SNK10 cells treated with TG (dotted line). Analysis: paired two-tailed Student’s t-test (n=3), ns 
- not significant. 
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Figure 3.6: The UPR is not activated during KHYG-1 cell-mediated cytotoxicity. Real-time PCR analysis 
was utilised to assess the expression of well-described targets of XBP1s including DNAJB9, DNAJB11, DNAJC3 
and PDIA6. No changes were observed in KHYG-1 cells alone (unstimulated) or co-cultured with K562 target 
cells (direct cytotoxicity). Real time expression data is normalised to the housekeeping gene B2M and presented 
relative to expression by KHYG-1 cells treated with TG (dotted line). Analysis: paired two-tailed Student’s t-test 
(n=3), ns - not significant. 
 
Figure 3.7: The UPR is not activated during NK-92 cell-mediated cytotoxicity. Real-time PCR analysis was 
utilised to assess the expression of well-described targets of XBP1s including DNAJB9, DNAJB11, DNAJC3 and 
PDIA6. No changes were observed in NK-92 cells alone (unstimulated) or co-cultured with K562 target cells 
(direct cytotoxicity). Real time expression data is normalised to the housekeeping gene B2M and presented relative 
to expression by NK-92 cells treated with TG (dotted line). Analysis: paired two-tailed Student’s t-test (n=3), ns 
- not significant. 
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 XBP1 splicing is effectively blocked in the presence of IRE1 inhibitor 
The small molecule inhibitor, 4-methyl umbelliferone 8-carbaldehyde (4μ8c), has been 
demonstrated to specifically block substrate access to the active site of IRE1, thereby 
preventing XBP1 splicing as well as IRE1-mediated mRNA degradation (RIDD) [150]. 
Further, the application of 4μ8c in MEF cells treated with ER-stress inducer (tunicamycin) 
inhibited cleavage of XBP1 in a dose-dependent manner, with a dose of 64μM showing the 
optimal efficacy [150]. I wanted to investigate whether this small molecule could also inhibit 
IRE1-mediated splicing of XBP1 in NK cells. For this, a range of NK cell lines was stimulated 
with K562 target cells in the presence of 60μM of 4μ8c for 2 hours prior the mRNA or protein 
expression analysis. As expected, the expression of the XBP1s mRNA was significantly 
inhibited upon the IRE1 blockade (Figure 3.8). Importantly, these changes were also reflected 
on the protein level (Figure 3.9).  
 
Figure 3.8: Production of XBP1s RNA is inhibited by 4µ8c. XBP1 splicing was assessed by the RT qPCR. The 
efficacy of IRE1 inhibitor in preventing XBP1 splicing was tested in a range of NK lines: SNK10 cells (A), 
KHYG-1 (B), and NK-92 (C) stimulated with targets (K562) in the presence or absence of IRE1 blockade for 2 
hours. The expression was normalised to the housekeeping gene B2M. Log2 fold-change expression in stimulated 
NK cells over unstimulated NK cells or Log2FC expression in stimulated NK cells in the presence of IRE1 
inhibitor over stimulated NK cells is presented; unstimulated NK cells (Log2FC=0).
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Figure 3.9: Production of XBP1s protein is inhibited in the presence of IRE1 inhibitor 4µ8c. Flow cytometry was utilised to assess XBP1s expression in SNK10 (A), 
KHYG-1 (B), and NK-92 cells (C) in the presence or absence of 60μM of 4µ8c for 2 hours. A representative FACS plot demonstrates changes in XBP1s expression in 
unstimulated NK-92 cells and those stimulated with K562 target cells in the presence or absence or IRE1 inhibitor (D). Analysis: paired two-tailed Student’s t-test (n=3), 
*P<0.05, **P<0.01.         
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 IRE1 inhibitor does not affect cell viability 
Multiple studies have utilised 4µ8c to study the role of the IRE1-XBP1 pathway in various cell 
and disease models. The available literature indicates that 4µ8c is a potent and safe small 
molecule inhibitor that does not affect cell viability [172] [150] [173]. I also determined 
whether treatment of NK cells with this inhibitor impacts the cell survival. Typically, NK cells 
were incubated with 60µM of the IRE1 inhibitor for no longer than 8 hours. Thereby, I 
examined the influence of 60uM of 4µ8c on cell viability by utilising the live/dead staining of 
the NK cells stimulated with target cells in the presence or absence of IRE1 inhibitor for up to 
8 hours. In addition, I also interrogated the target cell compartment to examine if the inhibitor 
affects the viability of these cells.  
I did not find significant changes in NK cell viability following incubation of NK cells in the 
presence of the inhibitor over the course of time (Figure 10). Although a decreasing trend in 
the number of viable cells was observed this did not reach a statistical significance (Figure 
10.B).   
 
Figure 3.10: IRE1 inhibitor, 4µ8c, does not significantly impair NK cell viability. SNK10 cells were treated 
with 60µM of IRE1 inhibitor for 2, 4, and 8 hours prior assessment of the viability with Zombie NIR staining. 
Graphs present percentage of viable cells (A) upon treatment with 4µ8c, as well as distribution of live and dead 
populations in the presence of 4µ8c (C). Analysis: one-way ANOVA test; no significant differences were found. 
Analysis of the target cell compartment revealed that the IRE1 inhibitor also did not 
significantly affect the viability of KM-H2 or HDLM-2 cells (Figure 11). The distribution 
analysis of live and dead cells shows that dead cells were accounting for less than 15% of cells 
at the end of 8 hour-incubation. 
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Figure 3.11: IRE1 inhibitor, 4µ8c, does not significantly impair target cells viability. KM-H2 or HDLM-2 
cells were treated with 60µM of IRE1 inhibitor for 2, 4, and 8 hours prior assessment of the viability with Zombie 
NIR staining. Graphs present percentage of viable KM-H2 (A) or HDLM-2 (C) cells upon treatment with 4µ8c, 
as well as distribution of live and dead KM-H2 (B) or HDLM-2 (D) cells in the presence of 4µ8c. Analysis: one-
way ANOVA test; no significant differences were found. 
 Concomitant with XBP1 splicing, expression of selected NK cell 
effector RNA molecules is increased  
Activation of the IRE1-XBP1 pathway has been linked with enhanced cytokine secretion in 
macrophages and T cells [122] [125]. Despite target cell lysis, NK cells have also a capacity to 
release immunoregulatory cytokines to recruit other immune cells, thereby shaping host’s 
immunity. In addition, NK cell-mediated function is restricted by the balance of activating and 
inhibitory signals received by receptors. To investigate the potential role of XBP1s in NK cell 
effector function I examined the gene expression of a set of established molecules known to be 
important for NK cell function. These molecules can be categorized into three groups 
pertaining to: cytokine production (IFNγ, TNFα), receptor expression (NKG2D, CD16), and 
target cell lysis (GZMB, FASL). To ensure that any potential changes in the expression of these 
genes are observable across different NK cell lines, three NK cell lines were tested: SNK10, 
KHYG-1, and NK-92. For this I utilised RT qPCR, and the gene expression was interrogated 
in the NK lines stimulated with K562 target cells for two hours in the presence or absence of 
IRE1 inhibitor. To ensure that the gene expression analysis encompasses only NK cells, but 
not target cells, at the end of NK cell stimulation target cells were removed by magnetic beads 
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labelling and on-column separation. Additionally, the purity of isolated NK cells was tested 
after each sort (refer to Chapter 2, section 2.8.1). 
Initially, to determine the contribution of the IRE1-XBP1 pathway in cytokine production, 
transcript expression of both IFNγ and TNFα was examined in stimulated NK cells in the 
presence or absence of IRE1 inhibitor. A significant reduction in the expression of both IFNγ 
and TNFα in stimulated NK cells following IRE1 inhibition was observed. This reduction was 
found to be significant for each tested cell line (Figure 3.12 Figure 3.13). The cytokine 
production in both unstimulated NK cells treated with the canonical IRE1- XBP1 ER stress 
inducer (TG) and with (non-canonical) target-stimulated NK cells was significantly up-
regulated, indicating that distinct mechanisms of upregulation are operational. 
 
Figure 3.12: Inhibition of IRE1 reduces IFNγ expression. NK cell lines treated with DMSO, 100nM TG or 
60μM of IRE1 inhibitor were stimulated with K562 targets for 2 hours. RT qPCR was used to assess expression 
of genes encoding interferon γ (IFNγ) in SNK10 cells (A), KHYG-1 cells (B), or NK-92 cells (C). The gene 
expression was normalized to a house-keeping gene B2M and expression of IFNγ relative to unstimulated (unstim) 
NK cells is presented. Analysis: paired two-tailed Student’s t-test (n=3), *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 3.13: Inhibition of IRE1 reduces TNFα expression. NK cell lines treated with DMSO, 100nM TG or 
60μM of IRE1 inhibitor were stimulated with K562 targets for 2 hours. RT qPCR was used to assess expression 
of genes encoding TNFα in SNK10 cells (A), KHYG-1 cells (B), or NK-92 cells (C). The gene expression was 
normalized to a house-keeping gene B2M and expression relative to unstimulated (unstim) NK cells is presented. 
Analysis: paired two-tailed Student’s t-test (n=3), *P<0.05, **P<0.01, ***P<0.001. 
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Then, to address the involvement of the IRE1-XBP1 axis in the production of molecules 
relevant for target cell lysis, I analysed the transcriptional expression of FASL and GZMB. 
Granzyme B (GZMB) is a protease that is a part of the lytic granule content that is released 
onto a target cell during NK cell-mediated cytotoxicity [79]. FASL is also a part of the lytic 
granule content, that induces apoptotic cell death via binding FAS (CD95) present on the 
surface of the target cells [174]. I found that upon the IRE1 blockade in stimulated NK cells 
the transcriptional expression of both molecules was significantly down-regulated, although to 
a different extent (Figure 3.14 and Figure 3.15). Again, pharmacological induction of the ER 
stress also induced the increased expression of FASL and GZMB, but to a different extent than 
stimulation with target cells. In case of the SNK10 cells, the induction of GZMB expression 
upon TG treatment did not lead to a significant increase in its expression. This might result 
from a high level of variation observed between analysed replicates, and there was a non-
significant trend. 
 
Figure 3.14: Inhibition of IRE1 reduces FASL expression. NK cell lines treated with DMSO, 100 nM of TG 
or 60μM of IRE1 inhibitor for 2 hours. RT qPCR was used to assess expression of genes encoding FASL in SNK10 
cells (A), KHYG-1 cells (B), or NK-92 cells (C). The gene expression was normalized to a house-keeping gene 
B2M and expression of FASL relative to unstimulated (unstim) NK cells is presented. Analysis: paired two-tailed 
Student’s t-test (n=3), *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 3.15: Inhibition of IRE1 reduces GZMB expression. NK cell lines treated with DMSO, 100 nM of TG 
or 60μM of IRE1 inhibitor for 2 hours. RT qPCR was used to assess expression of genes encoding GZMB in 
SNK10 cells (A), KHYG-1 cells (B), or NK-92 cells (C). The gene expression was normalized to a house-keeping 
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gene B2M and expression relative to unstimulated (unstim) NK cells is presented. Analysis: paired two-tailed 
Student’s t-test (n=3): ns - not significant, *P<0.05, **P<0.01. 
Lastly, I also assessed the contribution of the IRE1-XBP1 pathway to the expression of the 
activating receptor NKG2D. This revealed that both NKG2D expression is significantly down-
regulated upon inhibition of IRE1 in the majority of NK cell lines tested (Figure 3.16).  
 
Figure 3.16: Inhibition of IRE1 reduces NKG2D expression. NK cell lines treated with DMSO, 100 nM of TG 
or 60μM of IRE1 inhibitor for 2 hours. RT qPCR was used to assess expression of genes encoding NKG2D in 
SNK10 cells (A), KHYG-1 cells (B), or NK-92 cells (C). The gene expression was normalized to a house-keeping 
gene B2M and expression relative to unstimulated (unstim) NK cells is presented. Analysis: paired two-tailed 
Student’s t-test (n=3): ns - not significant, *P<0.05. 
A collective analysis of all tested genes revealed that inhibition of IRE1 with 4µ8c significantly 
impairs expression of IFNγ, TNFα, GZMB, FASL, and NKG2D. Importantly, this observation 
was universal across the majority of tested NK cell lines (Figure 3.17). To establish whether 
inhibition of IRE1 affects NK cell function I decided to investigate the protein expression of 
the same set of molecules. 
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Figure 3.17: The expression of selected genes is affected upon inhibition of IRE1. Gene expression of selected 
genes, relevant for NK cell function, was measured by the RT qPCR. Gene profiling was performed in a range of 
NK cell lines: SNK10 (green tab), KHYG-1 (orange tab), and NK-92 (red tab). Heatmap presents fold changes of 
mRNA expression of these genes in NK cells stimulated with K562 target cells over unstimulated NK cells 
(stimulated - pink) and fold changes of mRNA expression in NK cells stimulated with K562 target cells in the 
presence of the IRE1 blockade over NK cells stimulated with K562 target cells (inhibited - black). The gene 
expression was normalized to a house-keeping gene B2M. Unsupervised clustering was performed, and fold 
changes are presented as z-scores. 
 Inhibition of IRE1 impairs cytokine protein secretion 
Based on the gene expression data I decided to examine the protein expression of the same set 
of molecules, i.e. IFNγ, TNFα, FASL, GZMB, and NKG2D, to establish the contribution of 
the IRE1-XBP1 axis in NK cell effector functions. For this, either unstimulated NK cells or 
NK cells stimulated with target cells (K562) in the presence or absence of IRE1 inhibitor were 
examined. Typically, NK cells (SNK10/KHYG-1/NK-92) were stimulated for 2 hours with 
target cells, except for the analysis of intracellular proteins such as IFNγ, TNFα, and GZMB, 
where the cells were incubated for 4 hours to allow for accumulation and subsequent detection 
of tested proteins. The fold change of protein expression in stimulated NK cells over 
unstimulated and in stimulated NK cells in the presence of the IRE1 inhibitor over stimulated 
NK cells was interrogated to enable direct comparison with the transcriptome expression. The 
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protein expression analysis encompasses the percentages of the cells expressing certain protein 
as well as the mean fluorescence intensity (MFI) data to enable a comprehensive analysis. The 
percentages of a protein expression provide the information on the distribution of the protein 
expression within a cell population, while the MFI provides the information on the level of the 
expression in the proportion of cells that do express the protein. Altogether, I observed that 
inhibition of the IRE1 altered the expression of all tested molecules, depending on a tested 
molecule it either caused an up- or down-regulation of the protein expression.  
The most prominent down-regulation following the IRE1 inhibition in SNK10 cells was 
observed in the expression of both IFNγ and TNFα, notably this observation was consistent 
between the percentages and MFI (Figure 3.18). A similar trend was observed for GZMB. 
While the fold change of the FASL-expressing cells did not change significantly upon the IRE1 
blockade, the amount of the protein expression within a positive population significantly 
increased. A consistent increasing trend following the IRE1 inhibition was observed in the 
NKG2D expression (Figure 19).  
The analysis of the protein expression data in the KHYG-1 cells revealed that IFNγ and TNFα 
were also the molecules which expression was significantly impaired upon the IRE1 inhibition. 
Similarly, the expression of NKG2D was also impaired in KHYG-1 cells treated with the IRE1 
inhibitor, and this observation refers to both the percentages and MFI analysis. Even though, 
the inhibition of the IRE1 did not induce significant changes in FASL and GZMB, expression 
as demonstrated in the analysis of percentages, a decreasing trend in the level of their 
expression was observed in the MFI analysis (Figure 3.19).  
Finally, the analysis of the protein expression in NK-92 cells following the IRE1 inhibition 
indicates that the cytokine secretion demonstrated a decreasing trend, but a great level of 
variation observed in the TNFα expression contributed to the lack of statistical significance 
(Figure 3.20). The analysis of the FASL, GZMB and NKG2D molecules expression indicates 
that following the IRE1 inhibition their expression decreases, and this observation applies to 
both frequencies and MFI expression. Unexpectedly, the analysis of GZMB expression shows 
an inconsistent trend between the fold change of the percentages and the MFI, with the latter 
one exerting an increasing trend. 
In summary, a consistent decreasing trend following the IRE1 inhibition was observed across 
all tested cell lines in the expression of IFNγ and TNFα. Although NKG2D expression was 
also significantly impaired following the IRE1 blockade, this observation was restricted to the 
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KHYG-1 and NK-92 cells, but not SNK10. Whereas the remaining molecules exerted a lot of 
variation trend-wise (increasing vs decreasing) and cell line-wise. Collectively, the gene and 
protein expression data suggest that the cytokine secretion is significantly affected in various 
NK cell lines following the IRE1 inhibition and these changes are consistently detectable at 
both mRNA and protein level.  
 
Figure 3.18: Inhibition of IRE1 impairs expression of selected effector molecules in SNK10 cells. Flow 
cytometry was utilised to assess the protein expression in SNK10 cells. Protein expression was assessed in 
unstimulated SNK10 cells and SNK10 cells treated with DMSO or 60μM of IRE1 inhibitor and stimulated with 
K562 targets (direct cytotoxicity). The graphs present fold change in protein expression in stimulated SNK10 cells 
over unstimulated cells and in IRE1 treated stimulated cells over stimulated cells based on the percentage (A) or 
the MFI (B) expression. Analysis: paired two-tailed Student’s t-test (n=3), ns - not significant, *P<0.05, 
**P<0.01, ***P<0.001. 
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Figure 3.19: Inhibition of IRE1 impairs expression of selected effector molecules in KHYG-1 cells. Flow 
cytometry was utilised to assess the protein expression in KHYG-1 cells. Protein expression was assessed in 
unstimulated KHYG-1 cells and KHYG-1 cells treated with DMSO or 60μM of IRE1 inhibitor and stimulated 
with K562 targets (direct cytotoxicity). The graphs present fold change in protein expression in stimulated KHYG-
1 cells over unstimulated cells and in IRE1 treated stimulated cells over stimulated cells based on the percentage 
(A) or the MFI (B) expression. Analysis: paired two-tailed Student’s t-test (n=3), ns - not significant, *P<0.05, 
**P<0.01, ***P<0.001. 
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Figure 3.20: Inhibition of IRE1 impairs expression of selected effector molecules in NK-92 cells. Flow 
cytometry was utilised to assess the protein expression in NK-92 cells. Protein expression was assessed in 
unstimulated NK-92 cells and NK-92 cells treated with DMSO or 60μM of IRE1 inhibitor and stimulated with 
K562 targets (direct cytotoxicity). The graphs present fold change in protein expression in stimulated NK-92 cells 
over unstimulated cells and in IRE1 treated stimulated cells over stimulated cells based on the percentage (A) or 
the MFI (B) expression. Analysis: paired two-tailed Student’s t-test (n=3), ns - not significant, *P<0.05, 
**P<0.01. 
 Activation of the IRE1-XBP1 pathway is associated with increased 
expression of cytokine proteins 
NK cell function involves target cell lysis and cytokine secretion to recruit other immune cells 
to the immune response. Based on the compiled analysis of the gene and protein expression 
data in stimulated NK cell lines, I selected molecules that were down-regulated following IRE1 
blockade at both the mRNA and protein level, to be further examined. The molecules selected 
for this analysis include the cytokines i.e. IFNγ and TNFα. I sought to determine whether 
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stimulation of NK cells with various target cells induces similar responses. To do so, I utilized 
SNK10 cell line as NK cell model and three types of target cells such as K562, KM-H2, and 
HDLM-2. Notably, KM-H2 cell line expresses MHC-I molecules, while the other two cell 
lines, HDLM-2 and K562, do not express such molecules. For this, NK cells were stimulated 
with appropriate target cell type in a 1:1 ratio for a total of 6 hours in the presence or absence 
of IRE1 inhibitor.  
I noticed that IFNγ expression is significantly reduced upon IRE1 blockade, with the most 
prominent reduction of its expression in response to HDLM-2 cells. Similar rate of IFNγ 
secretion impairment was observed in response to K562 cells, and the lowest decrease in 
response to KM-H2 cells (Figure 3.21). In line with these observations, HDLM-2 cells induced 
the strongest secretion of IFNγ, K562 cells moderate, while KM-H2 cell the weakest. These 
differences may stem from the phenotypic differences across target cell types, including 
presence of MHC-I on KM-H2 cells. Nevertheless, the inhibition of IFNγ secretion occurs in 
response to all three target cell types but to a different extent.  
Interestingly, I observed similar response trends with regards to TNFα secretion. Particularly, 
the strongest response was induced by HDLM-2 cells, then by K562 cells, and the weakest by 
KM-H2 cells (Figure 3.22). Whereas following the inhibition of the IRE1 the secretion of 
TNFα was significantly reduced in stimulated NK cells with each of tested target cells. 
Altogether, the experiments presented in this section suggest that activation of the IRE1-XBP1 
signalling pathway by the innate immune system in NK cells is required for the optimal 
secretion of cytokines such as IFNγ and TNFα. 
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Figure 3.21: Inhibition of the IRE1 impairs IFNγ secretion by NK cells stimulated with different target cells. Flow cytometry was utilised to assess the protein expression 
in SNK10 cells in response to K562, HDLM-2 or KM-H2 cells. Protein expression was assessed in unstimulated SNK10 cells and SNK10 cells treated with DMSO or 60μM 
of IRE1 inhibitor and stimulated with K562 targets (direct cytotoxicity). The graphs present a representative plot showing IFNγ protein expression in SNK10 cells (A). 
Representative histograms are shown (B). Green line: SNK10 cells following stimulation, orange line: SNK10 cells following stimulation in the presence of 60μM IRE1 
inhibitor, grey line: unstimulated SNK10 cells. Changes in the percent of IFNγ producing cells (C) and the relative amounts of IFNγ being produced (D) was analysed. Analysis: 
paired two-tailed Student’s t-test (n=3), *P<0.05, **P<0.01, ***P<0.001. 
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Figure 3.22: Inhibition of the IRE1 impairs TNFα secretion by NK cells stimulated with different target cells. Flow cytometry was utilised to assess the protein expression 
in SNK10 cells in response to K562, HDLM-2 or KM-H2 cells. Protein expression was assessed in unstimulated SNK10 cells and SNK10 cells treated with DMSO or 60μM 
of IRE1 inhibitor and stimulated with K562 targets (direct cytotoxicity). The graphs present a representative plot showing TNFα protein expression in SNK10 cells (A). 
Representative histograms are shown (B). Green line: SNK10 cells following stimulation, orange line: SNK10 cells following stimulation in the presence of 60μM IRE1 
inhibitor, grey line: unstimulated SNK10 cells. Changes in the percent of IFNγ producing cells (C) and the relative amounts of TNFα being produced (D) was analysed. 
Analysis: paired two-tailed Student’s t-test (n=3), *P<0.05, **P<0.01, ***P<0.001. 
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 Inhibition of XBP1 splicing does not affect NK cell-target cell conjugate 
formation 
One of the earliest events in the immunological synapse formation process is the conjugation of the 
NK cell with a target cell. The adhesion of these two cells, which is a part of the pre-effector stage of 
the immune synapse formation, initiates a signalling cascade that triggers downstream conformational 
changes in NK cell leading to the NK cell-mediated anti-tumour responses [158]. I sought to 
determine whether the IRE1-XBP1 pathway is required for the NK cell-mediated conjugate 
formation. A model NK cell line KHYG-1 was employed to assess the ability of NK cells to form 
conjugates with HDLM-2 target cells. For this NK cells were mixed with target cells and incubated 
for up to 30 minutes in the presence or absence of IRE1 blockade to allow for the conjugate formation. 
At the end cells were fixed and analysed by flow cytometry to determine the percentage of conjugated 
NK cells in the presence or absence of IRE1 blockade (Figure 3.23). Unexpectedly, NK cells did not 
display a significant reduction in conjugate formation with HDLM-2 cells in the presence of IRE1 
blockade (Figure 3.24). Therefore, the IRE1-XBP1 pathway does not appear to be required for the 
NK cell-mediated conjugation of target cells.  
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Figure 3.23: The number of NK cells-HRS cells conjugates is not affected by IRE1 blockade. Contour plots show 
the percentage of collected events within the double-positive gate (Q2) denoting conjugates between Cell Tracker Violet 
(CTV)-labelled HDLM2 cells and Cell Tracker Red (APC)-labelled KHYG-1 cells formed after 5 (A), 15 (B), and 30 (C) 
minutes of incubation in the presence or absence of IRE1 blockade.  
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Figure 3.24: Inhibition of IRE1 does not affect the adhesion of NK cells to target cells is not affected. Flow cytometry 
was utilised to determine the number of conjugates formed between NK cells and HRS cells that were co-cultured for 5, 
15, and 30 minutes and fixed prior to acquisition on the FACS. The graph shows percentages of conjugates formed 
between NK cells (KHYG-1) and HRS cells (HDLM-2) over time. Analysis: paired two-tailed Student’s t-test (n=3), ns 
- not significant. 
 Inhibition of XBP1 splicing impairs actin polarization at the NK cell 
immune synapse interface 
To execute cytolytic function NK cells need to engage with a target cell to establish an immunological 
synapse (IS). Upon recognition of a target cell, a cytoskeleton rearrangement involving F-actin 
polymerization is an event that is a prerequisite step in the formation of the IS. I examined the IS 
formed between the KHYG-1 NK cell line and the HRS cell line (HDLM-2) in the presence and 
absence of the IRE1 inhibitor. To test this, conjugates formed (within 30 mins) between NK cells and 
HRS cells, were examined for the distribution of F-actin after staining with phalloidin. The extent of 
actin polymerization in NK cell conjugates was compared between untreated and treated with 4µ8c 
cells by quantitative analysis of fixed conjugates images taken by confocal microscopy. As expected, 
quantification of F-actin polymerization at the NK cell–HRS cell contact site showed that most 
conjugates, where NK cells were treated with 4µ8c, exhibited a weak band of F-actin at the immune 
synapse in comparison to the untreated cells (Figure 3.25). These data demonstrate that inhibition of 
the IRE1-XBP1 pathway in NK cells results in impaired actin polarization at the IS interface, 
indicating formation of a greater number of less stable conjugates.  
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Figure 3.25: IRE1 blockade impairs NK cell immune synapse formation with HRS cells. NK cells were allowed to 
conjugate with an HRS cell line HDLM-2 for 30 min in the presence or absence of IRE1 inhibitor. Conjugates were then 
fixed, stained, and scored for F-actin (phalloidin, green) polarization at the NK cell immune synapse. Data are the mean 
± SD from 3 independent experiments with 30 conjugates analysed per experiment. Representative images of NK cell 
synapse formation between KHYG-1 (DAPI, blue) and HRS cells (APC, red) are shown (B). Arrows indicate actin 
accumulation at the NK cell–HRS synapse site imaged with the Nikon spinning disc confocal microscope. Original 
magnification ×63. Statistical differences between experimental groups were evaluated by unpaired Student’s t-test (n=3), 
*P<0.05. 
 Inhibition of IRE1 impairs NK cell migration 
A prerequisite for NK cell-mediated surveillance is their cytoskeleton integrity and ability to migrate 
to remove malignant cells from the microenvironment. This aspect of NK cell function is controlled 
not only by the composition of chemokines present in the NK cell microenvironment, but also 
intracellular modulation of cytoskeleton required for NK cell to migration toward target cells. To 
determine whether IRE1 blockade affects NK cell migration, the NK cell line (KHYG-1) was seeded 
onto the migration chamber and incubated for 5hrs in the presence or absence of the IRE1 blockade. 
Addition of the IRE1 inhibitor impaired the migration of KHYG-1 cells which is demonstrated by a 
significant reduction in the number of cells which migrated through the transwell after 5 hours of 
incubation (Figure 3.26).   
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Figure 3.26: IRE1 blockade impairs migration of NK cells. NK cell line, KHYG-1, in the presence of IRE1 blockade 
or DMSO control, was seeded onto a transwell chamber with 5µM pore-size and incubated for 5 hours to allow cell 
migration to the bottom well containing medium (migration) (A). Migrant cells were collected from the well, stained, and 
analysed by the flow cytometry. The fold change of migrant cells treated with IRE1 inhibitor over untreated cells (DMSO 
control) are presented (B). Statistical differences between experimental groups were evaluated by paired Student’s t-test 
(n=3), **P<0.01. 
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 Summary of results 
The main aim of this chapter was to determine whether stimulation of NK cells with various target 
cells induces XBP1 splicing that is a marker of the IRE1-XBP1 pathway activation. Consistent with 
the previous results generated in my supervisor’s laboratory, it was demonstrated that stimulation of 
the SNK10 NK cell line with K562 leads to XBP1 splicing. In addition, it was found that the XBP1 
splicing occurs in two other NK cell lines, KHYG-1 and NK-92, upon the simulation with the same 
target cells. Interestingly, XBP1 splicing was also demonstrated to occur, in response to activation by 
HL target cell lines suggesting that it may be a general response of NK cells to stimulation with 
malignant target cells. Further, I have demonstrated that, although XBP1 is spliced in NK cells 
following addition of target cells, this appears to be independent of the canonical UPR system. Next, 
I have demonstrated that the IRE1-mediated splicing of XBP1 can be successfully inhibited using a 
small molecule inhibitor in stimulated NK cells. Subsequently, activation of the IRE1-XBP1 
pathway, through stimulation with various target cells, was associated with the increased 
transcriptome and protein expression of cytokines such as IFNγ and TNFα. Notably, their expression 
was significantly down-regulated upon the IRE1 blockade indicating that the IRE1-XBP1 pathway is 
required for optimal secretion of these cytokines. In addition, I demonstrated that inhibition of XBP1 
splicing significantly impairs NK cell migration. While application of this inhibitor did not affect NK 
cell adhesion to target cells, it impaired polarization of actin at the interphase of the IS indicating that 
XBP1s is critical for the IS formation.  
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3.4  DISCUSSION 
 XBP1 splicing occurs following NK cell activation 
Here I demonstrate that activation of the IRE1-XBP1 pathway via the contact-dependent interaction 
between NK cell and target cell leads to the optimal NK cell function involving migration, target 
cell recognition, and cytokine secretion. My findings suggest that NK cells utilize the IRE1-XBP1 
pathway, the most conserved branch of the UPR system, to ensure optimal recognition and response 
to target cells. Indeed, XBP1s is one of the most promising targets of the UPR pathway in cancer 
therapy e.g. in MM, where XBP1s promotes growth and survival of malignant cells[175], its high 
expression is a favourable prognosticator in patients treated with bortezomib [176] [177]. I show 
that activation of this pathway is involved in NK cell effector function, suggesting that targeting 
the pathway via proteasome inhibitors such as bortezomib (an agent typically used in MM) may 
potentially have adverse off target effects on innate immunity. 
The IRE1-XBP1 pathway has been extensively studied in a range of immune cells and diseases. 
Activation of this pathway i.e. detection of the XBP1 splicing and its importance for the immune cell 
functions was first demonstrated in plasma cells. It was shown that XBP1s is required for 
differentiation of B cells into plasma cells [121]. This discovery was followed by a series of studies 
investigating the IRE1-XBP1 pathway in other immune cells including T cells, macrophages, 
dendritic cells and eosinophils in a diverse array of diseases [123] [178] [122] [125] [162] [124]. A 
large body of evidence demonstrates that activation of the IRE1-XBP1 pathway is initiated via 
different mechanisms and is highly context-specific. I found that XBP1 splicing occurs also in a range 
of NK cell lines stimulated with leukemia or lymphoma target cells.  
In macrophages, TLR signalling induces the IRE1-mediated XBP1 splicing without triggering the 
canonical UPR [122]. In line with this finding, the induction of XBP1 splicing in stimulated NK cells, 
was not associated with increased expression of well-described target genes of XBP1s. This 
observation suggests that the IRE1-XBP1 pathway operates in NK cells outside of the canonical UPR. 
Conversely, in a study conducted in NK cells from patients with a type 2 diabetes (T2D), in whom 
high level of glucose triggers the ER stress, it was found that a range of ER stress related molecules 
including XBP1s is upregulated. This observation was associated with alterations in NK cell 
phenotype i.e. reduced expression of NKG2D [179].   
Multiple studies have shown that a small molecule inhibitor known as 4µ8c, which specifically targets 
the RNase activity of IRE1, efficiently inhibits IRE1-mediated splicing of XBP1 in different cell types 
[150] [176] [180]. To interrogate the role of IRE1-XBP1 pathway in NK cells, I also employed this 
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small molecule inhibitor. Consistent with previous findings, application of 4µ8c in stimulated NK 
cells successfully inhibited XBP1 splicing, as demonstrated by reduced expression of XBP1s, both 
mRNA and protein. 
 XBP1s is required for NK cell effector function 
As mentioned previously, Martinon et al. have demonstrated in an elegant study that the IRE1-XBP1 
pathway is activated in macrophages in an uncanonical manner. Further, XBP1s was shown to 
directly regulate expression of selected cytokines, amongst them TNFα, through binding to their 
promoter regions, thereby contributing to their optimal secretion [122]. Similarly, I also observed that 
activation of the IRE1-XBP1 pathway is associated with optimal production of TNFα and IFNγ by 
NK cells in response to various target cells. Notably, following the IRE1 inhibition the expression of 
these cytokines was consistently affected, both on mRNA and protein level. Conversely, in the study 
of the ovarian cancer it was demonstrated that activation of the IRE1-XBP1 pathway was associated 
with impaired secretion of IFNγ by T cells [126]. Whereas, in a study involving T helper cells, it was 
found that inhibition of the IRE1 with a small molecule inhibitor did not affect IFNγ secretion but it 
significantly reduced IL-4 production [181].  
A recent study reported that suppression of XBP1 splicing is associated with impaired migration of 
endothelial cells (EC). Damaging the endothelium led to increased expression of XBP1s that 
interacted with endothelial nitric oxide synthase (eNOS) to contribute to enhance migration of EC 
[182]. Interestingly, I also found that inhibition of IRE1, i.e. suppression of XBP1 splicing, 
significantly impairs migration of NK cell line KHYG-1.  
Dejeans et al. in their study demonstrated that impairment in IRE1 activity is associated with 
improved adhesion and migration of glioma cells. It was shown that IRE1 directly regulates 
expression of SPARC via regulated IRE1-dependent decay of mRNA (RIDD) mechanisms. In the 
event of the IRE1 inactivity the expression of extracellular matrix protein SPARC increases and 
contributes to changes in glioma cell adhesion and migration [183]. I did not observe any changes in 
NK cell-mediated adhesion to target cells, but I noticed that in the presence of the IRE1 inhibitor the 
accumulation of actin at the IS interphase is significantly impaired, which suggests that formed 
conjugates are less stable. However, the exact mechanism of action is yet to be established. 
 Conclusion 
In this study I present data showing that XBP1 splicing occurs following NK cell stimulation with 
leukaemia and HL MHC-I intact and deficient target cells, and it appears that XBP1s is acting outside 
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of a canonical UPR system. Next, I successfully inhibited XBP1 splicing in stimulated NK cells to 
enable interrogation of the IRE1-XBP1 pathway and its relationship with NK cell effector function. 
Specifically, the inhibition of the IRE1-mediated splicing of XBP1 affected the expression of 
cytokines known to be secreted by NK cells, including cytokines that have not previously been linked 
to the IRE1-XBP1 pathway. In concordance with the gene expression profile the analysis of protein 
levels of these cytokines indicated that upon IRE1 inhibition the expression decreases. These results 
suggest that XBP1s may have a key role in cytokine production by NK cells and subsequent 
recruitment of immune cells to potentiate anti-tumour responses. Further, I also show that NK cell 
migration and immune synapse formation with blood cancer target cells is significantly impaired in 
the presence of an IRE1 inhibitor. 
Collectively, I demonstrate a novel role of XBP1s during NK cell-mediated cytotoxicity in migration, 
formation of the immune synapse, and cytokine secretion by NK cells. To place these findings within 
a translational context, my next step was to determine if this pathway is dysfunctional in NK cells 
from patients with HL. 
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4.1 INTRODUCTION 
 The IRE1-XBP1 pathway in blood cancers 
XBP1s is an important transcription factor involved in the UPR signalling pathway. Under conditions 
of ER stress, XBP1 is activated through unconventional splicing by IRE1, excising a 26-nucleotide 
intron from its mRNA [118] [117] [109]. Removal of this intron causes a frame shift in the open 
reading frame, resulting in a 376-amino acid long protein with an alternate carboxy-terminus 
containing a transactivation domain (XBP1s). XBP1s then translocates to the nucleus where it binds 
the ER stress responsive element to cause an increase in transcription of chaperones and to the UPR 
element resulting in increased transcription of genes involved in protein degradation [170] [169]. A 
requirement for XBP1s during a healthy immune response was first recognized when XBP1s was 
identified as an essential transcription factor for plasma cell differentiation [121]. Since then, XBP1s 
has been demonstrated to be involved in both innate and adaptive immune responses [121] [184] 
[120] [123] [125] [122].  
The research on the IRE1-XBP1 pathway in the context of HL is sparse. In a study by Maestro et al., 
an immunohistochemistry assay was implemented to assess expression pattern of XBP1s in various 
lymphomas. While high expression of XBP1s was detected in plasmablastic DLBCL (64% of positive 
cases) and myeloma (100% positive cases), none of the tested HL cases expressed XBP1s [185].  
Furthermore, it was established that GCB DLBCL are characterised by a defective IRE1-XBP1 
pathway with reduced expression of IRE1 that prevents activation of XBP1. Importantly, it was 
demonstrated that reconstitution of the pathway in GCB DLBCL reduced tumour growth in a mouse 
xenograft model. In contrast, in the setting of multiple myeloma the IRE1-XBP1 pathway is 
implicated in a tumour-promoting role [186] [175]. These data emphasise a critical role of the IRE1-
XBP1 pathway in malignancies and indicate that it can either contribute to tumour promotion or 
tumour suppression. 
Although XBP1s is required for the function of specific immune cell subsets (e.g. plasma cells and 
macrophages), and for the differentiation and/or maturation of others (e.g. plasma cells, DCs and T 
cells), its role in NK cells has not been explored. In the previous chapters, I demonstrated a 
requirement for XBP1s during healthy NK cell effector function to ensure an optimal response against 
target cells. The malignant cells in HL are known to significantly affect the function of immune cells 
infiltrate in the TME. I sought to determine whether the IRE1-XBP1 pathway is dysregulated in 
circulating NK cells of patients with HL.  
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In the setting of HL, the lack of MHC-I expression on HRS cells prevents T cells from mounting 
effective anti-tumour responses. Nevertheless, HRS cells are amenable to NK cell-mediated 
cytotoxicity as their function is not restricted by MHC-I are able to instigate such responses. To 
investigate the function of NK cells in patients with HL I sought to investigate whether the IRE1-
XBP1 pathway is operative to ensure NK cells anti-tumour capacity is optimal.  
 NK cells in Hodgkin lymphoma 
NK cells represent an attractive component of host immunity to eliminate cancer cells as they are able 
to respond to tumour cells without previous sensitization [10]. Indeed, a longitudinal study of healthy 
participants, examining NK cell cytotoxic activity and cancer incidence, found an inverse association 
between NK cell cytolytic activity and the subsequent development of cancer [86].  
To execute their function, NK cells form an immunological synapse with a target cell to either mediate 
target cell death or secrete immunoregulatory cytokines. The outcome of this interaction is dictated 
by the balance of activating and inhibitory signals received by the array of receptors expressed at the 
surface of the NK cell [3]. One of the most critical molecules for NK cell function is MHC-I. 
According to the “missing-self” hypothesis, introduced by Ljunggren and Karre, NK cells 
preferentially lyse cells with reduced expression of MHC-I molecules while sparing cells with intact 
MHC-I expression [36].  
Notably, a multitude of cancer types, to escape T cell-mediated anti-tumour responses, exert 
decreased or lost expression of MHC-I molecules. The lack of MHC-I molecules renders malignant 
cells as potential targets for NK cell-mediated cytotoxicity [99]. The HRS cells (the malignant cells 
in HL), not only frequently exert a loss of MHC-I molecule on their surface, which prevents mounting 
T cell-mediated responses, but also have high expression of PD-L1 and PD-L2 ligands, which by 
engaging with the PD-1 molecule on effector cells (T cells, NK cells) dampen their function [140] 
[187]. Hence, a seemingly T cell rich TME in HL may instigate only modest anti-tumour responses 
[188].  
To overcome this issue, current treatment regimens include immunotherapeutic antibodies targeting 
immune cells to potentiate their anti-tumour function. In HL, PD-1 blockade has proven clinical 
efficacy, but to date, the emphasis has been on the role of T cells, with data on NK cells relatively 
sparse. Nevertheless, given existing T cell evasion mechanisms in the setting of HL, it is important 
to delineate the role of NK cells in the clearance of malignant cells upon PD-1 blockade. It is 
particularly important in the light of a recent study by Vari et al., which demonstrated expansion of 
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the CD3-CD56brightCD16loPD-1+ subset of NK cells in HL that is likely triggering the unique 
sensitivity of this disease to PD-1 blockade [93].  
 PD-1 blockade in HL 
PD-1 and its cognate ligands, PD-L1 and PD-L2, are known to play a critical role in the regulation of 
T cell function. In health, the interaction between these molecules promotes self-tolerance and 
regulates autoimmunity. Specifically, the signalling via PD-1/PD-L1/PD-L2 axis inhibits T cell 
activation, proliferation, and cytokine production [189]. This checkpoint inhibitor is expressed not 
only by ‘exhausted’ T cells but also NK cells, whereas its counter molecules, PD-L1 and PD-L2, are 
expressed on APCs or malignant cells. The latter often exploit this pathway, by expressing checkpoint 
ligands on their surface, to evade anti-tumour responses and thrive in the tumour microenvironment 
[187]. Hence, targeting PD-1 axis with monoclonal antibodies to reverse exhaustion of the immune 
cells and unleash their anti-tumour potential is an attractive therapeutic target [190].  
First clinical trials, in patients with relapsed/refractory HL, were to investigate the clinical efficacy 
of PD-1 blockade using two humanized monoclonal antibodies, known as nivolumab and 
pembrolizumab. The Phase I trial of nivolumab (CHECKMATE 039) resulted in the overall response 
rate (ORR) 87% and a complete response (CR) 17%. Evaluation of pembrolizumab in the Phase I 
trial KEYNOTE 013 resulted in similar outcomes: ORR 65% and CR 16%. These promising results 
led to subsequent Phase II trials to further investigate the clinical effect of PD-1 inhibitors, nivolumab 
in CHECKMATE 205 and pembrolizumab in KEYNOTE 087. The clinical efficacy of these agents 
was tested in two independent patient cohorts and resulted in the ORR 69% and CR 16% for 
nivolumab and ORR 69% and CR  22% for pembrolizumab [134] [187] [191] [192].  
After the success of these clinical trials both antibodies targeting PD-1 were approved in patients with 
relapsed/refractory HL. Nivolumab, was approved in May 2016 by the Food and Drug Administration 
(FDA) and in November 2016 by the European Medicines Agency (EMA), while pembrolizumab 
was approved almost a year later in March and May 2017 by FDA and EMA, respectively. Overall, 
the PD-1 blockade is associated with high response rates and durable effects with acceptable safety 
profiles in patients with relapsed/refractory HL [191] [192]. 
Notably, the advent of PD-1 inhibitors has improved treatment outcomes in patients with 
relapsed/refractory HL. The unique sensitivity of HL to PD-1 blockade therapies might be due to the 
malignant cells of HL that overexpress PD-L1 and PD-L2 ligands which by engaging with PD-1 
molecules on T-cells drive their exhaustion [134] [187]. However, HRS cells often have a variable 
loss of MHC-I/II expression, therefore a high response rate to PD-1 blockade is likely not solely 
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mediated by CD8 and CD4 T cells. Conversely, the loss of MHC-I may render HRS cells sensitive 
to NK cell-mediated cytotoxicity. However, the knowledge about the exact mechanism of PD-1 
blockade on unleashing NK cell function is limited and further investigations are necessary [189]. 
Overall, PD-1 blockade is an attractive way to reinstate host’s immune function in HL, but its effect 
on various immune cells needs to be further elucidated to ensure optimal benefits. 
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4.2 AIMS 
Based on studies in NK cell lines it was determined that following recognition of a target cell, IRE1-
XBP1 pathway is activated to ensure appropriate NK cell effector function. I hypothesise that IRE1-
XBP1 pathway is dysregulated in HL and that this can be reversed by PD-1 blockade. The main aim 
of this chapter was to determine if the IRE1-XBP1 pathway is dysregulated in NK cells from Hodgkin 
lymphoma patients during NK cell-mediated effector function and to establish if this dysregulation 
affects NK cell functions. Next, the ability of PD-1 blockade to reverse IRE1-XBP1 pathway-
mediated NK cell effector dysfunction was tested. The specific aims of this chapter are: 
1. To determine if the IRE1-XBP1 pathway is dysregulated in pNK from the peripheral blood of 
pre-therapy HL patients.  
2. To characterise in detail, the nature of NK cell dysfunction and its relationship with the IRE1-
XBP1 pathway in HL. 
3. To test the ability of PD-1 blockade to reverse IRE1-XBP1 pathway associated pNK cell 
dysfunction. 
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4.3 RESULTS 
 The IRE1-XBP1 pathway is not activated in the CD56brightCD16- subset of 
NK cells from HL patients 
In the previous chapter (refer to Chapter 3), the relevance of the IRE1-XBP1 pathway activation for 
appropriate NK cell function was demonstrated. Hence, I sought to determine whether the IRE1-
XBP1 pathway operates in the circulating NK cells of HL patients; the expression of XBP1s, an active 
form of XBP1, was assessed in unstimulated and HRS-stimulated NK cells from HL patients and age-
matched healthy controls. NK cell subset characterization was performed on peripheral blood CD3-
CD14-CD19-CD56+ mononuclear cells (Figure 4.2). NK cells were defined based on CD56 and CD16 
expression, and two subsets were further identified as follows: CD56brightCD16-, CD56dimCD16+. 
First, to establish the optimal time of pNK cells stimulation with HRS cells, a time-course experiment 
involving healthy individual cells was performed. Based on the results of this analysis a 4-hour time-
point was selected for further analysis (Figure 4.1). It was found that following HRS-stimulation, 
XBP1s expression in NK cells from HL was significantly lower than in age-matched healthy controls 
(Figure 4.3 A). This observation was restricted to the CD56brightCD16- subset of NK cells.  
 
Figure 4.1: A time-course of XBP1s expression in different subsets of pNK cells from healthy individuals in 
response to HRS cells-stimulation. The expression of XBP1s in NK cells from healthy individuals was tested by flow 
cytometry. Cells were stimulated with HRS cells (KM-H2 cell line) over the course of time to select a time-point with 
optimal activation of the IRE1-XBP1 pathway. Both subsets CD56dimCD16+ and CD56brightCD16- of healthy pNK cells 
display similar kinetics of the IRE1-XBP1 pathway activation, with the peak at 4-hour time-point, which was selected for 
further analysis. 
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Figure 4.2 : Gating strategy of different pNK cell subsets and XBP1s. NK cells were identified from total lymphocytes 
as shown (A). Then, both dead cells and targets cells were removed from analysis by gating on KM-H2-CTV/Live/dead- 
events (B). Successive gates were applied to exclude monocytes, T and B cells from analysis (C). To proceed with NK 
cell analysis CD56+ cells were gated on (D), which allowed to stratify them into two different subsets based on CD56 
and CD16 expression (E). Representative plots showing the expression of XBP1s in stimulated CD56brightCD16- (F) and 
CD56dimCD16+ (G) cells from a healthy control (HC, blue line) and a HL patient (HL, red line with shading) are presented.  
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Figure 4.3: XBP1s is not activated in primary NK cells from HL patients. The effect of HRS cells on XBP1s activation 
was tested in pNK cells of HL patients and age-matched healthy controls. PBMCs were incubated for 4 hours in the 
presence of HRS-cells (KM-H2) admixed in 1:1 ratio. XBP1s expression was measured by flow cytometry. XBP1s is 
suppressed in the CD56brightCD16- cells from HL patients following the stimulation with HRS-cells (A) but not in the 
CD56dimCD16+ cells (B). Analysis Mann-Whitney test (n=10), ***P<0.001. 
 The absolute NK cell count is reduced in patients with Hodgkin lymphoma  
To determine whether the size of NK cell compartment in the circulation of HL patients is altered, 
NK cell absolute counts in PBMCs from HL pre-therapy patients and age-matched healthy controls 
were calculated and compared. It was noted that the number of CD3-CD56+ NK cells in the peripheral 
blood of HL patients was significantly reduced in comparison to healthy controls (Figure 4.4.A). The 
analysis of the two conventional NK cell subsets, the CD56bright CD16- (Figure 4.4 B) and the CD56dim 
CD16+ (Figure 4.4 C), demonstrated the numbers of NK cells are decreased in both subsets in 
comparison to the healthy controls. In healthy participants, NK cells account for ˜10% of all 
lymphocytes. However, the number of NK cells in HL appeared significantly lower than in the healthy 
participants, in line with the recent finding demonstrated by Vari et al. [93].  
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Figure 4.4: NK cell compartment in Hodgkin lymphoma is contracted. The absolute numbers of NK cells in the 
peripheral blood of HL pre-therapy patients and age-matched healthy controls were calculated. The number of NK cells 
in HL patients is significantly lower than in healthy controls, which is reflected in the total NK cell counts (A), and 
individual NK cell subsets: CD56dimCD16+ (B) and CD56bright CD16- (C). Analysis Student’s t-test (n=10) *P<0.05. 
 XBP1s suppression is associated with impaired NK cell immune synapse 
formation  
To execute cytolytic function NK cells need to engage with a target cell to establish an IS. Upon 
recognition of a target cell, a cytoskeleton rearrangement involving F-actin polymerization is an early 
event that is a prerequisite step in the formation of the IS. Previous experiments demonstrated that 
following inhibition of the IRE1-XBP1 pathway with 4µ8c the IS between the KHYG-1 NK cell line 
and the HRS cell line (HDLM-2) was impaired as demonstrated by weak F-actin accumulation at the 
IS site. Here, I sought to determine whether inhibition of the IRE1-XBP1 pathway in pNK cells 
obtained from HL patients also display a similar defect in the IS formation. To test this, conjugates 
formed (within 30mins) between pNK cells and HRS cells, were examined for the distribution of F-
actin after staining with phalloidin. The extent of actin polymerization in NK cell conjugates from 
HL patients was compared between cells untreated and treated with 4µ8c by quantitative analysis of 
fixed conjugates by confocal microscopy. As expected, quantification of F-actin polymerization at 
the pNK cell–HRS cell contact site showed that most conjugates, where pNK cells were treated with 
4µ8c, exhibited a weak band of F-actin at the immune synapse in comparison to the untreated cells 
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(Figure 4.5). These data demonstrate that inhibition of the IRE1-XBP1 pathway in pNK cells in 
patients with HL results in impaired actin polarization.  
 
Figure 4.5: IRE1 blockade impairs NK cell immune synapse formation with HRS cells.  NK cells from HL patients 
(A) were allowed to conjugate with an HRS cell line HDLM-2 for 30 min in the presence or absence of IRE1 inhibitor 
4µ8c. Conjugates were then fixed, stained, and scored for F-actin (phalloidin, green) polarization at the NK cell immune 
synapse. Data are the mean ± SD from 3 independent experiments with 30 conjugates analysed per experiment. 
Representative images of NK cell synapse formation between CD3-CD56+ pNK cell (DAPI, blue) and HRS cells (APC, 
red) are shown (B). Arrows indicate actin accumulation at the NK-cell–HRS synapse site imaged with the Nikon spinning 
disc confocal microscope. Original magnification ×63. In the control assays, target cells and NK cells were co-incubated 
with IgG4 isotype control. Statistical differences between experimental groups were evaluated by Student’s t-test (n=3) 
**P<0.01. 
 PD-1 blockade rescues immune synapse formation 
To better understand if this defect in NKIS formation resulted from the signalling via PD-1/PD-
L1/PD-L2 axis (Figure 4.6), I also examined the potential improvement of actin accumulation at the 
IS upon a blockade of PD-1 with pembrolizumab, and whether it can reverse the impairment driven 
by the suppression of the IRE1-XBP1 pathway. The extent of actin polymerization in pNK cell 
conjugates from patients with HL was compared across cells treated with pembrolizumab or isotype 
control by quantitative analysis of fixed conjugates, randomly selected for analysis with confocal 
microscopy (Figure 4.7). As expected, quantification of F-actin polymerization at the pNK cell–HRS 
cell contact site showed that most conjugates formed with pNK cells treated with pembrolizumab 
exhibited a prominent band of F-actin at the immune synapse in comparison to the cells treated with 
isotype control. Interestingly, PD-1 blockade appears to be capable of enhancing F-actin 
polymerization at the IS, as well as partially reversing the impairment driven by suppressed XBP1s. 
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Collectively, these data demonstrate that PD-1 blockade enhances actin accumulation at the IS 
between pNK cells of HL and HRS cells contributing to formation of a stable contact.  
 
Figure 4.6: Expression of PD-1/PD-L1/PD-L2 axis molecules on pNK cells and HDLM-2 cells. Following the 
expansion of pNK cells the PD-1 expression was tested on CD3-CD56+ pNK cells of each patient’s sample (A, B, 
C). These cells were utilised for all functional experiments. In addition, expression of PD-1 ligands: PD-L1 (D) and PD-
L2 (E), was assessed on HDLM-2 cell line that was also utilised in all functional experiments. FACS plots present 
expression of tested molecules in unstained control (grey), PD-1 expression (blue), PD-L1 (green), PD-L2 (fuchsia). 
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Figure 4.7: PD-1 blockade enhances pNK cell immune synapse formation with HRS cells and rescues.  pNKIS 
formation in NK cells with a suppressed IRE1-XBP1 pathway. pNK cells from patients with HL (A) were allowed to 
conjugate with HRS cells HDLM-2 for 30 min in the presence or absence of PD-1 blockade and/or the IRE1 inhibitor 
4µ8c. Conjugates were then fixed, stained, and scored for F-actin (phalloidin, green) polarization at the NK-cell immune 
synapse. Data are the mean ± SD from 3 independent experiments with 30 conjugates analysed per experiment. 
Representative images of NK cell synapse formation between CD3-CD56+ pNK cell (DAPI, blue) and HRS cells (APC, 
red) are shown (B). Arrows indicate actin accumulation at the NK-cell–HRS synapse site. Original magnification × 63. 
In the control assays, HRS target cells and pNK cells were co-incubated with immunoglobulin G4 isotype control. 
Statistical differences between experimental groups were evaluated by Student’s t-test (n=3) *P<0.05, **P<0.01. 
 PD-1 blockade improves NK cell migration  
Next, I tested whether PD-1 blockade could increase NK cell migration in vitro. For this, I used the 
KHYG-1 NK cell leukemia cell line characterised by high expression of PD-1 (Figure 4.8 B). 
Migration fold change was calculated by dividing the number of migrant NK cells with blocking 
antibody by the number of migrant cells treated with isotype control; statistical significance was 
calculated against a fold change of 1.0. Compared with culture with isotype control antibodies, 
KHYG-1 cultured with pembrolizumab significantly improved migration of NK cells (Figure 4.8 A). 
This indicates that the interruption of the PD-1/PD-L1 axis is sufficient to enhance PD-1+ NK cells 
migration in an in vitro model.  
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Figure 4.8: PD-1 blockade improves NK cell migration. KHYG-1 cells, in the presence of PD-1 blockade or isotype 
control, were seeded into a transwell chamber with 5µM pore-size and incubated for 5 hours to allow cell migration to 
the bottom well containing medium. Migrant cells were collected from the well, stained, and analysed by the flow 
cytometry. The fold change of migrant cells treated with pembrolizumab over cell treated with isotype control are 
presented (A). Statistical differences between experimental groups were evaluated by Student’s t-test (n=3) ***P<0.001. 
Flow cytometry was utilised to assess expression of immune checkpoint PD-1 on KHYG-1 cell line (B). Plot presents 
expression of tested molecule in unstained control (grey), PD-1 expression (orange).  
 Suppression of XBP1s is associated with impaired IFNγ secretion  
NK cells not only directly engage with cancer cells, but they can also recruit other cells by secretion 
of immunomodulatory cytokines such as IFNγ. In the previous chapter it was shown that activation 
of the IRE1-XBP1 pathway resulted in IFNγ secretion by pNK cells following engagement with target 
cells. Similarly, Iwakoshi et al. demonstrated that XBP1s is required for efficient production of IFNγ 
in DCs [123].  
To determine whether downstream processes upon NKIS formation are affected by suppression of 
IRE1, I investigated the secretion of IFNγ by pNK cells from patients with HL with suppressed 
XBP1s. For this purpose, pNK cells from HL patients were expanded for 14 days in the presence of 
irradiated feeder LCL and supplemented with IL-2 and IL-15, as the numbers of NK cells in these 
patients are limited and are not sufficient to perform functional experiments. NK cells were stimulated 
with the HDLM-2 cell line in the presence or absence of 4µ8c, and then stained for IFNγ. To assess 
IFNγ expression in NK cells the gating strategy presented in Figure 4.9 was applied. A significant 
decrease of IFNγ production was observed in the pNK cells with suppression of the IRE1-XBP1 
pathway (Target cells 50.7 ±1.5%; Target cells+4µ8c 39.8±1.3%) (Figure 4.10). This data indicates 
that blockade of the IRE1-XBP1 pathway results in suboptimal IFNγ production in expanded pNK 
cells in patients with HL. 
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Figure 4.9: Gating strategy of IFNγ in NK cell subset. NK cells were identified from total lymphocytes as shown (A). 
Then, based on FSC-A/FSC-H (B) and SSC-A/SSC-H (C) scatters single cells were selected for further analysis. Dead 
cells were excluded from analysis by gating on APC-Cy7neg- events (D). Successive gate was applied to exclude from 
analysis non-lineage cells (CD3-CD14-CD19-) (E) and target cells stained with CellTrackerViolet (F). To proceed with 
NK cell analysis, CD56+ cells were gated on (G), which allowed to subsequently gate on CD56+CD16-/+ cells (H) and 
assess IFNγ expression in general NK cell population (I).  
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Figure 4.10: In patients with HL, expanded pNK cells with IRE1-XBP1 pathway blockade have impaired secretion 
of IFNγ. The expanded pNK cells from HL patients were stimulated with HRS cells for 6 hours and then stained 
intracellularly for IFNγ. The percent of CD3-CD56+ pNK cells untreated and treated with 60µM of 4µ8c is presented 
(n=3). Analysis Student’s t-test (n=3) ***P<0.001. Representative FACS histogram shows changes in IFNγ in untreated 
(blue line) and 4µ8c treated cells (blue shade) (B). 
Classically, NK cells can be subdivided into two subsets: CD56dimCD16+ and CD56brightCD16- that 
display distinct functions in vivo. Specifically, CD56dimCD16+ cells are involved in NK cell-mediated 
target cell lysis, while CD56brightCD16- cells are predominantly involved in cytokine secretion. Hence, 
expression of IFNγ was also interrogated in individual subsets to gain an in-depth overview of the 
IRE1 blockade impact on NK cell function. Following the IRE1 blockade a significant decrease of 
IFNγ secretion was observed in both NK cell subsets, but it was more significant in the 
CD56brightCD16- subset of NK cells (Figure 4.12). This data further supports the notion that NK cells 
with suppressed IRE1-XBP1 pathway demonstrate a suboptimal IFNγ production in both subsets of 
expanded pNK cells from patients with HL. 
 
Figure 4.11: Gating strategy of IFNγ in distinct NK cell subsets. NK cells were identified from total lymphocytes as 
shown in Figure 4.9. Then, based on CD56 and CD16 expression NK cells were stratified into two subsets: CD56dimCD16+ 
and CD56brightCD16- (A). Successive gate was applied on IFNγ+CD56brightCD16- (B) and IFNγ+CD56dimCD16+ cells (C) 
to facilitate analysis of IFNγ in different NK cell subsets. 
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Figure 4.12: In patients with HL, distinct subsets of expanded pNK cells have impaired secretion of IFNγ upon the 
IRE1 blockade. Expanded pNK cells from HL patients were stimulated with HRS cells for 6 hours and then stained 
intracellularly for IFNγ. The percent of CD56brightCD16- (A) and CD56dimCD16+ (B) pNK cells untreated and treated with 
60µM of 4µ8c is presented (n=3). Analysis Student’s t-test (n=3) *P<0.01, **P<0.01. Representative FACS histogram 
shows changes in IFNγ in untreated (grey shade) and 4µ8c treated (blue shade) CD56brightCD16- (C) or CD56dimCD16+ 
cells (D). 
 PD-1 blockade partially reverses IFNγ secretion 
PD-1 blockade has proven a clinical efficacy in the setting of relapsed/refractory HL. Nevertheless, 
up until now the efficacy of PD-1 blockade was attributable to reversal of T cell exhaustion. I sought 
to determine whether PD-1 blockade overcomes pNK cell exhaustion driven by the HL 
microenvironment and/or dysfunction associated with suppressed IRE1-XBP1 pathway. To 
determine if PD-1 blockade could affect IFNγ secretion, expanded pNK cells of HL patients were 
pre-incubated for 72hrs in the presence of anti-PD-1 antibody (pembrolizumab) or isotype control. 
Then expanded pNK cells were stimulated with HDLM2 cell line (of HL phenotype) for 6 hours in 
the presence or absence of 4µ8c and stained for IFNγ. I found that PD-1 blockade not only enhanced 
IFNγ secretion in pNK cells of patients with HL (Target cells 50.7±1.5; α-PD-1 66.3±3.1), but also 
partially reversed the impairment of IFNγ secretion due to IRE1-XBP1 pathway suppression (Target 
cells+4µ8c 39.8±1.3; α-PD-1+4µ8c 48.9±4) (Figure 4.13). 
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Figure 4.13: PD-1 blockade partially reverses IFNγ secretion by pNK cells from HL patients.  Expanded NK cells 
from patients with HL were stimulated with HRS cells (HDLM-2 cell line) for 6 hours in the presence or absence of PD-
1 blockade and/or IRE1 inhibitor 4µ8c. Cells were then stained, fixed, and analysed by flow cytometry to assess IFNγ 
secretion. In the control assays, target cells and primary NK cells were co-incubated with IgG4 isotype control. Statistical 
differences between experimental groups were evaluated by Student’s t-test (n=3) ***P<0.001. Representative FACS 
histograms present changes in IFNγ secretion in pNK cells treated with α-PD-1 (red shade) or isotype control (blue shade) 
(B), and 4µ8c alone (blue line) or combination of α-PD-1 and 4µ8c (red line) (C). 
Changes in IFNγ secretion upon PD-1 blockade were also examined in different pNK cell subsets. 
Analysis indicates that application of PD-1 blockade enhanced IFNγ secretion in both pNK cell 
subsets (Figure 4.14). In addition, application of PD-1 blockade in pNK cells with suppressed IRE1-
XBP1 pathway partially reversed IFNγ secretion but this observation was restricted to the 
CD56brightCD16- subset of NK cells (Figure 4.14 A).
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Figure 4.14: PD-1 blockade partially reverses IFNγ secretion by CD56brightCD16- cells from HL patients. Expanded NK cells from patients with HL were stimulated with HRS 
cells (HDLM-2 cell line) for 6 hours in the presence or absence of PD-1 blockade and/or IRE1 inhibitor 4µ8c. Cells were then stained, fixed, and analysed by flow cytometry to assess 
IFNγ secretion. In the control assays, target cells and pNK cells were co-incubated with IgG4 isotype control. Statistical differences between experimental groups were evaluated by 
Student’s t-test (n=3), ****P<0.001, *P<0.05, ns – not significant (p= 0.0874). Representative FACS histograms present changes in IFNγ secretion in CD56brightCD16- (C, D) or 
CD56dimCD16+ (E, F) cells treated with α-PD-1 (red shade) or isotype control (blue shade) (C, E), and 4µ8c alone (blue line) or combination of α-PD-1 and 4µ8c (red line) (D, F). 
 
CHAPTER 4: The IRE1-XBP1 pathway is dysregulated in NK cells from Hodgkin lymphoma 
99 
 The impact of IRE1 inhibition on TNFα secretion by pNK cells 
Another important cytokine produced by NK cells is TNFα. Therefore, I decided to investigate 
whether its secretion changes upon blockade of PD-1 or IRE1 in pNK cells from patients with HL. 
For this purpose, expanded pNK cells from patients with HL, preincubated with pembrolizumab or 
isotype control, were stimulated with the HDLM2 cell line in the presence or absence of 4µ8c and 
then stained for TNFα. Expression of TNFα was assessed in CD3-CD56+CD16+/- cells as presented 
in Figure 4.15.  
IRE1 inhibition caused a modest, but statistically significant, decrease in TNFα protein level (Figure 
4.16). These changes were demonstrated in the frequencies of TNFα+ pNK cells (Target cells 
13.5±3.4%; Target cells+4µ8c 10.3±4.5%). 
In line with this finding, the analysis of individual NK cell subsets, CD56dimCD16+ and 
CD56brightCD16- (Figure 4.17), demonstrated that following the IRE1 blockade secretion of TNFα is 
impaired in both subsets, with the CD56brightCD16- displaying a more prominent decrease (Figure 
4.18). 
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Figure 4.15: Gating strategy for TNFα in NK cells. NK cells were identified from total lymphocytes as shown (A). 
Then, based on FSC-A/FSC-H (B) and SSC-A/SSC-H (C) scatters single cells were selected for further analysis. Both 
dead cells and lineage positive cells were removed from analysis by gating on APC-Cy7neg- events (D). Successive gate 
was applied to exclude target cells stained with CellTrackerViolet from analysis (E). To proceed with NK cell analysis, 
first CD56+ cells were gated (F) and subsequently CD56+CD16+/- cells (G) which allowed assessment of TNFα 
expression in the general NK cell subset (H). 
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Figure 4.16: In patients with HL, expanded pNK cells with IRE1 blockade display impaired secretion of TNFα. 
The expanded pNK cells from HL patients were stimulated with HRS cells for 6 hours and then stained intracellularly for 
TNFα. The percent of CD3-CD56+ pNK cells untreated and treated with 60µM of 4µ8c is presented (A). Analysis 
Student’s t-test (n=3), **P<0.01. Representative FACS histogram shows changes in TNFα in untreated (blue line) and 
4µ8c treated cells (blue shade) (B). 
 
 
Figure 4.17: Gating strategy of TNFα in distinct NK cell subsets. NK cells were identified from total lymphocytes as 
shown in Figure 4.15. Then, based on CD56 and CD16 expression NK cells were stratified into two distinct subsets: 
CD56dimCD16+ and CD56brightCD16- for further analysis (A). Successive gate was applied on TNFα+ CD56brightCD16- (B) 
and TNFα+CD56dimCD16+ cells (C) to facilitate analysis of TNFα in different NK cell subsets. 
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Figure 4.18: In patients with HL, both subsets of expanded pNK cells have impaired secretion of TNFα upon the 
IRE1 blockade. The expanded pNK cells from HL patients were stimulated with HRS cells for 6 hours and then stained 
intracellularly for TNFα. The percent of CD56brightCD16- (A) and CD56dimCD16+ (B) pNK cells untreated and treated 
with 60µM of 4µ8c is presented (n=3). Analysis Student’s t-test (n=3): **P<0.01, *P<0.05. Representative FACS 
histogram shows changes in TNFα in untreated (grey shade) and 4µ8c treated (blue shade) CD56brightCD16- (C) or 
CD56dimCD16+ cells (D). 
 
 The impact of PD-1 blockade on TNFα secretion by pNK cells 
To determine if PD-1 blockade could affect TNFα secretion, expanded pNK cells of HL patients were 
pre-incubated for 72hrs in the presence of anti-PD-1 antibody (pembrolizumab) or isotype control. 
Then expanded pNK cells were stimulated with HDLM2 cell line (of HL phenotype) for 6 hours in 
the presence or absence of 4µ8c and stained for TNFα. Initially, expression of TNFα in the total 
population of pNK cells was analysed. Upon PD-1 blockade, a trend towards an increase of TNFα 
expression compared to the isotype control was noted, which was statistically significant (Target cells 
13.5±3.4%; α-PD-1 15.4±4.7%). Results indicate also that PD-1 blockade did partially reverse TNFα 
secretion in pNK cells with suppressed IRE1-XBP1 pathway activation (Target cells+4µ8c 
10.3±4.5%; α-PD-1+4µ8c 13.2±3.8%).  
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Figure 4.19: PD-1 blockade partially reverses TNFα secretion by pNK cells from patients with HL.  Expanded pNK 
cells from HL patients were stimulated with HRS cells (HDLM-2 cell line) for 6 hours in the presence or absence of PD-
1 blockade and/or IRE1 inhibitor 4µ8c. Cells were then stained, fixed, and analysed by flow cytometry to assess TNFα 
secretion. In the control assays, target cells and primary NK cells were co-incubated with IgG4 isotype control. PD-1 
blockade not only enhanced but also partially reversed TNAα secretion in pNK cells with XBP1s suppression (A). 
Statistical differences between experimental groups were evaluated by Student’s t-test (n=3), **P<0.01, *P<0.05. 
Representative FACS histograms present changes in TNFα secretion in pNK cells treated with α-PD-1 (red shade) or 
untreated (target cells - blue shade) (B), and 4µ8c alone (blue line) or combination of α-PD-1 and 4µ8c (red line) (C). 
Changes in TNFα secretion upon PD-1 blockade were also examined in different pNK cell subsets. 
Analysis indicates that application of PD-1 blockade did not enhance TNFα secretion in any of tested 
pNK cell subsets (Figure 4.20). However, application of PD-1 blockade in pNK cells with suppressed 
IRE1-XBP1 pathway partially reversed TNFα secretion in both CD56dimCD16+ and CD56brightCD16- 
subsets (Figure 4.20). 
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Figure 4.20: PD-1 blockade partially reverses TNFα secretion in both CD56brightCD16- and CD56dimCD16+ cells with suppressed IRE1-XBP1 pathway.  Expanded pNK cells 
from HL patients were stimulated with HRS cells (HDLM-2 cell line) for 6 hours in the presence or absence of PD-1 blockade and/or IRE1 inhibitor 4µ8c. Cells were then stained, 
fixed, and analysed by flow cytometry to assess TNFα secretion. PD-1 blockade or IRE1 inhibition did not induce significant changes in frequency of TNFα+CD56brightCD16- (A) or 
TNFα+CD56dimCD16+ cells (B). Statistical differences between experimental groups were evaluated by Student’s t-test (n=3) *P<0.05, ns – not significant. Representative FACS plots 
present TNFα expression in the CD56brightCD16- (C, D) or the CD56dimCD16+ (E, F) cells treated with α-PD-1 (red shade) or isotype control (blue shade) (C, E), and 4µ8c alone (blue 
line) or combination of α-PD-1 and 4µ8c (red line) (D, F). 
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 Suppression of the IRE1-XBP1 pathway is associated with impaired 
degranulation 
One mechanism of NK cell-mediated killing is through lytic granule release. To interrogate whether 
the IRE1-XBP1 pathway is involved in degranulation, expanded pNK cells from patients with HL 
patients were stained for CD107a surface expression. CD107a is present on the surface of NK lytic 
vesicles consisting of perforin and granzymes. During the process of degranulation, the membrane of 
the secretory lysosomes fuses with the plasma membrane of the activated NK cell and the lytic 
granules content is then released at the immunological synapse to induce death of the target cell [154]. 
Hence, CD107a is one method to assess NK cell degranulation.   
To determine whether the IRE1-XBP1 pathway is involved in this process, CD107a antibody was 
added to pNK cells of HL patients stimulated with HDLM2 target cells in the presence or absence of 
4µ8c for 6 hours. Then only cells were analysed for CD107a expression by flow cytometry (Figure 
4.22).  It was found that inhibition of the IRE1-XBP1 pathway resulted in decreased expression of 
CD107a following direct cytotoxicity (Target cells 73.4±6.7; Target cells+4µ8c 55.3±13.7). 
Addition of 60μM of IRE1 inhibitor caused a ~25% reduction of CD107a expressing CD3-CD56+ 
cells (Figure 4.21). 
 
Figure 4.21: In HL, pNK cells with suppressed XBP1s exert impaired degranulation.  The expanded pNK cells from 
HL patients were stimulated with HRS cells for a total of 6 hours and stained for CD107a. The percent of CD3-
CD56+CD16+/- pNK cells untreated and treated with 60µM of 4µ8c is presented (A, n=3). Statistical differences between 
experimental groups were evaluated by Student’s t-test (n=3), **P<0.01. Representative FACS histogram shows changes 
in CD107a in untreated (blue line) and 4µ8c treated cells (blue shade) (B). 
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Figure 4.22: Gating strategy of CD107a in NK cell subset. NK cells were identified from total lymphocytes as shown 
(A). Then, based on FSC-A/FSC-H (B) and SSC-A/SSC-H (C) scatters single cells were selected for further analysis. 
Dead cells were excluded from analysis by gating on APC-Cy7neg- events (D). Successive gate was applied to exclude 
non-lineage cells (CD3-CD14-CD19-) (E) and target cells stained with CellTrackerViolet from analysis (F). To proceed 
with NK cell analysis, CD56+ cells were gated on (G), which allowed to then gate on CD56+CD16-/+ cells (H) and assess 
CD107a expression in general NK cell population (I).  
The CD56dimCD16+ subset of NK cells is primarily involved in target cell lysis in vivo. Hence, 
changes in CD107a release were also interrogated in individual subsets of NK cells to determine 
potential differences between two NK cell subsets following the IRE1 blockade. Upon the IRE1 
blockade a significant decrease in CD107a release was observed in both NK cell subsets (Figure 
4.24). This data indicates that in HL patients, both NK cell subsets with suppressed IRE1-XBP1 
pathway demonstrate a suboptimal degranulation. 
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Figure 4.23: Gating strategy of CD107a in distinct NK cell subsets. NK cells were identified from total lymphocytes 
as shown in Figure 4.22. Then, based on CD56 and CD16 expression NK cells were stratified into two subsets: 
CD56dimCD16+ and CD56brightCD16- (A). Successive gate was applied on CD107a+CD56brightCD16- (B) and 
CD107a+CD56dimCD16+ cells (C) to facilitate analysis of CD107a in different NK cell subsets. 
 
Figure 4.24: In HL, both NK cell subsets display impaired degranulation in the presence of IRE1 blockade. The 
expanded pNK cells from HL patients were stimulated with HRS cells for a total of 6 hours and stained for CD107a. The 
percent of CD56brightCD16- (A) and CD56dimCD16+ (B) pNK cells untreated or treated with 60µM of 4µ8c is presented 
(n=3). Statistical differences between experimental groups were evaluated by Student’s t-test (n=3), ****P<0.001, 
**P<0.01. Representative FACS histogram shows changes in CD107a in untreated (grey shade) and 4µ8c treated (blue 
shade) CD56brightCD16- (C) and CD56dimCD16+ (D) cells. 
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 PD-1 blockade does not significantly enhance NK cell degranulation 
To determine whether PD-1 blockade could enhance NK cell degranulation, expanded pNK cells 
from patients with HL were pre-incubated for 72hrs in presence of pembrolizumab or isotype control. 
Then cells were stimulated with HDLM2 target cells for 6 hours in the presence or absence of 4µ8c, 
and antibody against CD107a. I observed that neither did PD-1 blockade enhance NK cell 
degranulation over control nor reversed degranulation of pNK cells with a suppressed IRE1-XBP1 
pathway (Figure 4.25). These observations might result from variations across tested patients and 
limited number of patient samples tested. In the previous study by Vari et al, PD-1 blockade was 
demonstrated to improve degranulation of a sorted subset of the KHYG-1 NK cell line that had 
uniformly high expression of PD-1. Hence, the level of PD-1 expression may underlie the strength of 
the PD-1 blockade effectiveness, as well as the greater homogeneity of KHYG-1 cells in contrast to 
pNK cells.  
 
Figure 4.25: PD-1 blockade does not significantly improve degranulation of pNK cells in patients with HL.  
Expanded pNK cells from HL patients were stimulated with HRS cells (the HDLM-2 cell line) for 6 hours in the presence 
or absence of PD-1 blockade and/or IRE1 inhibitor 4µ8c. Cells were then stained and analysed by flow cytometry to 
assess degranulation based on CD107a marker (A). In the control assays, target cells and pNK cells were co-incubated 
with IgG4 isotype control. Statistical differences between experimental groups were evaluated by Student’s t-test (n=3) 
ns – not significant (Target cells vs α-PD-1: p= 0.54; Target cells+4µ8c vs. α-PD-1+4µ8c: p= 0.67). Representative FACS 
histograms present changes in CD107a release in NK cells treated with α-PD-1 (red shade) or isotype control (blue shade) 
(B), and 4µ8c alone (blue line) or combination of α-PD-1 and 4µ8c (red line) (C). 
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I also examined changes in CD107a release upon PD-1 blockade in different NK cell subsets. Analysis indicates that neither did application of PD-1 
blockade enhance CD107a release in any of tested NK cell subsets nor reversed impaired CD107a release in NK cell subsets with suppressed IRE1-
XBP1 pathway (Figure 4.26). 
 
Figure 4.26: PD-1 blockade does not improve degranulation by CD56brightCD16- or CD56dimCD16+ cells in patients with HL. Expanded pNK cells from HL patients were 
stimulated with HRS cells (the HDLM-2 cell line) for 6 hours in the presence or absence of PD-1 blockade and/or IRE1 inhibitor 4µ8c. Cells were then stained and analysed by flow 
cytometry to assess degranulation based on CD107a marker (A). In the control assays, target cells and pNK cells were co-incubated with IgG4 isotype control. Statistical differences 
between experimental groups were evaluated by Student’s t-test (n=3) ns – not significant (A: Target cells vs α-PD-1: p= 0.48; Target cells+4µ8c vs. α-PD-1+4µ8c: p= 0.31. B: Target 
cells vs α-PD-1: p= 0.43; Target cells+4µ8c vs. α-PD-1+4µ8c: p= 0.74). Representative FACS histograms present changes in CD107a release in the CD56brightCD16- (C, D) or the 
CD56dimCD16+ (E, F) cells treated with α-PD-1 (red shade) or isotype control (blue shade) (C, E), and 4µ8c alone (blue line) or combination of α-PD-1 and 4µ8c (red line) (D, F). 
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 Thapsigargin enhances NK cell degranulation and cytotoxicity 
To determine if IRE1 activators may improve effector function of NK cells with suppressed 
expression of XBP1s I interrogated the effect of TG, a known IRE1 activator, on NK cell-mediated 
cytotoxicity and degranulation in response to HRS cells. For this, pNK cells from HL patients were 
incubated with CTV stained HDLM-2 target cells at a 1:1 ratio for 6 hours in the presence of DMSO 
(control), 60 μM of 4μ8c and/or 100nM of TG.  
 
Figure 4.27: Thapsigargin reverses impaired target cell lysis mediated by pNK cells with suppressed expression of 
XBP1s. pNK cells from patients with HL were stimulated with HDLM-2 target cells for 6 hours in the presence of DMSO, 
60μM of 4μ8c and/or 100nM of TG. The ability of pNK cells to lyse target cells was assessed using flow cytometry. The 
percent of target cell lysis is presented (A). These cells were also stained with CD107a antibody to assess the level of 
degranulation in CD56+ subset of NK cells (B), CD56dimCD16+ (C), or CD56brightCD16- (D).  
It was found that addition of 60μM IRE1 inhibitor to pNK cells resulted in a significant reduction in 
the lysis of HDLM-2 target cells (Figure 4.27.A), it was also reflected in reduced level of 
degranulation (Figure 4.27.B). In contrast, application of TG to pNK cells resulted in increased 
cytotoxicity towards HDLM-2 cells that was further supported by enhanced degranulation. Notably, 
application of TG to pNK cells with suppressed XBP1s expression reversed impaired cytotoxicity 
and degranulation. In case of degranulation it was also interrogated in different NK cell subsets i.e. 
CD56brightCD16- (Figure 4.27) and CD56dimCD16+ (Figure 4.27), however no significant changes 
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were observed between these two groups. This analysis indicates that TG is a potent drug that not 
only enhances NK cell effector function but also reverses the impairment of NK cell function driven 
by suppressed XBP1s. 
 Summary of results 
The main aim of this chapter was to determine whether the IRE1-XBP1 pathway is dysregulated in 
NK cells from HL patients following the stimulation with HRS cells. The flow cytometry results 
demonstrated that XBP1s, an activation marker of the IRE1-XBP1 pathway, is not activated in NK 
cells following the stimulation with HRS-cells and this observation was restricted to the 
CD56brightCD16- subset of NK cells. Concomitantly, NK cells with suppressed XBP1s were found to 
exert impaired migration, immune synapse formation with HRS cells, degranulation, IFNγ and TNFα 
secretion. Additionally, in depth analysis of distinct NK cell subsets, CD56dimCD16+ and 
CD56brightCD16-, revealed that the IRE1 blockade impairs cytotoxicity, degranulation, IFNγ and 
TNFα secretion in both tested subsets. Notably, application of IRE1 activator, TG, reversed impaired 
cytotoxicity and degranulation of NK cells. 
PD-1 is expressed on a range of immune cells including NK cells, and its expression increases 
following NK cell stimulation. Due to the proven clinical efficiency of PD-1 blockade in HL, the 
effect of this checkpoint blockade on NK cell effector function was also interrogated. As 
demonstrated in the result section of this chapter, PD-1 blockade alone enhances NK cell migration, 
immune synapse formation, IFNγ and TNFα secretion. In addition, subset analysis revealed that 
secretion of IFNγ was significantly enhanced in both NK cell subsets. Whereas application of PD-1 
blockade in NK cells with suppressed XBP1s partially reversed the immune synapse formation 
capacity and IFNγ secretion in the CD56brightCD16- but not in the CD56dimCD16+ cells. In addition, 
analysis of NK cell subsets demonstrated that PD-1 blockade partially reversed TNFα secretion and 
this observation was restricted to both NK cell subsets. 
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4.4 DISCUSSION 
 The IRE1-XBP1 pathway is impaired in NK cells from HL patients 
In this chapter, I show that NK cells of patients with HL patients exert a dysregulation of IRE1-XBP1 
pathway demonstrated by suppressed expression of XBP1s. This observation was restricted to the 
CD56brightCD16- subset of NK cells. Although the role of IRE1-XBP1 pathway can vary across 
different cell types and diseases, I show that in NK cells of patients with HL, suppression of the IRE1-
XBP1 pathway is associated with a multifaceted impairment of NK cell function, including migration, 
actin accumulation at the NKIS, degranulation, and IFNγ secretion.  
Conventionally, NK cells are subdivided into two distinct subsets: CD56dimCD16+ and 
CD56brightCD16-. To determine if the IRE1-XBP1 pathway is dysregulated in the setting of HL I 
interrogated the expression of the activation marker – XBP1s in these two NK cells subsets. I found 
that the pathway is not operative in the CD56brightCD16- subset of NK cells compared to healthy 
controls. Interestingly, in a study of HL, the latter subset of NK cells was found to be expanded and 
expressed high level of PD-1 [93]. Nevertheless, whether suppression of the IRE1-XBP1 pathway is 
directly linked to PD-1 overexpression remains to be determined. 
Another important aspect of NK cell function is recognition of a target cell and subsequent formation 
of IS to mount an executive response. In this study, it was noted that NK cells with an IRE1 blockade 
formed a less stable IS, as manifested by limited actin accumulation at the NKIS. To determine the 
consequences of this aberration the functional mechanisms that occur following the IS formation i.e. 
degranulation and cytokine release were also assessed.  
I investigated the effect of IRE1 blockade on degranulation assessed by the expression of CD107a, a 
marker that indicates the NK cell activation status [154]. Notably, a significant reduction in CD107a 
release in the presence of IRE1 blockade was observed, which suggests that activation of NK cells in 
patients with HL is impaired. As this assay evaluates the presence of a membrane coating the lytic 
granules fused with the plasma cell membrane upon the release of the lytic granule content, these data 
imply that IRE1-XBP1 pathway might be involved in the trafficking of the lytic granules towards the 
cell membrane. Importantly, application of IRE1 activator (TG) reversed impaired degranulation of 
NK cells with suppressed XBP1s. In addition, NK cells from HL patients demonstrated also reduced 
cytotoxicity against HRS-cells in the presence of IRE1 blockade, but application of TG reversed this 
impairment. 
Furthermore, NK cells of HL patients with a suppressed IRE-1-XBP1 pathway, demonstrated a 
marked decrease in IFNγ and TNFα secretion. Similarly, IRE1 blockade was shown to impair 
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secretion of IFNβ and TNFα in macrophages or IFNγ in Th1 cells [122] [193]. In contrast, in the 
study of ovarian cancer upregulation of XBP1s in T cells was associated with decreased expression 
of IFNγ [126]. It should be emphasized that in this study we investigated IRE1-XBP1 pathway solely 
in NK cells from the peripheral blood. Further research encompassing tumour infiltrating NK cells is 
required. 
 PD-1 blockade enhances NK cell function 
PD-1 pathway blockade is a highly promising therapy and has elicited durable anti-tumour responses 
and long-term remissions in a subset of patients with a broad spectrum of cancers [194] [195] [196] 
[197]. In health, the expression level of PD-1 on NK cells is limited but its expression increases in a 
variety of diseases [93] [91] [198]. A recent study of HL demonstrated a marked expansion of the 
CD56brightCD16-PD-1+ subset, which suggests enhanced sensitivity of NK cells in patients with HL 
to PD-1 blockade [93]. In the light of this finding, I investigated the effect of pembrolizumab on NK 
cell effector function.  
A previous study of MM showed that PD-1 blockade enhanced immune complex formation between 
NK cells and MM cells, as well as NK cell migration towards MM cells [91]. In line with these 
findings, we found that application of PD-1 blockade improved NK cell migration. Additionally, the 
accumulation of actin at the NKIS, between NK cell and HRS cell, was more pronounced following 
PD-1 blockade suggesting enhanced immune synapse formation between NK and HRS cells.  
To test the downstream events following the NKIS formation, I tested the efficacy of pembrolizumab 
on NK cell degranulation and cytokine secretion. In a study of NK cells from post-transplant 
lymphoproliferative disorder (PTLD) patients, a significantly up-regulated PD-1 was associated with 
functional impairment of NK cells. Moreover, disruption of PD-1/PD-L1 signalling enhanced IFNγ 
release but did not enhance degranulation examined by CD107a staining [198]. In line with these 
findings, I also found that PD-1 blockade enhanced IFNγ secretion in NK cells of HL patients, but 
not NK cell degranulation (CD107a). In contrast, in the study by Vari et al., blockade of PD-1 on the 
PD-1 high subset of NK cells from the KHYG-1 cell line did improve NK cell degranulation evaluated 
by CD107a staining [93]. This discrepancy may be explained by differences between NK cell line 
and pNK cells, and the level of PD-1 expression on tested cells, as well as in the experimental 
approaches. 
Interestingly, I did observe significant increase of TNFα secretion upon PD-1 blockade in the total 
NK cell population. However, interrogation of individual NK cell subsets i.e. CD56dimCD16+ and 
CD56brightCD16- did not reveal any improvement in TNFα secretion upon PD-1 blockade. 
CHAPTER 4: The IRE1-XBP1 pathway is dysregulated in NK cells from Hodgkin lymphoma 
114 
Nevertheless, it should be emphasized that the number of samples tested in this study was limited. 
Therefore, to clarify these findings further investigations into the effect of PD-1 blockade on TNFα 
secretion are required.  
Data presented in this chapter, indicate that further research is needed to clarify the impact of PD-1 
blockade on NK cell effector function. Moreover, these findings suggest that blockade of other 
checkpoint inhibitors, such as LAG-3 or TIM-3, to boost NK cell function should be considered.  
 The interplay between IRE1-XBP1 pathway and PD-1 in HL 
Based on the finding that IRE1-XBP1 pathway is dysregulated in pNK cells in patients with HL, I 
tested whether PD-1 blockade can reverse the impairment driven by XBP1s suppression. I found that 
pembrolizumab partially reversed IS formation and IFNγ secretion in NK cells with a suppressed 
IRE1-XBP1 pathway. This suggests that treatment with PD-1 blocking mAbs may reverse certain 
pNK cells effector function defects that arise in the context of suppression of the IRE1-XBP1 
pathway. 
However, I found that pembrolizumab did not reverse impaired degranulation or TNFα secretion in 
NK cells. Interestingly, analysis of NK cell subsets indicates that PD-1 blockade partially reverses 
TNFα secretion in both CD56dimCD16+ and CD56brightCD16- subsets in the presence of a IRE1-XBP1 
pathway inhibitor. Collectively, these results suggest that while PD-1 blockade may influence some 
aspects of IRE1-XBP1 pathway mediated NK cell dysfunction, others effector functions are not 
reversed. It should also be highlighted that in this study we did not determine whether IRE1-XBP1 
pathway and PD-1/PD-L1/PD-L2 signalling are interconnected. Further investigations into these 
pathways are required to dissect the molecular mechanisms underpinning the potential interplay 
between these two pathways, so that appropriate treatment regimens could be implemented to boost 
the anti-tumour capacity of NK cells in the setting of HL. 
 Conclusion 
In conclusion, in experiments performed on a range of NK cells lines and pNK cells (refer to Chapter 
3) I observed that the IRE1-XBP1 pathway in pNK cells of HL patients is involved in NK cell effector 
function. The pathway is dysregulated in pNK cells of HL patients and this observation was restricted 
to the CD3-CD56brightCD16- (that is known to be enriched in PD-1). The consequences of this 
dysregulation were: impaired NKIS formation, degranulation and cytokine secretion. Given that the 
PD-1 blocking antibody pembrolizumab is a critical component of current treatment strategies in 
relapsed/refractory HL, we also tested whether it can overcome NK cell impairment mediated by the 
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IRE1-XBP1 pathway. We found that PD-1 blockade alone can enhance IFNγ secretion and IS 
formation and partially reverses IRE1-XBP1 pathway mediated NK cell impairment.  
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5.1  INTRODUCTION 
NK cells as a key component of innate arm of the immune system are able to lyse malignant cells 
without previous exposure to their antigens. In contrast to T cells, NK cells attack “non-self” cells 
within the host and elicit a rapid immune response involving NK cell-mediated cytotoxicity or 
secretion of regulatory cytokines to recruit the adaptive responses and potentiate the anti-tumour 
potential of the immune system [10] [23]. That NK cell function is not limited by the MHC-I 
recognition, exerts broad cytotoxicity and are activated rapidly makes them a unique armament of 
our immune system. The potential of NK cells to lyse tumour cells has led to intensification of 
research focusing on development of immunotherapies utilising these cells [199] [200]. 
Limited knowledge of NK cell biology contributed to the failure of the initial attempts of re-infusion 
of IL-2 stimulated autologous cells. Subsequently there was some encouraging therapeutic signals 
seen with alternate approaches including use of KIR-mismatched cell infusions [100] [101]. Notably, 
a significant role of NK cells in controlling cancer development has been demonstrated by a long-
term follow-up study of a large population of healthy cancer-free individuals. After over a decade of 
surveillance, those with high levels of NK cell cytotoxicity were found to be significantly less likely 
to develop cancer than those individuals with lower levels of NK cell cytotoxicity [86]. Although NK 
cells have an impressive capacity to eliminate tumour cells, often the TME develops strategies to 
disable NK cell surveillance. Amongst others, these strategies may involve upregulation of inhibitory 
ligands on tumour cells or shedding of ligands for activating receptors to disable NK cell activation 
[142] [201].  
Since dysfunction of the IRE1-XBP1 pathway has been implicated in multiple diseases including 
cancer I sought to interrogate the role of this pathway in NK cells as well as NK cells from HL patients 
[202] [203] [204] [175]. In this study, I demonstrate for the first time that the IRE1-XBP1 pathway 
is required for optimal NK cell function. Notably, activation of this pathway was dysfunctional in NK 
cells in patients with HL. As such, strategies targeting this pathway to restore NK cell function in HL 
may be of potential benefit. Following on from recent observations by my laboratory that show that 
NK cells from patients with HL display a skewed phenotype including expansion of PD-1 expressing 
CD56brightCD16- cells [93], I went on to test the impact of PD-1 blockade on NK cell activity. 
Therefore in this chapter, potential therapies targeting not only the IRE1-XBP1 pathway but also PD-
1 checkpoint blockade will be discussed.  
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5.2 XBP1 SPLICING IN NK CELLS  
In a healthy individual, the IRE1-XBP1 pathway operates within the UPR system as a physiological 
response to ER stress triggered by physiological stimuli such as oxidative stress, glucose depletion 
and hypoxia. These processes lead to accumulation of misfolded and unfolded proteins in cells which 
in turn induce IRE1 auto-phosphorylation followed by dimerization and activation of endonuclease 
activity to splice out a 26-nucleotide intron from XBP1 mRNA, leadings to generation of XBP1s 
[205]. This molecule is a potent transcription factor involved in ER stress mitigation by regulation of 
a range of chaperones, foldases and glycotransferases [204] [184] [170] [206]. 
However, activation of this pathway has also been associated with immune effector cell function, as 
well as ER stress mitigation, indicating that this pathway operates outside of the UPR system. For 
instance, activation of the IRE1-XBP1 pathway is required for the optimal secretion of pro-
inflammatory cytokines i.e. TNFα and IFNγ in macrophages, DCs development and survival [122] 
[123], and differentiation of cells such as eosinophils and B cells [162] [121]. Interestingly, in 
multiple myeloma, malignant cells exploit the IRE1-XBP1 pathway to successfully persist in the 
tumour microenvironment [177]. 
Within this study it was found that following the stimulation of NK cells with blood cancer target 
cells, either leukaemia or lymphoma, the IRE1-XBP1 pathway was activated as demonstrated by 
XBP1 splicing (Figure 1). Investigation of known down-stream targets of XBP1s suggests that within 
NK cells the IRE1-XBP1 pathway operates in a non-canonical manner i.e. independent of the UPR 
system. Furthermore, the XBP1 splicing was successfully inhibited by a small molecule inhibitor, 
enabling a detailed analysis of NK cell function upon IRE1 blockade. Collectively, it was established 
that the IRE1-XBP1 pathway is required for optimal NK cell function. Following IRE1-XBP1 
pathway blockade, NK cells had impaired migration. While the blockade of IRE1 did not influence 
the number of conjugates formed between NK cells and HRS cells, it did impact actin polarization at 
the immune synapse interphase indicating the formation of less stable conjugates. Finally, IRE1 
blockade impaired the secretion of both cytokines - TNFα and IFNγ. 
Notably, investigations of the IRE1-XBP1 pathway in circulating pNK cells from patients with HL 
suggest that the pathway is not activated in these cells in response to HRS cells. Of note, this 
observation was restricted to the CD56brightCD16- subset of pNK cells that my laboratory has 
previously shown to be expanded in patients with HL [93]. The successful expansion of ex vivo pNK 
cells enabled investigations of the IRE1-XBP1 pathway in pNK cells from HL patients. Similar to 
the results of in vitro studies, it was found that suppression of the pathway was associated with 
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impaired immune synapse formation and IFNγ secretion. Interestingly, expanded pNK cells 
demonstrated also impaired release of CD107a, a surrogate marker of NK cell degranulation.  
Altogether, these findings highlight the importance of the IRE1-XBP1 pathway not only in NK cells 
function but also in the context of existing immune evasion mechanisms in HL. Therefore, targeting 
this pathway might be of potential interest to augment NK cell anti-tumoural function. 
5.3 PD-1 BLOCKADE EFFECT ON NK CELL FUNCTION 
The rich infiltrate of immune cells in HL is controlled by the malignant cells that promote 
immunosuppressive environment, and thereby the immune responses are limited. Hence, therapeutic 
approaches in HL focus not only on targeting the malignant cells but also the cellular interactions in 
the tumour microenvironment [207] [201] [133]. One mechanism that tumour cells utilise to control 
the surrounding immune cells is by overexpression of PD-L1/PD-L2 ligands that through interaction 
with PD-1 receptor inhibit the immune effector function. In health, PD-1/PD-L1/PD-L2 axis restrains 
the immune system to maintain the tolerance and prevent unwanted overreactions from happening, 
however malignant cells hijack this pathway to compromise the anti-tumour activity [208]. Hence, 
disruption of the PD-1/PD-L1/PD-L2 signalling with the PD-1 blocking monoclonal antibodies has 
become an attractive strategy to harness the immune effector cells anti-tumour potential [208] [191] 
[209]. These observations have led to multiple clinical trials examining the effectiveness of PD-1 
blockade in HL that led to the approval of the PD-1 blockade in HL therapy. Currently, available data 
indicate that the cure rates of PD-1 blockade in refractive/relapsed cases of HL are 70-80% [192].  
So far, the accepted paradigm dictated that the impressive results of PD-1/PD-L1/PD-L2 axis 
disruption in HL is principally due to the restoration of T cell function. However, recent studies have 
demonstrated that NK cells also display increased expression of PD-1 in multiple cancer types 
including HL [93] [91] [210] [211] [212]. This observation suggests that increased expression of PD-
1 on NK cells may impose a brake on their anti-tumour activity [213], and that the benefits of the PD-
1 blockade might be attributable to restoration of both T cell and NK cell function. Yet little is known 
about the functional impact of disrupting the PD-1/PD-L1 axis on NK cells. To date, there is limited 
data from other blood cancers that report that blockade of PD-1 improves NK cell-mediated anti-
tumour effects. For example, in MM, following the PD-1 blockade NK cells display enhanced 
trafficking and conjugate formation [91]. Previous data from my supervisor’s laboratory indicates 
that the high-rate of clinical response to PD-1 blockade observed in HL may in part result from 
disruption of interactions between PD-1+ NK cells and PD-L1/L2 expressed on Hodgkin Reed-
Sternberg cells and TAMs [93]. 
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The results of my study further support the notion that PD-1 is a key checkpoint for NK cell function, 
and the high efficacy of PD-1 blockade therapy in HL may result from mobilization of NK cells to 
instigate anti-tumour responses. Firstly, PD-1 blockade on a PD-1 expressing NK cell line enhanced 
migration. Next, I found that PD-1 blockade improves actin accumulation at the immune synapse 
interphase leading to formation of more stable immune conjugates, and enhanced secretion of IFNγ 
but not TNFα or lytic granules (Figure 1).  
 
Figure 5.1: The IRE1-XBP1 pathway is required for the optimal NK cell function. In healthy NK cells the IRE1-
XBP1 pathway is activated following the stimulation with target cell e.g. HRS cells (A), whereas in NK cells from HL 
patients the pathway is not activated, and this is restricted to the CD56brightCD16- subset of NK cells (B). The induction 
of XBP1 splicing is associated with optimal NK cell function i.e. migration, immune synapse formation, cytokine 
secretion and degranulation. These functions are impaired in NK cells from HL patients, but application of PD-1 blockade 
partially reverses impaired immune synapse formation and IFNγ secretion. Although PD-1 blockade enhanced NK cell 
migration, it was unable to reverse the effects of IRE1 blockade on NK cell migration in my experimental system.  
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5.4 CLINICAL IMPLICATIONS  
Checkpoint blockade has led to a renewed focus on understanding the tumour microenvironment. The 
focus of this research has principally been on understanding the operative immune escape 
mechanisms by which malignant cells circumvent host T cells. Similarly, advances in 
immunotherapeutics such as in chimeric antigen receptor (CAR) T cells, and in bispecific T cell 
engager ‘BiTE’ antibodies that re-direct host T cell function, have also given prominence to T cell 
research. By contrast, NK cell research to date has been relatively neglected. However, NK cells is 
also an important component of host anti-tumoural immunity, and may have potential applicability 
as cellular immunotherapy, particularly with regard to the treatment of haematological malignancies 
[92] [214]. 
There are a number of reasons why NK cells are an attractive area to research host anti-tumoural 
immunity. Firstly, malignant B cells frequently have aberrant expression of MHC-I molecules making 
them less likely to be able to be lysed by effector T cells. Paradoxically, cells that lack MHC-I are 
more susceptible to NK cell lysis (the ‘missing self’ hypothesis). Next, NK cells have advantages in 
terms of immunotherapies, including the ability to be pre-generated and available as “off-the-shelf” 
therapy. CAR NK cells, NK cell lines in which a chimeric antigen receptor has been inserted, are 
currently in pre-clinical development. As NK cells do not produce IL-6, they are far less likely to 
induce cytokine release syndrome (CRS) than ‘conventional’ CAR T cells [215] [216] [217]. NK 
cell-based therapies are discussed in a greater detail in an earlier chapter (Chapter 1, section 1.4) 
In this study, I established that the IRE1-XBP1 pathway is involved in regulating NK cell motility, 
IS formation and cytokine release. Also, I showed that NK cells from patients with HL have a 
dysfunctional IRE1-XBP1 pathway that is not activated in response to HRS cells. Further 
understanding of the pathway dysfunction in NK cells might result in the development of a potential 
strategy to enhance NK cell function, by targeting the IRE1-XBP1 pathway. One approach would be 
to develop small molecules, with high specificity (to minimize off-target effects), that target IRE1 
RNase activity to augment the XBP1 splicing. Alternatively, this could be achieved by genetic 
manipulation e.g. using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR 
associated protein 9 (Cas9) to generate ex vivo NK cells with XBP1s overexpression. CRISPR/Cas9 
is a robust technology for gene editing that is faster and more accurate than previously used techniques 
for DNA editing. This system requires two components to mediate gene editing i.e. an enzyme called 
Cas9 and a guide RNA (gRNA). The gRNA is a short sequence complementary to host’s DNA 
sequence that enables Cas9 to target the specific sequence in the genome [218] [219]. Utilising this 
approach in HL xenograft mouse model would facilitate in vivo study of the IRE1-XBP1 pathway 
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impact on NK-HRS cells interaction. In xenograft mouse models, existing HL cell lines are engrafted 
into immunodeficient mice to avoid graft rejection. Importantly, M’Katcher et al. established a 
xenograft model of HL, where NSG mice are engrafted with the L428 cell line, enabling the study of 
novel candidate drugs [220]. 
Currently, the NK-92 cell line is the only FDA-approved NK cell line for clinical trials [215] [226]. 
Recent studies investigating generation of UCB-derived NK cells indicate that these cells might be 
superior to NK-92 cells as they exert a longer lifespan in vivo than NK-92 cells. Indeed, a recent study 
by Liu et al. have shown that UCB-derived NK cells are a good resource to generate CD19-specific 
CAR NK cells with improved transfection rates and longer lifespan in vivo [227]. The latter was 
achieved by introduction of IL-15 gene to ensure NK cell proliferation and persistence in vivo [226, 
227]. The use of the NK-92 cell line or UCB-derived NK cells with an operative IRE1-XBP1 pathway 
would enable infusion of effective NK cells without the need to genetically modify them beforehand. 
In my study the NK-92 cell line was found to have a functional IRE1-XBP1 pathway, hence infusion 
of NK-92 cell lines would enable infusion of effective NK cells without the need to genetically 
enhance this pathway beforehand.  
PD-1 blockade is an approved therapy for patients with relapsed/refractory HL. However, there 
remains minimal data on the role of PD-1 blockade on NK cells in HL. My data demonstrates that 
PD-1 blockade partially reverses the NK cell impairment caused by dysfunctional IRE1-XBP1 
pathway activation. In addition, it would be interesting to delineate the impact of other immune 
checkpoint blockades such as LAG-3, TIM-3, or TIGIT on NK cell function and examine whether 
simultaneous targeting of multiple checkpoints amplifies the effect of single agent therapies.  
Furthermore, HL is characterised by the presence of TAMs that promote an immunosuppressive 
microenvironment. Recently it was demonstrated that these cells exert elevated expression of PD-L1 
and PD-L2 that may interact with NK cells via PD-1 to further promote immunosuppressive 
environment [228] [93]. Targeting the IRE1-XBP1 pathway in NK cells from HL may contribute to 
IFNγ-induced polarization of TAMs away from an M2 ‘tumour tolerogenic’ to a M1 
‘proinflammatory anti-tumoural’ phenotype [229]. Moreover, the broad regulatory effects of IFNγ 
secreted by NK cells to the TME may further shape hosts’ immune responses by inducing maturation 
of DCs [230]. Notably, mature DCs have increased antigen presentation capacity, hence effectively 
‘bridging the gap’ between the innate and adaptive immune system [231].  
CHAPTER 5: Final Discussion 
123 
5.5 CONCLUSION 
Although cure rates are high in HL (~80% in advanced and >90% in early stage disease), because the 
standard care of treatment has significant short and long-term adverse effects, there is a need to 
develop less toxic therapies. An immune cell-rich TME and a paucity of malignant cells highlights 
that targeting immune cells is a viable strategy in HL. Indeed HL is the ‘poster child’ of PD-1 
blockade, with current response rates of relapsed/refractory cases of HL 70-80% [192] [190]. 
Notably, this includes patients that have relapsed or remained refractory to the prior round of 
chemotherapy, suggesting that HL has the potential to be one of the first lymphoid malignancies that 
is treated by a ‘chemotherapy-free’ immune-mediated regimen.  
The frequent loss of MHC-I and elevated expression of PD-L1/PD-L2 ligands on HRS cells renders 
NK cells a viable strategy in HL [128]. As such, I aimed to investigate the NK cell compartment from 
patients with HL to determine potential contributions of the IRE1-XBP1 pathway to NK cell 
dysfunction and explore the potential of PD-1 blockade to restore NK cell functionality. I demonstrate 
a hitherto unrecognized mechanism underlying NK cell dysfunction in HL i.e. the IRE1-XBP1 
pathway suppression that contributes to the impaired migration, immune synapse formation, 
degranulation, and IFNγ secretion. Interestingly, application of PD-1 blockade, an approved 
therapeutic in HL, partially restored the impaired immune synapse formation and IFNγ secretion by 
NK cells. These results suggest that the promising outcomes in HL patients treated with the PD-1 
checkpoint blockade may not be only mediated by T cells, but also by NK cells.  
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